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Previous studies aimed at identifying biomarkers of tolerance in kidney 
transplant patients have revealed an expansion of peripheral blood B cells and over-
expression of B cell-related genes. In humans, Memory, Naïve and Transitional B cells 
are the main B cell subsets found in circulation, and it is has been shown that the 
Transitional subset, defined by its regulatory properties, is expanded in tolerant 
recipients compared to non-tolerant kidney transplant patients. However, the role this 
population plays in kidney transplantation tolerance remains unclear. Here, we report 
three different mechanisms to explain the contribution of B cells in transplantation 
tolerance.  
Kidney transplant patients were divided into five groups; tolerant, stable, 
monotherapy, patients who lost tolerance and chronic rejector. In addition, this study 
also included a group of age/gender-matched healthy volunteers. B cells from each 
group of patients were tested for antigen presentation, antibody production, cytokine 
production, and co-stimulatory function. 
B cells from tolerant patients produced higher levels of IL-10 and lower levels 
of TNF-α than B cells from chronic rejector after CD40 and CpG activation. Moreover, 
B lymphocytes from tolerant patients also exhibited a failure in the BCR signalling 
pathway, suggesting a certain degree of anergy or responsiveness by these cells. Donor-
specific assays revealed that B cells from tolerant patients were inefficient to recognise 
donor-antigens, compared to B cells from chronic rejector. This impairment prevented 
the triggering of the Th1 response by recipient CD4+ T cells and donor-specific antibody 
production by Plasma cells. Finally, Transitional B cells were the lowest CD4+ T cell-
activating cells, compared to Naïve and Memory B cells. This reduced CD4+ T cell 
activation was due to low cell viability, reduced CD86 expression and high IL-10 
production. 
In conclusion, these data suggest that B cells from kidney tolerant recipients 
contributed to maintaining organ acceptance and graft survival by donor-specific and 
non-specific regulatory properties exhibited by all their subsets, especially Transitional 
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 1 Introduction 
	  
1.1 Kidney Transplantation 
	  
Transplantation is the medical treatment used to replace tissues that are no 
longer functional within humans. This treatment has undergone many advances since its 
discovery; types of transplant, organs used, antigen recognition and complementary 
medication are some of the aspects that have improved over time. A brief description 
documenting organ transplantation from its early times will be discussed below to 
contextualise the research project carried out in this thesis.     
1.1.1 Brief History of Organ Transplantation 
Documented reports of organ transplantation begins in 1869, when Swiss 
surgeon Jacques Louis Reverdin performed the first clinical experimental transplant 
between two genetically different individuals, using fresh human skin as a source for the 
allograft. Skin then became the first tissue used in human transplantation. Then, in 1905, 
a second tissue was introduced into this field. Austrian surgeon Eduard Zirm used a 
cornea from an 11-year-old boy to restore the sight of Alois Glogar, a labourer who had 
been blinded by accidentally burning his eyes with caustic lime.  
In the 1940s, UK researcher	  Peter Medawar studied the phenomenon of allograft 
rejection, and recognised that whereas autologous skin grafts were accepted, those given 
from one relative to another were rejected; he received the Nobel Prize in 1960 for 
demonstrating that graft rejection can be entirely prevented in mice and chickens if 
foreign cells from the future donor are introduced into the recipient during foetal or 
neonatal life (Terasaki 1991). In 1954, kidneys were used in human transplantation, 
with great success. Dr. Joseph E. Murray, who received the Nobel Prize for Medicine in 
1990, achieved the first successful kidney transplant between identical twins in Boston, 
USA. Since then, the field of transplantation has seen a wealth of successful transplants 
using a variety of different tissues. For instance, in the early 1960s, transplants of lung, 
pancreas and liver were achieved, and in 1967, the first human heart transplant was 
performed by a South African heart surgeon named Christian Barnard at Groote Schuur 
Hospital in Cape Town. Christian Barnard replaced the diseased heart of dentist Louis 
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Washkansky with that of a young accident victim. Although immunosuppressive drugs 
prevented rejection, Washkansky died of pneumonia 18 days later.  
The first heart transplant and liver transplant to be carried out in the UK 
occurred in 1968, and three years later, donor cards were introduced to help supply the 
need for organs. Over time, organ transplantation has become a regular treatment used 
in the USA, Europe and the rest of the world.     
In 1978, the immunosuppressive drug cyclosporine was successfully introduced 
into organ transplantation, and was approved by the USA Food and Drug 
Administration (FDA) in 1983. In 1994, the FDA approved FK506 or tacrolimus, 
another fungal product. This drug exhibited the same mode of action as cyclosporine, 
but with a higher immunosuppressant effect.  
Finally and more recently, hands, partial face and complete face transplants have 
been performed in France, China, the USA and Spain (Brent 1997; Epstein 2011); and it 
is expected that continued clinical, scientific and technological advances will lead to 
better outcomes and a larger variety of tissues for allotransplantation in the following 




Picture 1: Transplantation Time Line	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1.1.2 Solid Organ Transplantation in Europe and the UK 
Solid organ transplantation is the treatment of choice for individuals with severe 
organ failure. Once the organ has been replaced, stable graft function and patient 
survival are the best indicators for the success of the transplant. Survival rates of 
transplant patients have improved over the last few decades, indicating that the 
treatment is evolving and improving. Despite these successes, the limited number of 
organs available for donation remains the main obstacle in transplantation.        
Between 2006 and 2007, over 3,000 patients in the UK received a transplant, but 
another 1,000 died whilst waiting, or after being removed from the waiting list because 
they had become too ill (Organ Donation 2008). The UK has one of the lowest organ 
donation rates in the developed world; the current active transplant waiting list stands at 
7,235 and is rising by approximately 8% each year (Organ Donation 2008). In 1995, the 
UK and Ireland donor rate was 15,8 per million populations (pmp), and was comparable 
with the 15,1 pmp rate reported by the Eurotransplant (the Netherlands, Belgium, 
Germany, Luxembourg, Austria, Slovenia and Croatia), and the 15,5 pmp rate reported 
in France. More recently, the UK rate has dropped to 12,9 pmp, while Spain has 
achieved 35,5 pmp (Organ Donation 2008). This wide gap demonstrates the necessity of 
donation campaigns and better organ clinical care in the UK.  
Finally, around 100,000 solid organ transplants are performed per year 
worldwide; 68,250 kidney, 19,850 liver, 5,179 heart, 3,245 lung, and 2,797 pancreas 
(Matesanz et al. 2009). The kidney is by far the main organ used in transplantation, 
mainly because a single kidney has enough functionality to allow the donor and 
recipient to survive with a good quality of life. In the following sections, kidney 
transplantation will be reviewed in more detail as the samples used in this thesis were 
obtained from kidney transplant recipients. 
1.1.3 Kidney Transplantation Origin 
In 1954, Joseph Murray and colleagues performed the first successful kidney 
transplant at Boston’s Peter Bent Brigham Hospital, in the USA. The team had 
previously carried out a series of human kidney grafts with partial success, maintaining 
stable organ function only for a couple of days or even months. In 1954, the surgeons 
transplanted a kidney from 23-year-old Ronald Herrick into his twin brother Richard. 
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As the donor and recipient were genetically identical, the procedure was successful. Dr. 
Murray received the Nobel Prize for Medicine in 1990.  
A number of important advances in the field of kidney transplantation have been 
made in the past years regarding individual matching, immunosuppressive medication, 
origin of the organ, and quality of life of the recipient. The following paragraphs will 
introduce the immune responses operating in kidney transplantation, the effect of 
immunosuppressive drugs used to maintain stable graft function and the different 
outcomes displayed by recipients, especially the interesting development of spontaneous 
transplantation tolerance.   
1.1.4 Kidney Transplantation 
Transplantation is the gold-standard treatment for end-stage diseases in solid 
organs. In the context of end-stage kidney disease, transplantation is superior to other 
forms of renal replacement therapy (RRT), as it improves both morbidity (quality of life) 
and mortality (Wolfe et al. 1999; Magee et al. 2004).  
Unlike other types of transplants, a living person can donate a kidney because it 
is possible to survive with one remaining organ; this type of donation is called living 
donation. Donation can also come from deceased donors, but their long-term survival is 
lower when compared to organs from a living donor (Hariharan et al. 2000).  
Immediately after transplantation (independently of the type of donation), the 
allorecognition towards the foreign organ plus the damage caused by surgery, both 
trigger the activation of the cardiovascular and immune system. In order to control these 
responses from the surgery, immunosuppressive drugs have to be taken by transplant 
recipients for the rest of their life (Chinen et al. 2010). Unfortunately, 
immunosuppressant regimens elicit unpleasant adverse side effects such as increased 
risk of infection, cardiovascular disease and cancer (Chinen et al. 2010). Therefore, 
transplanted patients have to balance both effects for life, using these drugs at optimal 
concentrations to control their immune system with minimal side-effects (Womer et al. 
2001).  
1.1.5 Immunological effect of Kidney Transplantation 
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One of the main characteristics of the immune system is its ability to distinguish 
self from non-self antigens therefore, the activation of immune responses in a healthy 
individual should be triggered only by foreign antigens (Eremin et al. 2011). The final 
outcome of a kidney transplant will depend on a good control of the alloresponse in 
each particular patient.  
The innate and the adaptive immune responses both play a critical role in 
rejection and are activated after transplantation. The innate response is induced by tissue 
stress through the interactions between damaged cells and pattern recognition receptors 
(PRRs) on neutrophils, monocytes, and dendritic cells (DCs). As a result of this 
activation, reactive oxygen species (ROS) and pro-inflammatory cytokines such as 
TNF-α are released (Murphy et al. 2012). The adaptive immune response begins with 
the recognition of certain donor-proteins as foreign or non-self antigens. One of the 
most important proteins in this recognition are the highly polymorphic class I and class 
II cell surface molecules encoded by the Major Histocompatibility Complex (MHC) 
genes (the Human Leukocyte Antigen (HLA) system in humans) (Snell 1951; Snell et al. 
1951). Additionally, the ABO system and minor Histocompatibility (mH) antigens are 
also important antigens to consider in human transplantation. 
1.1.6 Transplantation Antigens 
MHC 
 The MHC was described in the mouse model in 1948 by George Snell and Peter 
Gorer. They designated individual histocompatibility loci using the letter H and a serial 
number; the first identified H locus was designated H2 in recognition of the fact that it 
encoded antigen II (Snell 1948). Snell and colleagues also provided the first indication 
that MHC genes might be highly polymorphic. Several years later, the HLA system was 
recognised as the human version of MHC. The genes of the HLA locus are located on 
the short arm of chromosome six, and they encode two distinct classes of cell surface 
molecules: class I and class II (Duquesnoy et al. 1988).  
Humans have three main highly polymorphic MHC class I genes, known as 
HLA-A, HLA-B, and HLA-C. These genes transcribe proteins which, in combination 
with the β 2-microglobulin (β 2M), form the class I molecules HLA-A, HLA-B, and 
HLA-C.	  There are six main MHC class II genes in humans: HLA-DPA1, HLA-DPB1, 
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HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1. These genes encode the class II 
molecules HLA-DR, -DP, and -DQ (Bach et al. 1967; Mehra et al. 2003; Eremin et al. 
2011) (Picture 2).   
Peptides presented by class I HLA molecules are derived from cytosolic proteins, 
such as viral pathogens and their gene products, whereas peptides presented by class II 
molecules are generated by breakdown of endosomal proteins. Class I molecules are 
expressed constitutively by most nucleated cells of the body, but class II molecules are 
restricted to cells that have the capability to process and present exogenous soluble and 
particulate antigens such as B lymphocytes, DCs, macrophages, and monocytes 
therefore, those cells are called antigen-presenting cells (APCs) (Halloran et al. 1986; 
Eremin et al. 2011; Murphy et al. 2012).  
According to the latest data available from the IMGT/HLA database 
(http://www.ebi.ac.uk/imgt/hla/stats.html), a total of 3,296 HLA-A, -B, and -C α -chain 
alleles (expressed as 2,520 distinct proteins), have been identified. In practice, three of 
the HLA loci are usually typed and matched for kidney transplantation: HLA-A, HLA-
B, and HLA-DR. 
Given their high polymorphism and their ability to stimulate strong immune 
responses, it was recognised long ago that transplant outcomes were much improved 
when donor and recipient were well matched. 
 
ABO  
Erythrocytes, or red blood cells, express a number of protein–carbohydrate 
molecules that stimulate coagulation responses. The best studied are those stimulated by 
the H antigens. These antigens have three allelic forms: A antigens, B antigens, or 
unchanged H antigens designated as O (Picture 2). Every person possesses naturally-
occurring IgM antibodies against their non-expressed A or B antigens, developed during 
the childhood in response to bacteria that express cross-reactive antigens in the 
gastrointestinal tract. ABO matching is a requirement for organ transplantation, 
although there are now effective plasmapheresis procedures for extracting circulating 





Minor Histocompatibility (mH) antigens  
In 1990, Rammensee and his colleagues used high-performance liquid 
chromatography (HPLC) to separate peptides eluted from MHC molecules, providing 
the first direct evidence for minor H antigens being peptides (Rotzschke et al. 1990; 
Wallny et al. 1990). mH antigens are encoded by polymorphic genes that belong to non-
HLA related genes (Dzierzak-Mietla et al. 2012). In the context of transplantation, the 
fact that genetic polymorphisms are present in endogenous proteins expressed by the 
donor and not the recipient (Bleakley et al. 2010) can lead to these proteins being 
recognised as non-self antigens. Therefore, these proteins can stimulate a donor-specific 
response (Simpson 1991; Simpson et al. 1997; Robertson et al. 2007). The male-
specific H-Y antigen, encoded by non-HLA related genes, is an example of mHs 
(Rotzschke et al. 1990). This antigen is expressed on the cell surface as several peptides 
rather than an intact molecule, but either way, it may lead to accelerated graft rejection 






Picture 2: HLA and ABO system 
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1.1.7 Allorecognition in Kidney Transplantation 
Allogeneic molecules expressed in the graft can trigger a specific alloimmune 
response in the recipient when a transplant is performed between genetically disparate 
individuals of the same species. HLA antigens expressed in donor, but not recipient 
cells, are the main antigens involved in the immune alloresponse after transplantation 
(Lechler et al. 1982), and can be recognised by the adaptive immune system through 
three different mechanisms: direct, indirect and semi-direct recognition (Hernandez-
Fuentes et al. 1999; Herrera et al. 2004; Gokmen et al. 2008). 
Direct pathway: After transplantation, APCs from the donated organ, leave the 
graft and migrate into regional lymph nodes to activate alloreactive T cells from the 
recipient (Lindahl and Wilson, 1977; Sandner et al., 2003). Donor DCs are the main 
APCs that primarily trigger the recipient immune response via the direct pathway. Thus, 
depletion of donor DCs leads to loss of immunogenicity that is only restored following 
addition of donor DCs (Lechler et al. 1982). In addition, the alloresponse towards the 
engrafted tissue is reduced in animals lacking secondary lymphoid tissues (Larsen et al., 
1990; Lakkis et al., 2000).  
Once donor DCs induce the activation of alloreactive T cells, these effector T 
cells migrate back to the graft and destroy the transplanted tissue. This mechanism of 
allorecognition is known as the direct pathway and involves recipient CD4+ T and CD8+ 
T cells recognising intact donor MHC II and MHC I molecules on the surface of donor 
APCs, respectively (Rosenberg et al. 1987). This occurs because T cells recognise 
foreign peptides in a self-MHC restricted manner (Zinkernagel and Doherty, 1974) and 
as such, the T cell repertoire of the recipient shows a high level of direct anti-donor allo-
reactivity (Suchin et al., 2001; Baker et al., 2001b). This pathway is primarily 











Indirect pathway: The indirect pathway of allorecognition refers to identification of 
processed peptides of allogeneic histocompatibility antigens presented by self-MHC in a 
self-restricted manner (Lechler et al. 1982; Shoskes et al. 1994). Alloantigens shed from 
a graft are, in general, processed as exogenous antigens and therefore presented by 
professionals APC, such as B cells, DCs and macrophages, to CD4+ T cells in a self-
MHC class II dependent manner (Afzali et al. 2007). For example, it has been observed 
that when direct responses were reduced by CD8 depletion or MHC class I deficiency in 
transplants models, rapid rejection was observed. Thus, foreign MHC class I peptides 
were presented via self-MHC class II to CD4+ cells (Auchincloss, Jr. et al., 1993) 
Furthermore, when animals elicit indirect rather than direct responses due to 
immunisation with peptides of allogeneic MHC, a vigorous allograft rejection response 
was demonstrated  (Fangmann et al., 1992). All these studies indicate that the indirect 
pathway has an important role in the allograft rejection. 
B cells require the presence of CD4+ T cells in order to induce class switching 
and to differentiate into antibody-secreting Plasma cells. These T cells recognise 
peptides derived from antigens internalised by the immunoglobulins on the B cell 
surface. The presence of class-switched alloantibodies is indicative of T cell help 
provided via the indirect pathway (Lanzavecchia et al. 1985; Steele et al. 1996). 
Furthermore, it has been demonstrated that indirect alloantigen presentation by 
recipients' B cells plays an important role in the efficient progression of acute 
vascularised allograft rejection. Noorchashm and colleagues have shown that cardiac 
allograft survival was markedly prolonged in mice with defective B cell antigen 
presentation when compared to control counterparts (Noorchashm et al. 2006).  
However, B cells are not the sole APCs required for graft rejection as mice that 
have B cell or immunoglobulin deficiencies are still able to reject allografted tissues 
(Nozaki et al. 2008). DCs have been shown to be instrumental in allorecognition via 
presentation of peptides from allogeneic donor MHC by in a self-MHC specific manner 
(Inaba et al., 1998). Inaba et al. described how DCs process phagocytosed cell 
fragments onto MHC class II products with unexpected efficacy. They suggest that 
when migratory donor DCs die upon reaching the lymph node, they are phagocytosed 
and processed by resident recipient DCs (Inaba et al., 1998).  
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Comparing the efficiency of these two APCs, it has been observed that specific 
B cells are highly efficient at presenting antigens to T cells due to surface 
immunoglobulin recognition (Lanzavecchia 1985; Lanzavecchia et al. 1985). However, 
it has also been shown that DCs are as efficient as antigen-specific B cells in presenting 
tetanus toxoid (TT) to specific T cell clones when activated with 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-4 (Sallusto et al. 
1994)., suggesting that both DCs and B cells are equally efficient in antigen 
presentation to T cells. 
The indirect pathway has been linked to graft rejection (Dalchau et al., 1992; 
Liu et al., 1992; Liu et al., 1996; Tugulea et al., 1997), suggesting an important role in 
long-term alloantigen presentation when donor APC have been exhausted (Vella et al., 
1997; Hornick et al., 2000; Baker et al., 2001a), but also in direct allorecognition, as in 
the absence of direct responses, the indirect pathway alone can also result in rapid acute 











Semi-direct pathway: Semi-direct allorecognition involves the interaction of recipient 
T cells with recipient APCs that have acquired intact donor MHC:peptide complexes 
from donor cells through MHC transfer (Herrera et al. 2004). It has been shown that 
cells from the immune system have the capacity to exchange surface molecules 
(reviewed in (Smyth et al., 2007)). Specifically, DCs are able to acquire intact 
MHC:peptide complexes from other DCs and endothelial cells, and to present them to 
alloreactive T cells (Bedford et al., 1999; Herrera et al., 2004; Smyth et al., 2006). 
Intact MHC can be acquired by direct cell-to-cell contact (Harshyne et al., 2001; 
Herrera et al., 2004; Game et al., 2005) or via the release and uptake of small vesicles 
(“exosomes”) (Denzer et al., 2000; Morelli et al., 2004). Then, as self-APCs have not 
only acquired intact donor-MHC, but have also processed these allogeneic 
histocompatibility proteins and presented them as peptides in the context of MHC class 
II, these APCs can simultaneously stimulate CD8+ T cells through the direct pathway, 






Picture 5: Semi-direct recognition 
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1.1.8 Immunosuppressive Drugs 
Controlling the reactions of the immune system is essential to maintain a stable graft 
function and prevent rejection after transplantation. This control is achieved through the 
anti-inflammatory effect of immunosuppressive agents (Magee et al. 2004). These drugs 
are extremely heterogeneous and more than one can be used in induction (intense 
immunosuppressant therapy at the beginning of transplantation), maintenance, and 
reversal of established rejection (Halloran 2004). Unfortunately, one particular 
characteristic commonly found in all types of immunosuppressant, is that they all cause 
adverse side-effects (Niethammer et al. 1999).  
The main immunosuppressive drugs, with their corresponding side-effects, used in 
kidney transplantation are as follows:  
• Glucocorticoid: Steroids penetrate the cell through the membranes to bind to 
the steroid receptor in the nucleus. They decrease levels of IL-1, TNF-α, GM-
CSF, IL-3, IL-4, IL-5 IL-8, nitric oxide, prostaglandins and leukotrienes, inhibit 
leukocyte emigration from vessels, and activate lymphocyte apoptosis 
(Niethammer et al. 1999). Adverse Effects: Glucose intolerance, hypertension, 
hyperlipidemia, osteoporosis, osteonecrosis, myopathy, cosmetic defects and 
growth suppression in children.   
• Cyclosporine: Cyclosporine binds to cyclophylin (CpN) in the cytoplasm, 
forming the cyclosporine–CpN complex. This complex binds and blocks the 
function of the calcineurin (CaN), which in turn, fails to dephosphorylate the 
cytoplasmic component of the nuclear factor of activated T cells (NF-ATc). As a 
result of this failure, the transport of NF-ATc to the nucleus and the binding of 
NF-ATc to the nuclear component of the nuclear factor of activated T cells (NF-
ATn) are inhibited. The NF-ATc–NF-ATn complex ordinarily binds to the 
promoter of the IL-2 gene and initiates IL-2 production. Hence, the presence of 
cyclosporine prevents IL-2 production by T cells, which is necessary for full T-
cell activation (Wiederrecht et al. 1993; Ho et al. 1996). This drug ultimately 
inhibits synthesis of IL-2, IL-3, IL-4, GM-CSF, TNF-α in lymphocytes, and 
proliferation of T and B cells (Niethammer et al. 1999). Adverse Effects: 
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Nephrotoxicity, hyperlipidemia, hypertension, glucose intolerance, hirsutism, 
gum enlargement. 
• Tacrolimus: Tacrolimus (FK506) binds to FK506-binding protein (FKBP), 
forming a FK506–FKBP complex that binds to and blocks calcineurin. The 
FK506–FKBP–calcineurin complex inhibits the activation of NF-ATc, thus 
preventing its entrance into the nucleus. This drug ultimately inhibits 
lymphocyte synthesis of IL-2 (Siekierka et al. 1992; Wiederrecht et al. 1993). 
Adverse Effects: Diabetes mellitus, hypertension, hyperlipidemia, and cosmetic 
defects (less common).   
• Azathioprine: This pro-drug is converted in the body to the active metabolite 6-
mercaptopurine. Azathioprine acts to inhibit purine synthesis necessary for the 
proliferation of cells, particularly leukocytes and lymphocytes. It also reduces 
immunoglobulin production, monocytes activation and cytokine production 
(Niethammer et al. 1999; Maltzman et al. 2003). Adverse Effects: 
Predominantly bone marrow suppression, hepatitis and/or pancreatitis (rare).   
 
• Mycophenolate Mofetil: This pro-drug is immediately converted to 
mycophenolic acid (MPA), an inhibitor of inosine monophosphate 
dehydrogenase (IMPDH). IMPDH is the first of two enzymes responsible for the 
conversion of inosine monophosphate (IMP) to guanosine monophosphate 
(GMP), which is normally converted to GDP, GTP, and dGTP. Measurements 
show that MPA causes a reduction of GTP and dGTP in lymphocytes, but not 
neutrophils (Ransom 1995; Niethammer et al. 1999). Mycophenolate Mofetil 
inhibits leukocyte proliferation and GTP-dependent metabolic events, and is 
relatively more selective for lymphocytes than azathioprine. Adverse Effects: 
Bone marrow suppression, nausea, abdominal pain, diarrhea. Invasive CMV 
disease is more common than with azathioprine.  
 
• Sirolimus: This drug is an antifungal agent that forms an immunosuppressive 
complex with intracellular protein, FKBP12. This complex blocks the activation 
of the cell-cycle-specific kinase, TOR. The downstream events that follow the 
inactivation of TOR result in the blockage of cell-cycle progression at the 
juncture of G1 and S phase, therefore, sirolimus inhibits leukocyte proliferation 
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(Sehgal 2003). Adverse Effects: Bone marrow suppression, hyperlipidemia, 
diarrhea and interstitial pneumonitis (rare).    
• Chimeric monoclonal antibodies Basiliximab and Daclizumab are monoclonal 
antibodies against the IL-­‐2 receptor (Pascual et al. 2001); Campath-1H, or 
Alemtuzumab, is a humanised IgG1 monoclonal antibody against CD52, a 
protein expressed on a variety of lymphoid neoplasm and most human 
mononuclear cell subsets (Alinari et al. 2007); Anti-thymocyte globulin (ATG) 
is a polyclonal antibody capable of binding to various immune-cell subsets such 
as T cells, B cells, natural killer cells, monocytes/macrophages, neutrophils and 
DC (Hoegh-Petersen et al. 2013); OKT3 is a murine monoclonal antibody 
against CD3, part of a multimolecular complex found only on mature T cells and 
medullary thymocytes, and block T-cell receptor function (Norman 1995).	  
Adverse Effects: Cytokine release syndrome, and post-transplant 
lymphoproliferative disorder (PTLD) for ATG. 
1.1.9 Clinical events secondary to immune alloresponses 
Even though immunosuppressive drugs improve graft survival, several factors 
such as HLA antigen matching, production of donor-specific antibodies, co-morbid 
conditions, age, organ origin and recipient quality of life are also important in 
understanding the different outcomes after transplantation:      
Hyper acute rejection: Also known as pre-formed antibody mediated rejection. 
This occurs immediately after revascularisation of the graft and is characterised by 
widespread glomerular capillary thrombosis, and necrosis. Both effects are caused by 
the interaction of lymphocytotoxic recipient antibodies with donor HLA and other 
endothelium associated donor-antigens (Solez et al. 1993). Once these antibodies 
recognise their targets, the complement system is triggered in the endothelium, 
activating coagulation cascade via complement. Both sequential activations induce 
thrombus formation in the capillaries of the kidneys (Collins et al. 1999). Antibody-
mediated rejection is frequently associated with graft loss because of its irreversible 
nature, and the only option of treatment is graft removal (Chinen et al. 2010).  
Accelerated rejection:  Also known as delayed hyper acute rejection. This 
occurs a few days after transplantation and is characterised by haemorrhage-induced 
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vascular disruption mainly caused by non-complement-fixing antibodies (Solez et al. 
1993). The treatment of choice to reverse this type of rejection is anti-lymphocyte 
reagents (Chinen et al. 2010).  
Acute rejection: This is most frequently observed in the first three months after 
transplantation, and is characterised by tubulitis and vasculitis (Chinen et al. 2010). 
Tubulitis is defined as the invasion of tubules by mononuclear cells (lymphocytes or 
macrophages) across the tubular basement membrane (Ganji et al. 2007; McKay et al. 
2010); and vasculitis occurs when antibodies induce inflammation of the blood vessels. 
Other causes of acute allograft dysfunction include interstitial nephritis, infection, acute 
tubular necrosis, toxicity by drugs, and obstruction in the urinary tract (Ganji et al. 
2007). Diagnosis can only be made by allograft biopsy. High-dose pulses of steroids 
and lymphocyte depleting agents reverse the T cell response in about 80% to 90% of 
patients.  
Chronic rejection: This occurs from months to years following transplantation. 
It is characterised by graft arterial occlusions induced by collagen production by 
fibroblasts, and smooth muscle cell proliferation. This fibrosis can cause ischemia and 
cell death in the graft (Solez et al. 1993). Chronic rejection has been associated with 
increased immune responses, mediated by indirectly activated T cells (Baker et al. 2001; 
Baker et al. 2001). This process is usually treatment resistant, although progression may 
be delayed by immunosuppressive drugs (Chinen et al. 2010).  
Stable function: This is a “host–graft adaptation” state characterised by reduced 
donor-specific responses and low risk of rejection, in the presence of 
immunosuppressive therapy, after a successful transplant (Starzl et al. 1963).  
Tolerance: The most widely accepted definition for transplantation tolerance is 
the absence of a destructive immune response to the allograft without the need for 
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1.2.1 Transplantation Tolerance 
Despite the immune down-regulation obtained through the use of 
immunosuppressive drugs in graft maintenance, side-effects still remain an important 
concern in kidney transplantation. An ideal outcome for patients would be to develop 
spontaneous tolerance to the foreign organ, or tolerance induced by new therapeutic 
strategies.  
Tolerance has been generally defined as a state of specific immunologic 
unresponsiveness to the antigens of the graft, in the absence of immunosuppression 
(Nickerson et al. 1994; Dong et al. 1999). More specifically, in animal models, 
tolerance is the absence of acute rejection with indefinite graft survival and acceptance 
of a second test graft from the original donor, while maintaining the ability to reject a 
third party graft (Dong et al. 1999). Although the former ideas are correct, the definition 
of tolerance in the clinic should also include: absence of donor-specific alloantibodies, 
no signs of destructive lymphocyte infiltration in allograft biopsies and, if systemic 
tolerance is sought, proof of donor-specific unresponsiveness with recovered third party 
responses in functional assays in vitro (Thomas et al. 2001). 
1.2.2 Basis of Tolerance 
The induction of self-tolerance is a multistep process that begins in the thymus 
during foetal ontogeny (Geenen et al. 2001) and continues in the thymus for T cells, and 
in the bone marrow for B cells, during central-tolerance development. This process is 
responsible for the unresponsiveness of T and B cells to self-molecules, and involves a 
negative and positive selection. Negative selection is when "self-reactive" T and B cells 
are commanded to undergo apoptosis because they become activated after contact with 
self-antigens, whilst positive selection is when T cells are able to recognise peptides 
only in the context of self MHC I and II (Murphy et al. 2012). Peripheral tolerance 
occurs after the T and B cell maturation process. T cells and B cell then leave the 
thymus and the bone marrow, respectively, and enter into peripheral circulation. Several 
mechanisms control and maintain central and peripheral self-tolerance.  
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1.2.3 Mechanism of Tolerance in Transplantation 
Allograft tolerance mechanisms are the same as those applied to self-tolerance: 
deletion, ignorance (Fehr et al. 2004), anergy (Dong et al. 1999) and 
regulation/suppression. This has been amply studied in animal models of transplantation. 
Deletion of self-reactive T and B cells is performed during the maturation process in 
central tolerance (Lechler et al. 2003). The participation of deletion in peripheral 
tolerance is not well established but studies on Veto cells, a subset of suppressor cells, 
demonstrate that T cells were led to inactivation or deletion after Veto cell recognition 
(Thomas et al. 1991; Thomas et al. 1994). 
Ignorance can occur in two principal situations: when donor-antigens cannot reach the 
recipient’s lymph nodes, or when the immune cells from the recipient cannot invade the 
foreign graft. In both cases, the immune system from the recipient remains ignorant to 
donor-antigens. This applies to non-vascularised grafts and graft without lymphatic 
drainage (Fehr et al. 2004).   
Anergy is a state of functional inactivation in which antigen-specific T cells are present 
as functionally inert, or unable to respond cells (reviewed in (Lechler et al. 2001)). This 
impairment can be observed as failures in T cell proliferation, activation and cytokine 
production (Schwartz 1990; Dong et al. 1999; Womer 2005). Absence of co-stimulatory 
signals as CD2:LFA-3, LFA-1:ICAM-1 and CD28:CD86/CD80, can also induce cell 
unresponsiveness. Another important protein in the induction of anergy is CTLA-4. 
Unlike CD28-CD80/86 interaction, CTLA-4-CD80/86 interaction down-regulates the 
activation of the immune response. CTLA-4 also has higher affinity for the CD80/86 
co-stimulatory molecules than CD28, therefore its presence is able to interrupt the 
interaction between CD80/86 and CD28 (Dong et al. 1999). 
Regulation/suppression: Regarding peripheral tolerance, the role of regulatory or 
suppressor cells seem to be crucial in graft acceptance. Different cells have been shown 
to be involved in peripheral tolerance:  
• CD4+ T regulatory cells 
Regulatory T cells (Tregs) maintain actively immunological self-tolerance for life. 
In the context of transplantation, multiple populations with different phenotypes and 
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regulatory mechanisms have been described as key players in graft acceptance and 
stable function maintenance. One of the populations described is the natural occurring 
subset of CD4+ T cells that arise during T cell development in the thymus (Walsh et al. 
2004). These endogenous Tregs leave the thymus as a functionally unique and mature T 
cell subpopulation. Most endogenous CD4+ Tregs constitutively express high levels of 
CD25, the alpha-chain of the IL-2 receptor (Sakaguchi et al. 1995); and the 
transcription factor, Foxp3 (Hori et al. 2003). The mechanisms used by these cells to 
suppress effector T cell proliferation in vitro involves: cell contact–dependent 
mechanisms (Takahashi et al. 1998), CTLA-4 mediated signalling (Takahashi et al. 
2000), GITR (Shimizu et al. 2002),  IL-10 (Hara et al. 2001) and TGF-β production 
(Josien et al. 1998).  
In vivo, experiments in organ transplantation demonstrated that pro-inflammatory 
CD45RBhigh T cells were capable of inducing rejection in grafted T cell-depleted mice. 
However, when natural Tregs were co-transferred with CD45RBhigh T cells into these 
mice, Tregs prevented graft rejection by inhibiting the onset of the immune system 
activation (Powrie et al. 1994; Hara et al. 2001).  
A second population of regulatory CD4+ cells could be defined as inducible CD4+ 
Tregs. Unlike natural Tregs, inducible Tregs have acquired their immunosuppressive 
capacity in periphery. Th3 and Tr1 cells are recognised as inducible Tregs; both types 
seem to function independently of cell-cell contact and the main regulatory mechanism 
performed is cytokine secretion. The first population is characterised by their capacity 
to secrete TGF-β (Chen et al. 2003), and the second population, described and studied 
by Roncarolo’s groups, exhibited the ability to produce IL-10 (Roncarolo et al. 2006). 
The relevance of these cytokines can be explained by the fact that TGF-β has been 
found in situ in tolerated grafts. This means that TGF-β was involved in the suppression 
of the allograft rejection, demonstrating that TGF-β-producing Tregs were participating 
in the maintenance of tolerance (Josien et al. 1998).	  IL-10 is a regulatory cytokine with 
an anti-proliferative role. It has been shown that IL-10 inhibits T cell proliferation and 
IL-2 production in humans (Taga et al. 1992). Blockade of IL-10 by the administration 
of either IL-10-specific, or IL-10-receptor-specific antibodies abrogated the suppression 
of skin-allograft rejection by Tregs cells that were present during both the induction 
(Kingsley et al. 2002), and maintenance of tolerance (Hara et al. 2001). Induced 
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regulatory T cells have been proposed as a major player in maintenance of tolerance 
after transplantation (Walsh et al. 2004). 
• CD8+ T cells 
CD8+ T cells are not conventional regulatory cells, but specific subsets have been 
reported to be involved in the maintenance of tolerance. It was demonstrated that 
CD8+CD28− T cells suppressed the alloresponse of CD4+ T cells in both primates and 
rodents (Colovai et al. 2001; Liu et al. 2001). It was also demonstrated that IL-10–
producing CD8+ Tr cells, induced by allogeneic CD40L–activated plasmacytoid DCs, 
displayed a poor secondary-proliferative and cytolytic response (Gilliet et al. 2002). 
Other groups described that novel human CD8+/TCRαβ+ T cells, with a specific 
regulatory phenotype and non-cytolytic function, have the ability to inhibit the immune 
response in vitro by secreting IL-4, IL-5 and IL-13 (Jarvis et al. 2005). Li and 
colleagues, using a model of transplantation tolerance mediated by CD8+ Tregs 
following CD40Ig treatment in rats, showed that the accumulation of tolerogenic CD8+ 
Tregs and plasmacytoid DCs in allograft and spleen was associated with tolerance 
induction in vascularised allograft recipients (Li et al. 2010). Finally, a recent study 
reported that polyclonal naïve CD8+ T cells stimulated with allogeneic DCs in the 
presence of IL-2, TGF-β1 and retinoic acid, have the ability to proliferate robustly and 
differentiate into allosuppressive CD8+Foxp3+ T cells. These cells were capable of 
enhanced expression of CD103, CTLA-4, and CCR4, and suppressing T cell 
proliferation and IFN-γ production in an alloantigen-specific and contact-dependent 
manner. They also induced CD4+CD25+Foxp3+ Tregs in a TGF-β-dependent fashion, 
and both, CD8+Foxp3+ and CD4+CD25+Foxp3+ Tregs, protected full MHC-mismatched 
skin allograft (Lerret et al. 2012). 
• Invariant Natural Killer T (NKT) cells 
NKT cells are characterised by co-expression of NK receptors, and a single 
invariant TCR (Seino et al. 2001). They represent <1% of total T cells in blood and ∼30% 
of all T cells in the marrow. Experimental results demonstrated that transplantation of 
sorted CD4+ and CD8+ T cells from the blood or marrow were able to induce acute 
lethal graft versus host disease (GVHD). Interestingly, when NK1.1+ T cells were 
present in this model, the disease was suppressed. The marrow NK1.1+ T cells secreted 
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high levels of both IFN-γ and IL-4, whereas NK1.1− T cells only secreted high levels of 
IFN-γ. The suppressive activity of the NK1.1+ T cells was dependent on their secretion 
of IL-4, as NK1.1+ T cells from IL-4−/− donor mice failed to ameliorate, and even 
worsened, GVHD, compared to wild-type mice. Together, these results demonstrate that 
GVHD is regulated by the differential cytokines produced by NK1.1− and NK1.1+ T 
cells (Zeng et al. 1999). In humans, Vα24+Vβ11+ CD4+ NKT cells isolated from 
peripheral blood secrete substantial amounts of IL-2 after stimulation with DC and α-
Galactosylceramide. Since IL-2-producing NKT cells induced the expansion of anergic 
CD4+CD25+ cells, this indicates that NKT cells promote CD4+CD25+ regulatory cell 
proliferation (Jiang et al. 2005). 
One study looked at the role of NKT cells in allograft rejection and tolerance, within 
a murine model of transplantation. They found that NKT cells played a critical role in 
the induction of vascularised cardiac allograft tolerance by blockade of lymphocyte 
LFA-1, ICAM-1 or CD28/B7 interactions (Seino et al. 2001). A second study focussing 
on transplantation, observed that host NKT cell were required for heart graft acceptance. 
Host secretion of IL-4 and IL-10 were critical in determining the induction of tolerance 
to both bone marrow and heart grafts in this model (Higuchi et al. 2002). The 
interactions between NKT cells and Tregs also facilitated tolerance in a model of 
combined organ and bone marrow transplantation. Tolerance was dependent on IL-10 
production by Tregs, which in turn, was dependent on IL-4 production by NKT cells 
(Hongo et al. 2012). 	  
• Dendritic cells (DCs) 
DCs are professional APCs that modulate the outcome of the immune response 
towards immune activation or tolerance. The maturation status and the stimulation used 
by DCs present in the grafted tissue are undoubtedly critical factors in the outcome of 
the alloimmune response. Immature DCs residing in peripheral tissues, such as 
epidermal Langerhans cells, failed to induce T cell activation. This was due to moderate 
levels of expression of MHC class II, and very low levels of co-stimulatory molecules 
(Lutz et al. 2000). Immature DCs can also induce T cell unresponsiveness through the 
specific DCs markers 33D1 and DEC-205, and through a sub-optimal stimulation of 
effector T cells, due to a low expression of T cell co-stimulatory factors and pro-
inflammatory cytokines (Hawiger et al. 2001).  
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DCs can act as tolerogenic cells because of the expression of the inducible enzyme 
indoleamine 2,3-dioxygenase (IDO); this enzyme is responsible for the degradation of 
tryptophan, an amino acid essential in cell proliferation. DCs can also act as tolerogenic 
cells by expression of the inducible co-stimulator ligand (ICOS-L), and/or the 
programmed death 1 ligand (PDL-1); both mediate Treg development, and suppression 
of self- and alloreactive cells (Gehrie et al. 2011).  
• B cells 
The role of B cells in kidney transplantation has been focused mainly in B cell-
derived-Plasma cells and the production of donor-specific antibodies (DSA) (Terasaki et 
al. 2005). Current theories explaining the role of B cells in tolerance or rejection, now 
consider the cytokine production and the antigen-presenting role of B cells as important 
mechanisms. B cells in mice transplant models have been shown to actively participate 
in allograft rejection when T-cells were depleted or suppressed, but the depletion of B 
cells could not prevent a T-cell driven rejection (Brandle et al. 1998). In another study, 
passive transfer of donor-specific immune serum to B cell-deficient recipients 
significantly accelerated allograft rejection (Zarkhin et al. 2008). In human translational 
research, certain studies strongly associate B cells with severe graft rejection and steroid 
resistance (Sarwal et al. 2003; Hippen et al. 2005; Tsai et al. 2006). However, other 
studies show that CD20+ B cells are not responsible for poor outcomes or glucocorticoid 
resistance (Doria et al. 2006; Bagnasco et al. 2007; Kayler et al. 2007; Mengel et al. 
2007). The same applies to anti-CD20 therapies (Becker et al. 2004; Alausa et al. 2005; 
Genberg et al. 2006; Lehnhardt et al. 2006; Faguer et al. 2007). As the role of B cells in 
transplantation tolerance is an important topic in this thesis, it will be discussed in more 
detail in the following chapter and in the discussion.    
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1.2.4 Immunological Tolerance in Kidney Transplantation  
Developing transplantation tolerance, long-term graft acceptance without 
immunosuppressant therapy, is the ideal outcome for kidney transplant recipients. Even 
when immunosuppressive drugs control acute rejection and improve graft survival in 
organ transplantation, their side-effects (increased risk of infection, cardiovascular 
diseases, cancer, and renal failure) (Soulillou et al. 2001; Fishman 2007) maintain 
recipients in an unpleasant and undesirable clinical state.   	  	  
In 1953, Billingham et al. demonstrated the feasibility of “actively acquired 
tolerance” in a neonatal mouse model. They demonstrated that injection of foreign 
antigens in mice at foetal stage induced skin graft tolerance to the same donor at adult 
stage. They proposed the definition of true tolerance to be stable graft function without 
histological signs of rejection in an immunocompetent host, in the absence of 
immunosuppression, accepting a second graft of the same donor, but rejecting one from 
a third-party graft (Billingham et al. 1953).  
Decades later, the concepts of intrathymic injection of alloantigens (Ildstad et al. 
1985; Posselt et al. 1990) and mixed chimerism (Kurtz et al. 2004) were introduced in 
the induction of central tolerance to foreign antigens.  
Intrathymic injection of alloantigens was used to achieve transplantation 
tolerance by Remuzzi et al. They observed no donor-specific response after the 
injection of isolated glomeruli from Brown-Norway rat kidneys into Lewis rats 
(Remuzzi et al. 1991). The same group followed on from this with a human study, by 
injecting donor cells into the thymus before heart transplantation; however, this 
technique was insufficient to induce the long-term graft survival observed in mice 
(Remuzzi et al. 1995). 
Mixed chimerism was defined by David Sachs and Megan Sykes as the state in 
which donor and host haematopoietic elements of multiple lineages coexist at levels 
detectable by flow cytometry (Sykes et al. 1999; Sykes et al. 2001). This technique 
consists in the engraftment of allogeneic bone marrow in the recipient compartment, to 
provide the recipient with a permanent source of donor-antigens. Allogeneic T cell 
maturation is a key mechanism in mixed chimerism as engrafted donor T cells emerging 
from recipient bone marrow are not recognised as foreign cells by the central tolerance 
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system during negative/positive selection. In turn, the recipient identifies them as self-T 
cells. Reactive cells against both self-peptides and allogeneic peptides from the 
engraftment are then eliminated before entering into circulation as mature T cells. This 
intrathymic deletion of donor-reactive thymocytes was shown to be the dominant 
mechanism for the maintenance of tolerance in mixed chimerism transplantation (Kurtz 
et al. 2004).  
Although specific tolerance to the donor was achieved due to a constant source 
of donor-antigen, no evidence of peripheral mechanisms were found in these models 
(Khan et al. 1996). Mouse models demonstrated improvements in graft survival with 
mixed chimerism, without a complete lethal ablation of host’s immune system (Cobbold 
et al. 1986) or using a non-lethal conditioning regimen in skin allograft model (Sharabi 
et al. 1989). 
In humans the phenomenon of mixed chimerism was observed in two HLA-
matched bone marrow transplanted patients who, a few years later, were able to accept a 
kidney graft from the same donor without immunosuppressant therapy (Sayegh et al. 
1991). 
Scandling et al. developed a clinically relevant, non-myeloablative regimen to 
induce tolerance in human kidney transplantation. The first clinical case reported was a 
kidney post-transplanted recipient maintained with a regimen of total lymphoid 
irradiation plus injection of rabbit anti-thymocyte immunoglobulins. Stable mixed 
chimerism and stable graft function, without immunosuppressant regimens, were 
observed in this patient. The immune responses did not suffer any counterproductive 
effect. This study demonstrated that persistent mixed chimerism and graft tolerance are 
possible without the development of GVHD (Scandling et al. 2008). 
Kawai et al. reported mixed chimerism in patients with stable renal allograft-
function, after complete withdrawal of immunosuppressive therapy (Kawai et al. 2008). 
Unlike Scandling’s study, they used bone marrow and kidney transplantation from HLA 
mismatched donors. All patients displayed stable creatinine levels and stable graft 
function, despite the presence of anti-donor HLA II antibodies and C4d deposits in three 
of the four recipients. High-level of Foxp3 expression was observed in tolerated grafts, 
suggesting regulatory T cells were involved in the maintenance of tolerance. Authors 
were unable to detect mixed chimerism after 14 days. 
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Not only has central tolerance been targeted to induce graft acceptance, 
peripheral tolerance has also been shown to be an interesting mechanism to regulate the 
immune response in order to prevent graft rejection. Inhibitors of T cell signalling such 
as cyclosporin A, tacrolimus and sirolimus have been used to improve transplantation 
outcomes and graft survival, despite their undesirable adverse effects (Galon et al. 
2002). Monoclonal antibodies have been also used to achieve peripheral tolerance in 
animal models and humans (Table 1).  
Monoclonal 
antibody 




Thymocyte globulin Deplete alloreactive peripheral 
T cells 
(Strober et al. 
1984; Strober et 
al. 1989) 
OKT3 Anti-CD3 monoclonal 
antibody 
Block activation of T cell in 
vitro 
(Cosimi et al. 
1981) 
anti-IL-2R IL-2 receptor Inhibit proliferation of activated 
T cells in vitro 
(Kirkman et al. 




Rat monoclonal antibody 
that blocks the α and β chain 
association of the IL-2 
receptor. 
No interaction between IL-2 and 
its receptor. 
Prevent acute rejection. 
(Soulillou et al. 
1990) 
(Brennan et al. 
2006) 




Humanised rat monoclonal 
antibody. It binds CD52, a 
glycoprotein expressed by T 
and B lymphocytes, 
monocytes and granulocytes. 
Massive depletion of peripheral 
lymphocytes. 
Treatment of lymphoma. 
Induction of kidney 
transplantation tolerance. 
Decrease acute rejection and 
opportunistic infections. 
Increase the number of Tregs 
 
(Hale et al. 2002) 
(Calne et al. 1998) 






Binds surface costimulatory 
ligands (CD80 and CD86) of 
APCs. 
Blockade of second signal 
inducing death and anergy of 
effector T cells. 
(Schwartz 1990) 
(Sayegh et al. 
1998) 
(Vincenti et al. 
2005) 
(Bluestone et al. 
2008) 
Anti-CD28  Selective CD28 blocker Reduce alloreactivity and 
increased the pool of peripheral 
T regulatory cells 
(Poirier et al. 
2012) 
Table 1: Monoclonal antibodies 
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1.2.5 Spontaneous Tolerance in Human Kidney Transplantation  
Development of spontaneous tolerance in humans, characterised by a stable graft 
function after quitting immunosuppressive therapy, has been reported in the last decades, 
mainly in liver transplantation (Lerut et al. 2006; Castellaneta et al. 2010; Mazariegos 
2011; Sanchez-Fueyo et al. 2011), but also in kidney transplantation (Roussey-Kesler et 
al. 2006). Identification of this spontaneous tolerance was a completely random event in 
humans, as doctors observed that some of the patients who deliberately decided to stop 
immunosuppression, displayed a stable function a long time after immunosuppressants 
were withdrawn.  
In 2010, three major studies were published that focused on identifying 
biomarkers of tolerance in kidney transplant patients, Pallier et al. (Pallier et al. 2010) 
from France; Indices of Tolerance (IOT), (Sagoo et al. 2010) from Europe; and Immune 
Tolerance Network (ITN), (Newell et al. 2010) from the USA. All studies were carried 
out independently of each other, and all showed that tolerant patients displayed an 
expansion of peripheral blood B cells, an absence of donor-specific antibodies and an 
increased expression of multiple B cell-related genes. No strong evidence of other 
subsets was observed in tolerant recipients among these three studies.       
1.2.6 B cells as a signature of Spontaneous Tolerance in Kidney Transplantation 
In 2007, Brouard et al. performed the first study trying to identify biomarkers of 
tolerance from peripheral blood samples. The idea was to use these biomarkers to 
determine tolerance in immunosuppressed patients with stable graft function (Brouard et 
al. 2007). They measured gene expression using microarray analysis and identified a 
“tolerant fingerprint” of 49 genes. The group found that in tolerant recipients, there was 
an over expression of genes encoding proteins presented in the B cells, such as CHEK1, 
PIM2, LCK, ZAP70, IKBKB, PDGFRA, and LPXN (Brouard et al. 2007).  
The same group continued with the biomarkers of tolerance investigation but 
this time, focused solely on the B cell population. They compared peripheral B cell 
subsets from patients with stable graft function, chronic rejection, healthy volunteers 
and tolerance, and found that tolerant recipients exhibited a significant increase in 
absolute B cell numbers and frequency of total B cells, particularly activated Memory 
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and early Memory B cells. They suggested that B cells exhibited an inhibitory 
phenotype. Evidence for this was based on the decreased FcγRIIA/FcγRIIB ratio and 
high expression of CD1d and CD5 observed in these cells.	   They also found a 
significantly enriched transcriptional B-cell profile in cells from peripheral blood 
(Pallier et al. 2010).  
In the same year two multicentre studies, the European IOT study (Sagoo et al. 
2010) and the USA ITN study (Newell et al. 2010), reported a clear B cell signature in 
kidney transplant tolerant patients. The IOT and INT studies included 11 and 19 
operationally tolerant recipients, respectively. Both studies found an expansion of 
peripheral blood B cells and an over-expression of multiple B cell differentiation genes. 
They also used the following set of genes to distinguish tolerant from non-tolerant 
recipients: MS4A1, FCRL1, FCLR2, CD79B, TCL1A, HS3ST1, SLC8A1, TLR-5, 
SH2D1B and PNOC (IOT study); IGKV1D-13, IGKV4-1 and IGLL1 (ITN study). 
Finally, the ITN study also found an up-regulation of CD20 mRNA in urine sediment 
cells, and elevated numbers of peripheral blood Naïve and Transitional B cells in 
tolerant participants, compared with those receiving immunosuppression.  
The former findings in spontaneous tolerance described in the last paragraphs, 
were the preliminary data used to structure the main idea of this thesis. Identification of 
spontaneous tolerance would also be a beneficial clinical diagnosis for some kidney 
transplant patients with stable function. For all these reasons, the role of the B cells and 
their subsets in tolerance was extensively studied in this thesis. However, the fact that B 
cells have always been associated with antibody production, and therefore, to chronic 
rejection cannot be ignored. Naturally, this poses the question: why could B cells be 
playing a regulatory role in tolerance? In order to understand and answer this question, 
the following subchapter will introduce B cells and the different subsets found in 
peripheral blood, explain the different roles of the B cell in the immune response, and 
most importantly, will describe immune regulation displayed by these cells in 
transplantation tolerance.     
50	  
	  
1.3 B cells as part of the Immune System 
	  
The immune system is a complex structure of organs and cells that recognise 
foreign pathogens in the body, generating a defensive response to protect the organism. 
The interaction between the immune organs, immune cells, signalling pathways and 
proteins are essential to maintain this system in operation.  
The defensive response of the immune system can be academically divided into 
the innate and adaptive immune response. The innate immune response is a rapid 
response that initiates the first recognition of pathogens without specificity, and the 
adaptive immune response is a specific response of late-onset that requires pathogenic 
antigen processing. The main cells involved in these two responses come from 
precursors from the bone marrow, where they mature and differentiate into several cell 
lineages to finally form the different types of leukocytes. The myeloid lineage conceives 
the innate participants, such as macrophages, granulocytes, mast cells and DCs (Murphy 
et al. 2012), whereas the lymphoid lineage conceives lymphocytes and NKs. 
Lymphocytes are the main players in the adaptive response, while NKs participate 
mainly in the innate response (Murphy et al. 2012).  
1.3.1 B cells 
B cells are the key players of the humoral response in the immune system. Their 
main role is antibody production by B cell derived-Plasma cells, but besides this 
function, B cells can play a role as professional APCs. This is because they process and 
present antigens in the context of MHC class II, and can regulate the immune response	  
through cytokines secretion.  
1.3.2 The origin of the B cell 
B cells originate from the bone marrow when a multi-potent hematopoietic stem 
cell is differentiated into a common-lymphoid progenitor (CLPs) after successive 
rounds of lineage fate restriction, commanded by transcription factor Ikaros and Purine 
box factor 1.  
CLPs then undergo the first round of differentiation, into the B cell lineage 
through transcription factors E box binding protein 2A (E2A) and early B cell factor-1 
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(EBF1). These two transcription factors induce transcription factor Pax-5, that in turn, 
promotes genes for the B cell co-receptor Igα, CD19 and B-cell linker protein (BLNK). 
These allow the CLPs to differentiate into Pro-B cells (Ramirez et al. 2010). 
Rearrangement of D-JH gene segment starts in the early Pro-B cell, while VH-DJH 
rearrangement occurs in the late Pro-B cell.  
After VDJH rearrangement, the cell begins to expresses a pre-B cell receptor 
(BCR) and a complete immunoglobulin µ heavy chain, before developing into a Pre-B 
cell (Allman et al. 1999). E2A and EBF1 then induce the expression of λ5 and VpreB, 
and together, these two proteins form the surrogate light chain; λ5 replaces the C 
domain, whereas VpreB replaces the V domain, plus an extra region. The pre-BCR is 
completed when the heavy chain, the surrogate light chain and the heterodimer Igα/Igβ  
are assembled in the surface of the cell (Monroe 2006).  
The expression of this pre-BCR significantly reduces λ5 production and induces 
the rearrangement of the light-chain locus. The light-chain lacks D segments; therefore 
rearrangement occurs only in the V-JL gene segment. VJL-CL assembling completes the 
light-chain of the BCR, and both the light and heavy chains form the proper BCR. This 
is located on the surface of the B cell, and the cell becomes an immature B cell during 
its permanence in the bone marrow.     
1.3.3 Mice B cells phenotype 
B cells emerge from the bone marrow as an immature B cell. The first immature 
population that arrives in periphery is called Transitional 1 (T-1), or newly formed (NF) 
B cell, and it is characterised by the expression of B220+ CD19+ sIgMhigh sIgD-/low 
CD23- AA4+ and CD21/35-/low. T1 cells can become Transitional 2 (T-2) B cells, 
characterised as B220+ CD19+ sIgMhigh sIgDhigh CD23+ AA4+ and CD21/35low, and T-2 
can become Transitional 3 (T-3) B cell characterised as B220+ CD19+ sIgMlow sIgDhigh 
CD23+ AA4+ and CD21/35low (Allman et al. 2008). These three populations of 
transitional cells represent the first maturation process of the B cells that enter into the 
periphery for the first time. Even when the daily output of immature B cells is roughly 
5-10% of the total B cells, the majority of these do not even reach the follicles; they 
normally die and do not continue with the maturation process. A small fraction of 
immature B cell escapes the deadly fate and become part of the Naïve population of B 
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cells that can be divided into follicular (FO) B cells, marginal zone (MZ) B cells and 
long-lived B-1 B cells (Casola 2007).  
FO B cells can be classified as follicular type I (B220+, CD19+, sIgMlow, sIgDhigh, 
CD23+, CD21/35int) derived from T2 and T3 B cells, and follicular type II (B220+, 
CD19+, sIgMhigh, sIgDhigh, CD23+, AA4-, CD21/35int) derived from T2 B cells. FO B 
cells reside in follicles and participate in both T-cell dependent and T-cell independent 
immune responses.  
MZ B cells (B220+, CD19+, sIgMhigh, sIgDlow, CD23-, AA4-, CD21/35high CD1d+) 
are derived from the MZ precursor (PMZ) (B220+, CD19+, sIgMhigh, sIgDlow, CD23+, 
AA4-/low CD21/35high CD1d+), which in turn, is derived from T2 B cells. MZ B cells 
reside in the marginal zone between the red and white pulp, and because they are 
located close to the marginal sinus, they respond rapidly to blood-borne pathogens 
(Pillai et al. 2005).  
The decision that determines the final B cell lineage from T2 cells is given by 
the BCR signalling. If the BCR reacts fairly well with a self-antigen, this B cell is 
induced to differentiate in a Btk-pathway-dependent manner into an FO B cell. If BCR 
reacts poorly or not at all with a cognate self-antigen, it continues to survive because of 
BAFF and constitutive BCR signalling, but in the absence of stronger BCR stimulation 
it is receptive to inductive signals that drive it to an MZ B cell fate (Pillai et al. 2005).  
B-1 cells come from a progenitor population detected in foetal liver and foetal 
bone marrow, defined as Lin-CD45Rlo-negCD19+, that generates functional B-1a 
(sIgMhiCD11b+CD5+) or B-1b (sIgMhiCD11b+CD5-) B cells, but not the rest of the B 
cell subsets (Montecino-Rodriguez et al. 2006). B-1 cells reside in the peritoneal and 
pleural cavities, and contribute to the generation of IgM responses to T-independent 
antigens (Allman et al. 2008). 
 
1.3.4 Human B cells phenotype  
Similarly to mouse development, human immature B cells leave the bone 
marrow and enter into the circulation as B cells with a transitional phenotype. In bone 
marrow and cord blood, the immature B cell phenotype was characterised by Sims and 
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colleagues, who found that markers such as IgM, IgD, CD20, CD24 and CD38 were 
highly expressed; markers such as CD5, CD10 and CD1d were equally expressed; and 
markers such as CD21, CD23 and CD27 were poorly expressed or not expressed at all 
in immature B cells (Sims et al. 2005). Once the immature phenotype was characterised, 
the same group evaluated the same markers in B cells from peripheral blood, and a 
small population with the same phenotype as immature B cells was found in circulation. 
Because of the high levels of IgM but low levels of CD21, CD23 and CD62L expressed 
by these cells, they were associated with the transitional phenotype exhibited in mice. 
Probably for this reason, this human population was also defined as Transitional B cells. 
They were distinctively distinguished from mature Naïve B cells by their high 
expression of CD10, CD24 and CD38, and the low expression of CD44.  
Naïve B cells gradually lose the high expression of CD38 and CD24, and are 
therefore recognised as IgM+IgD+CD19intCD20+CD38intCD24+CD27- cells. Following 
this, Memory B cells up-regulate CD27, and they are recognised as IgD-
CD19intCD20+CD38intCD24intCD27+ cells (Sims et al. 2005; Aaltonen et al. 2010)   
In summary, the human B cell phenotype has permitted the identification of B 
cell subsets at different stages of maturation. These surface markers have then 
facilitated the study of the B cell function and its participation in the immune response.   
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1.3.5 Human B cell surface molecules 
Surface molecules Function Expressed in Also found in 
BCR Antigen recognition All B cells - 
CD20 ? Role in B cell 
activation or regulation; 
calcium channel 
All B cells - 
CD19 B cell activation; forms a 
co-receptor complex 
with CD21 and CD81 
which delivers signals 
from BCR complex 
All B cells - 
CD1d Presentation of non-
peptide (lipid and 
glycolipid) antigens to 











CD10 Metalloproteinase; B cell 
development 






CD11a Cell:cell adhesion; binds 
to ICAM-1, ICAM-2 and 
ICAM-3 
All B cells Leukocytes 
CD21 Receptor for complement 
fragment CD3d; forms a 
co-receptor complex 
with CD19 and CD81 
which delivers activating 
signals in B cells; 
Epstein-Barr virus 
receptor  
Mature B cells Follicular  DCs 
CD22 Regulation of B cell 
activation; adhesion 
molecule 
All B cells - 
CD23 Low-affinity Fcε 
receptor, induced by IL-4 
Activated B cells Monocytes, 
macrophages 
CD24 Unknown Transitional B 
cells (++) Naïve  
B cells (+)  
Granulocytes 
CD25 Binds IL-2 because it is a 
subunit of the IL-2 
receptor 
Activated B cells Activated T cells, 
regulatory T cells 
and macrophages 
CD27  Binds CD70; can 
function as a co-
stimulator for T and B 
cells 
Memory B cells Medullary 
thymocytes, T 
cells, NKs 
CD32 Fc receptor for 
aggregated IgG; binds C-
reactive protein; role in 
phagocytosis, acts as an 
inhibitory receptor that 
terminates activation 
signals initiated by the 
BCR 




CD38  NAD glycohydrolase, 
augments B cell 
proliferation 
Transitional B 
cells (++) Naïve  
B cells (+) 
Activated T cells, 
germinal centre B 
cells and Plasma 
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cells   
CD40 Binds CD154; role in T 
cell-dependent B cell, 
activation, as well as 
macrophage, DCs, and 
endothelial cell 
activation  
All B cells Macrophage, 
DCs, and 
endothelial cell 
CD44 Binds hyaluronic acid 
and mediates adhesion of 
leukocytes 
MatureB cells Leukocytes and 
erythrocytes 
CD62L  Leukocyte-endothelial 
adhesion; homing of 
Naïve  T cells to 
peripheral lymph nodes 
All B cells T cell, monocytes, 
granulocytes and 
some NKs 
CD79a Required for B cell 
surface expression of, 
and signal transduction 
by, the BCR-antigen 
complex 
All B cells - 
CD79b Required for B cell 
surface expression of, 
and signal transduction 
by, the BCR-antigen 
complex 
All B cells - 
CD80 Co-stimulator for T 
lymphocyte activation; 
ligand for CD28 and 
CTLA-4 
Activated B cells Macrophage and 
DCs 
CD81 B cell activation; forms a 
co-receptor complex 
with CD19 and CD21 
which delivers signals 
that synergise with 
signals from BCR-
antigen complex 
All B cells T cells, NK cells, 
DCs, thymocytes 
and endothelium 
CD86 Co-stimulator for T cell 
activation; ligand for 
CD28 and CD152 
Activated B cells Monocytes, DCs 
and some T cells 
CD138 Heparan sulphate 
proteoglycan binds 
collagen type I  
Plasma cells B cells 
(Murphy et al. 2012) 
Table 2: Human B cell surface molecules 
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1.3.6 The Humoral Response 
Antigen recognition 
The humoral response begins when the immunoglobulin from the BCR 
recognises and binds specific antigens with high affinity. Depending on the type of 
antigen the humoral response can be Thymus Independent (TI), when antigens can 
induce antibody production in the absence of helper T cells, or Thymus Dependent (TD), 
when antigens require antigen-specific T cell help to produce antibodies.  
 
Thymus independent response 
 
Antigens, such as bacterial polysaccharides, polymeric proteins and 
lipopolysaccharides, are capable of stimulating Naïve B cells to induce B cell activation, 
maturation and differentiation in the absence of T helper cells. TI antigens can be 
divided in two classes: TI-1 antigens that possess the intrinsic capacity to induce cell 
division, and TI-2 antigens, which contain no intrinsic B cell-stimulating activity. 
Whereas TI-1 antigens can activate both immature and mature B cells, TI-2 antigens can 
activate only mature B cells. LPS is an example of a B cell mitogen and TI-1 antigen, 
while polysaccharide capsule from bacteria is an example of TI-2 antigen. 
 
Thymus dependent response 
 
Linked recognition by both B cell and T helper cells that respond to the same 
antigen, is essential in the TD response to induce differentiation of Naïve B cells into 
Memory or antibody-secreting Plasma cells. Beside peptide/MHC class II-TCR 
recognition between B and T cells, CD40-CD40L is another important interaction in the 
correct function of this response. CD40 ligand (CD154) is a T cell effector protein from 
the TNF family-member that interacts with CD40; CD40 is an activation molecule from 
the TNF-receptor family member and it is important in the DI response because along 
with IL-4, CD40 activation induces B cell proliferation, immunoglobulin class 
switching, and somatic hypermutation. CD30/CD30L, CD28/CD80-CD86, B7-
RP/ICOS are other cell-bound proteins participating in the DI responses, and IL-5 and 
IL-6, are as well cytokines involved in this interaction.       
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The B cell co-receptor 
 
The B cell-co-receptor complex is formed by three surface proteins: CD19, 
CD21 and CD81. This complex reduces the threshold for B cell activation via BCR, by 
linking the antigen specific recognition with CD21-mediated complement. CD21 is a 
complement receptor that binds the C3d fragment. Thus, CD3d-bound pathogens can 
cross-link with the BCR signalling pathway through this co-receptor complex. After 
BCR activation, the Src-family tyrosine kinase induces phosphorylation of the CD19 
cytoplasmic tails, and after phosphorylation, PI 3-kinases continue with the signalling 
pathway activating transcription factors such as NFkΒ, NFAT and AP-1, to finally 
induce cell proliferation and differentiation.               
 
Antigen specific B cell – T cell encounter 
 
Following the BCR recognition and activation, circulating Naïve B cells migrate 
into peripheral lymph nodes through endothelial venules, and enter in the T cell areas to 
find an antigen-specific T cell that shares the same antigen-specificity. The chance of a 
random encounter between these antigen-specific cells is between 1 in 108 to 1 in 1012 
(Murphy et al. 2012). To facilitate the encounter, once the B cell has bound the 
antigenic protein, the cell expresses adhesion molecules (LFA-1), and chemokine 
receptors (CCR7, CCL19, CCL21); both signals trap the B cell in the T cell zone. After 
contact, antigen-specific B and T cells migrate to the border of the red pulp, where the B 
cells proliferate to form a primary focus, or migrate into a primary lymphoid follicle to 
form a germinal centre. 
 
Antibody-producing cell  
In the primary focus, proliferation of antigen specific T and B cell can last 
several days after encounter. Some of the proliferating B cells differentiate into 
antibody-synthesising Plasmablasts. After a few more days, these stop dividing and 
either die or differentiate into Plasma cells. Some of these short-lived Plasma cells will 
remain in the lymphoid organ, while the majority will migrate to the bone marrow.  
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The rapid antibody secretion pathway described above, is an immediate 
protective response for the infected individual. However, there is a more effective 
response that includes somatic hypermutation which occurs when B cells migrate into a 
primary lymphoid follicle and forms a germinal centre with T helper and follicular DCs. 
Germinal centre B cells differentiate into long-lived Plasma cells, able to secrete all 
antibody classes, or long-lived descendant class-switch Memory B cells that inherit the 
genetic changes that occurred in the germinal centre. These Memory B cells express the 
class-switch corresponding immunoglobulin in their surface, but they are incapable of 
secreting antibodies.  
 
Antibodies 
Antibodies, secreted by Plasma cells, are the main players in the humoral 
effector response. They are proteins from the globulin family that exhibit diverse 
structures, locations and function. Two domains, variable and constant, form the basic 
immunoglobulin structure, and both domains are located in the heavy and light chain of 
the antibody.  
The specificity of an antibody response is determined by the antigen-binding site, 
located in the variable domain, but the final effector action will be determinated by the 
isotype of the heavy chain from the constant domain; both regions experience changes 
in order to improve antibody function and affinity.  
Class-switch recombination involves only the constant region of the antibody, 
while somatic hypermutation and gene conversion affects mainly the variable region. In 
the former process, an alternative heavy-chain replaces the Cµ heavy-chain C region, 
and the latter process alters the affinity of the antibody for the antigen. IgM, IgD, IgG, 
IgA and IgE are the five-immunoglobulin classes described in humans and their names 
are derived from the corresponding heavy chain (µ, δ, γ, α and ε). Moreover, IgG can be 
divided in four sub-classes, IgG1, IgG2, IgG3 and IgG4 and IgA can be divided in two 
sub-classes, IgA1 and IgA2.  
All Naïve B cell express cell-surface IgM and IgD. Even when IgM is the first 
antibody secreted, IgG and IgA are the predominant antibodies found in circulation, 
implying the importance of the class switch process. The mechanism of class switching 
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between regions occurs when the rearranged V region is located in front of the 
corresponding C region. The selection of a C region is not random and is regulated by 
specific cytokines secreted by T cells, or other cells, during the humoral response. IL-4 
preferentially induces IgG1 and IgE, TGF-β induces IgG2b and IgA, IFN-γ induces 
IgG2a and IgG3, and IL-5 augments IgA production. Cytokines induce class switching 
in part by stimulating the production of RNA transcripts from the switch recombination 
sites in the heavy-chain domain. CD40L-CD40 interaction is another signal required for 
class switching. Several cases of hyper IgM syndrome has been reported, in which 
CD40L-deficient individuals exhibit abnormally high levels of IgM, with low levels of 





Structure: IgM normally exists as a 
pentamer, but it can also exist as a 
monomer. In the pentameric form, all 
heavy and light chains are identical. 
IgM has an extra domain on the µ chain 
(CH4) and it has another protein 
covalently bound via an S-S bond called 
the J chain. This chain plays a role in 





Location: B cell surface and serum. 
 
Secretion: IgM is the third most common serum Ig.  
 
Function: IgM is the first Ig produced by the foetus, and the first Ig expressed by Naïve 
B cells before antigen encounter. As a consequence of its pentameric structure, IgM is 
also a good complement fixing and a good agglutinating Ig. Furthermore, IgM 
antibodies are very proficient in clumping microorganisms for eventual elimination 






Structure: Exists only as a monomer. 
Location: Primarily found on B cell 
surfaces.  
Secretion: Low levels in serum.  
Function: B cell Receptor 
IgG 
 
Structure: The structures of the IgG 
subclasses are all monomers. The 
subclasses differ in the number of 
disulphide bonds and length of the 
hinge region. 
 
Location: B cell surface, serum and 





Secretion: IgG is the major Ig in serum (75% of serum), and the major Ig in extra 
vascular spaces. 
 
Function: IgGs fix complement and can then be recognised by macrophages, 
monocytes, PMNs and some lymphocytes because of the Fc receptors exhibited by 
these cells. Although not all subclasses bind Fc receptors equally well, as IgG2 and 
IgG4 are not able to bind Fc receptors, the binding of other subclasses such as IgG1 and 
IgG3 improve the internalisation of the antigen in PMNs, monocytes and macrophages 
(Brooks et al. 1989). The term opsonin is used to describe substances that enhance 








Structure: IgA is a monomer in serum, and a dimer with an associated J chain in 
secretions. When IgA is found in secretions, another protein called the secretory piece 
or T piece is associated with the antibody. The secretory piece is made in epithelial cells, 
and is added to the IgA as it passes into the secretions. 
 
Location:  B cell surface, secretion and serum.  
 
Secretion: IgA is the main Ig in secretion as tears, saliva, colostrums and mucus. It is 
also the 2nd most common serum Ig. 
 
Function: IgA is important in local mucosal immunity. IgA can bind to some cells – 




Structure: IgE exists as a monomer and 
has an extra domain in the constant 
region. 
 
Location: B cell surface (the least Ig 





Secretion: Allergic reaction and parasitic infections.  
 
Function: IgE binds very tightly to Fc receptors on basophils, mast cells and 
eosinophils. IgE is involved in allergic reactions as a consequence of binding to 
basophils and mast cells, and is also involved in parasitic reactions as a consequence of 
binding Fc receptors on eosinophils. 
 The importance of the B cells in antibody production is undeniable, particularly 
due to the different functions displayed by these Igs. In spite of that, B cells can also 
function as professional APCs and cytokine-secreting cells. These alternative functions 
can participate in both rejection and tolerance depending on the B cell subset, immune 
environment, activation, number of antigens, and so on. 
1.3.7 B cells as APCs 
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 As mentioned previously, B cells are professional APCs because they present 
antigenic peptides in the context of MHC class II.  
In addition, they exert several APC properties: 
• They up-regulate the expression of chemokines that allow expression of other 
cytokines in T cells, which then allow the migration of T cells to secondary 
lymphoid organs.  
• BCR-mediated endocytosis allows them to concentrate small amounts of 
specific antigens.  
• The HLA-DO expression on B cells favours presentation of peptides derived 
from antigens internalised through the BCR (Rodriguez-Pinto 2005). 
In terms of the regulatory role of B cells that act as APCs, CD40-activated B 
cells expressed high levels of MHC class I and II, and high levels of the co-stimulatory 
molecules CD80 and CD86 (Tu et al. 2008). These activated B cells can induce 
alloantigen-specific CD4highCD25+ Treg (Tu et al. 2008) and alloantigen-specific 
CD8high Tregs (Zheng et al. 2009); both T cell subsets express FoxP3, CTLA-4 and 
CD62L. The same group demonstrated that CD40-activated B cells are more potent in 
generating large number of antigen-specific Tregs compared to immature DCs (Zheng 
et al. 2010). Another group demonstrated that CD40-activated B cells induce T-cell 
chemotaxis by expressing CD62L, CCR7/CXCR4, and LFA-1 (von Bergwelt-Baildon 
et al. 2006).  
The interaction between the T and B cell requires communication between 
proteins from both cells and although molecule interaction between B and T cells are 
described (Clark et al. 1994), it is still unknown how B cells can command a pro-
inflammatory or an anti-inflammatory response on T cells.   
1.3.8 Cytokine-Producing B cells  
Although B cells are not traditionally known as cytokine-secreting cells, they 
can produce several cytokines depending on the activation used. These cytokines can 
exert a pro-inflammatory or an anti-inflammatory role in the immune response, 
depending on the function and the type of cytokine secreted. 
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O’Garra et al. examined the B cell ability to produce cytokines in murine Ly-1+ 
B lymphomas and in normal murine peritoneal B cells. Results showed that all the B 
cells studied were capable of expressing IL-6, TNF-α, TNF-β and IL-10, after LPS 
activation. B lymphomas also produced different cytokines to normal B cells such as IL-
3, IL-4 and GM-CSF (O'Garra et al. 1990). 
Kouskoff et al. studied cytokine production after BCR activation in B cells from 
a 3-83 transgenic mouse. They found no changes in IL-4, IL-5, IL-9, IL-10, IL-13, and 
IL-15 mRNAs levels after antigen activation. Despite that, after 6 hours of stimulation 
with P31, a clear increase in mRNAs was observed for IL-6, IL-2, and IFN-γ (Kouskoff 
et al. 1998). 
Kindler et al. identified IL-2 production by normal human B cells. They 
investigated various B cell-activating conditions, and showed that B cells secreted IL-2 
when first activated by CD40, over 24 hours before PMA and ionomycin activation. 
Lower IL-2 expression was detected when cross-linking anti-IgM antibodies were used 
instead of PMA plus ionomycin. Their results showed that the production of IL-2 by 
normal B lymphocytes occurs as a late event relative to their activation and proliferation 
(Kindler et al. 1995). 
IL-4 is known as an immunomodulatory cytokine secreted by relatively few cell 
types, and plays an important role in promoting the production of the IgE antibody. IL-4 
was found in supernatants of Epstein-Barr virus (EBV)-positive B cell lines from 
PBMCs of patients with atopic dermatitis (AD). This report was the first evidence of IL-
4 production by an EBV-transformed B cell line (Ohnishi et al. 1997). IL-12 was also 
found in supernatant from human EBV-transformed B cell lines. However, phagocytic 
cells rather than B cells appear to be the most important physiological producers of IL-
12 (Sartori et al. 1997).  
Harris et al. identified in humans, two populations of “effector” B cells, Be1 and 
Be2, which produced distinct patterns of cytokines depending on the cytokine 
environment in which the cells were stimulated during their primary encounter with 
antigen and T cells. Be1 cells regulated the differentiation of naïve CD4+ T cells into 
Th1 cells via IFN-γ and IL-12 secretion, while Be2 induced Th2 differentiation through 
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IL-4, IL-6 and IL-10 production. In conclusion cytokines produced by B cells were able 
to regulate T cell polarisation (Harris 2000).  
Finally, Duddy’s group reported that different B cell subsets secreted different 
type of cytokines in human cells. Firstly, cytokine expression was studied in B cells 
after BCR/CD40 activation. Results showed that B cells appropriately stimulated by 
sequential BCR and CD40 stimulation, proliferated and secreted TNF-α, LT, and IL-6. 
In contrast, CD40 stimulation alone, induced negligible pro-inflammatory cytokines, but 
significant production of IL-10 (Duddy et al. 2004). Secondly, the same group 
evaluated similar activation in B cells subsets. Results revealed that Memory B cells 
were the main LT and TNF-α−secreting cells after BCR/CD40 stimulation, whereas 
Naïve B cells secreted mainly IL-10 when CD40 activation was used alone (Duddy et al. 
2007). More recently, CD24hiCD38hi Transitional B cells, but not CD24intCD38int Naïve 
or CD24hiCD38- Mature B cells, were capable of producing IL-10 after CD40L 
stimulation (Blair et al. 2010).     
1.3.9 B cells as a regulatory cell in mice 
In 1996, Wolf et al. demonstrated for the first time the role of the B cell as a 
regulatory cell in an animal model of Experimental Autoimmune Encephalomyelitis 
(EAE), an autoimmune central nervous system disease mediated by CD4+ T cells. They 
studied the participation of B cells in the induction and progression of EAE, and found 
that B cell-deficient mice exhibited a greater response in the disease onset and severity, 
compared to controls. Their data suggested that B cells did not play a role in the 
activation of encephalitogenic T cells, but played a role in the immune regulation of 
EAE through T cell deviation from Th1 to Th2 cytokines, possibly by altering peptide 
dose, complexity, or co-stimulation expression (Wolf et al. 1996).  
One year later, Mizoguchi et al. suggested that although B cells were not 
required for the initiation of colitis, they suppressed colitis, presumably by affecting the 
clearance of apoptotic cells (Mizoguchi et al. 1997). Although this may be true, years 
later, IL-10 production was proposed as the main regulatory mechanism used by B cells 
in EAE (Fillatreau et al. 2002) and arthritis (Mauri et al. 2003) in mice. The main IL-
10-producing cells were characterised as CD19+CD21hiCD23hiCD24hiCD1dhi cells and 
they were found after CD40 activation within the immature transitional two-marginal 
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zone precursor B cell subset (T2-MZP) in arthritis (Evans et al. 2007) and lupus (Blair 
et al. 2009) in mouse models. In addition, another study demonstrated that B cells 
immune-regulated autoimmune disease in a murine lupus model. CD19 deficient mice 
exhibited early pathologic manifestations of nephritis and reduced survival, compared to 
wild type mice (Watanabe et al. 2010). 
A regulatory role of the B cells was observed in diabetes. LPS-activated B cells, 
but not control B cells, expressed Fas ligand and secreted TGF-β. In addition, 
transfusion of activated B cells, but not control B cells, into pre-diabetic NOD mice, 
inhibited spontaneous Th1 autoimmunity, but did not promote Th2 responses to β cell 
autoantigens. These data suggested that activated B cells down-regulated pathogenic 
Th1 response via TGF-β production (Tian et al. 2001). 
Other studies revealed a protective role of B cells in inflammatory bowel disease. 
Mesenteric lymph node B cells protected mice from colitis induced by Gai2-/- CD4+ T 
and CD4+CD45RBhi T cells. B cells were associated with the induction of regulatory T 
cells in the mucosal immune homeostasis (Wei et al. 2005). 
Several mechanisms have been described for regulatory B cells in mice, 
especially in autoimmune diseases. Cell contact and cytokine secretion seem to be 
involved in B cell mediated-suppression. Knowing this, groups moved to humans to 
verify if these cells were also a playing an important role in different diseases.     
1.3.10 B cells as a regulatory cell in humans 
The identification of regulatory B cells in humans is not fully established and the 
first studies were based on the phenotype described in mice. The characterisation of 
human regulatory B cells present some similarities and some differences to the IL-10-
producing B cell subset in mice; for example, human B cells secreted IL-10 after CD40 
activation, the same way that B cells from mice did (Duddy et al. 2004; Jamin et al. 
2008); conversely, the main location of mouse B cells was from the spleen, whereas in 
humans, regulatory B cells were mainly located in the bone marrow and peripheral 
blood.  
To identify this subset, Sims and colleagues studied the phenotype of B cells 
during different stages of maturation. They revealed that the transitional population, 
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located in peripheral blood, was very similar to the phenotype exhibited by immature B 
cells from the bone marrow (Sims et al. 2005; Palanichamy et al. 2009).  
Interestingly, before the complete description of the transitional B cell 
phenotype in humans, these cells were related to immunodeficiency, as patients with 
severe immunodeficiency exhibited an increment of circulating immature/transitional B 
cells with a notorious reduction of circulating Memory B cells (Martinez-Maza et al. 
1987; De Milito et al. 2001). Expansion of functionally immature Transitional B cells 
was observed in human-immunodeficient states, characterised by impaired humoral 
immunity (Cuss et al. 2006). A novel form of primary immune disorder was also 
characterised with circulating B cells unable to respond to CpG stimulation. These cells 
exhibited the CD24hiCD38hiCD27- Transitional phenotype, and B cells from these 
patients did not proliferate and failed to secrete immunoglobulins after in vitro CpG 
stimulation (Plebani et al. 2007). 
Continuing with the characterisation, Transitional B cells exhibited low viability 
in humans. IL-4, CD40L and Mesenchymal Stem Cells (MSC) were able to increase the 
viability of these cells in culture (Sims et al. 2005; Cuss et al. 2006; Tabera et al. 2008; 
Lee et al. 2009), and to suppress B-cell terminal differentiation (Asari et al. 2009).  
Finally, as was mentioned previously, CD40–activated B cells IgD+IgM+CD86+ 
were able to inhibit the immune response, increasing the CD4 and the CD8 Treg 
population, demonstrating a regulatory role as an APC (Tu et al. 2008; Zheng et al. 
2009). In addition, CD19+CD24hiCD38hi regulatory B cells were able to inhibit CD4+ T 
cells pro-inflammatory cytokine production by cell-cell contact and IL-10 production, 
demonstrating a regulatory role as a cytokine producing cell (Blair et al. 2010). 
Interestingly, CD19+CD24hiCD38hi regulatory B cells from patients with systemic lupus 
erythematosus were impervious to CD40 stimulation, losing the regulatory properties 
exhibited in healthy individuals (Blair et al. 2010). Kidney transplant recipients that 
developed spontaneous tolerance after withdrawing immunosuppressive therapy 
exhibited an increased number of B cells and a B cell gene signature in peripheral blood, 
suggesting an unknown regulatory role in graft maintenance (Newell et al. 2010; Pallier 
et al. 2010; Sagoo et al. 2010). With this background a number of questions remain 
unanswered, particularly in transplantation tolerance. This thesis was proposed to test 
the following hypothesis and aims.       
67	  
	  
2 Hypothesis and Aims 
 
2.1 Transitional B cells are expanded in peripheral blood samples from 
tolerant kidney transplant recipients. 
 
Aims 
• Measure the percentage of the B cell subsets in kidney transplant patients 




2.2 Transitional B cells from tolerant recipients modulate an anti-




• Measure the expression of B cell activation markers and cytokine 
production after CD40L and CpG activation in B cells from kidney 
transplant patients and healthy controls to establish differences between 
B cell regulatory responses between groups. 
 
 
2.3 Transitional B cells are able to modulate active allogeneic responses 
and therefore play a key role in inducing donor-specific tolerance. 
 
Aims 
• Measure the percentage of donor-specific B cells and the CD4+ T cell 





2.4 Identification of B cell-related genes and measurement of their 
expression in kidney transplant patients would allow a better 
prediction of the outcome of a renal transplant.  
 
Aims 
• Analysis of genes tolerance-related in kidney transplant patients and 
healthy controls to find a relationship between the function of the genes 




2.5 Transitional B cells exhibit an anti-inflammatory response 
compared to Naïve and Memory B cells. 
 
Aims 
• Perform co-cultures between allogeneic CD4+ T cells and the different B 
cell subsets in order to study the participation of Memory, Naïve and 
Transitional B cells in the induction of T cell proliferation, activation and 




3 Materials and Methods 
 
3.1 Phenotypical and functional characterisation of B cell subsets in 
kidney transplant patients. 
3.1.1 Study purpose 
The purpose of this thesis was focused on identifying the role of Transitional B cells in 
renal transplant tolerance. Samples facilitated from the Genetic Analysis & Monitoring 
of Biomarker of Immunological Tolerance (GAMBIT) study were used in this research 
project.     
3.1.2 Study design 
The GAMBIT study is cross-sectional observational study established to validate a set 
of biomarkers of tolerance in kidney transplantation. Of the patients included in 
GAMBIT, the following ones have been used in this project:  
 
a) Tolerant: Functionally stable kidney transplant recipients (serum creatinine 
CRT < 160umol/l and < 10% rise in the last 12 months) despite having 
stopped all their immunosuppression for longer than one year 
 
b) Stable: Functionally stable kidney transplant recipients (serum creatinine 
CRT < 160umol/l and < 10% rise in the last 12 months) maintained with 
immunosuppressive agents. Recipients were age and gender matched to 
tolerant patients. 
 
c) Stable in Monotherapy: Functionally stable kidney transplant recipients 
(serum creatinine CRT < 160umol/l and < 10% rise in the last 12 months) 
maintained only with one immunosuppressive agent at a low dose. 
 
d) Chronic rejector: Kidney transplant recipients with graft dysfunction and a 




e) Healthy Control: Healthy volunteers, age and gender matched to tolerant 
patients.  
 
Patients that had been identified as tolerant for a period of time, but showed graft 
dysfunction eventually, have been identified as “Loss Tolerance”. Although these 
patients were also studied, their results have not been included in the statistical analysis 
used by the former patient groups, as only three patients were recruited.  
 
f) Loss Tolerance: Previous tolerant kidney transplant recipients that lost their 
state of tolerance and started to present signs of graft dysfunction. 
 
Peripheral blood and serum samples were taken after informed consent was obtained. 
The study was approved by the Institute of Child Health/Great Ormond Street Hospital 
Research Ethics Committee 09/H0713/12. All samples were processed and analysed in a 
blinded fashion. 
3.1.3 Recruitment sites  
Recruitment sites from the UK:  
 Guy’s Hospital, London.  
 The Evelina Children’s Hospital, London.  
 Great Ormond St Children Hospital, London.  
 Royal Free Hospital, London.  
 St George’s Hospital, London.  
 King’s College Hospital, London.  
 Salford Royal Hospital, Salford.  
 Cardiff and Vale University Health Board, Cardiff.  
 Queen Alexandra Hospital, Portsmouth.  
 Hull Royal Infirmary, Hull.  
 St James's University Hospital, Leeds.  
 Leicester General Hospital, Leicester.  
 Manchester Royal Infirmary, Manchester.  
 Northern General Hospital, Sheffield.  
 Kent and Canterbury Hospital, Kent.  
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 Glasgow General Hospital, Glasgow. 
 
Recruitment site from Switzerland:  
 INSELSPITAL, Universitätsspital, Bern. 
 
Recruitment site from Czech Replublic:  
 Transplantační laboratoř IKEM, Prague.  
 
Recruitment site from Spain: 
 Hospital Universitari Vall d'Hebrón, Barcelona.  
 
3.1.4 Inclusion and exclusion criteria 
Renal transplant patients from all groups with haemoglobin >10 mg/dL were included 
in the study. Patients with acute infection, Human Immunodeficiency Virus, active 
Hepatitis C Virus or Hepatitis B Virus were excluded from the study. 
3.1.5 Data collection 
Data collection included non-clinical and clinical parameters, transplant data and 
immunosuppressive therapy used; all these parameters have been described in Table 3. 
Data was collected from patient medical records and entered into an encrypted SQL 





Table 3: Clinical and demographic data of kidney transplant patients. 
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3.1.6 Blood and serum samples collection from kidney transplant patients and 
healthy controls  
Blood and serum samples collection from kidney transplant patients and healthy 
controls was performed by the team of research nurses from the GAMBIT study. All 
volunteers were maintained seated during 15 minutes prior to phlebotomy in order to 
eliminate possible interferences of blood distribution due to different posture. After this 
interval, a vein was located and blood samples were drawn using winged infusion set 
(butterfly needle, Greiner bio-one) directly into vacuum EDTA 
(Ethylenediaminetetraacetic acid) purple tubes (BD Vacutainer) and serum red tubes 
(BD Vacutainer). Blood sample tubes were properly labelled and delivered into the 
laboratory for further processing and storage. Three blood samples were collected 
between three to six months. 60ml of blood was collected in the two first samples each 
and 150ml of blood was collected in the last sample.    
3.1.7 Blood and serum samples processing and storage from kidney transplant 
patients and healthy controls 
PBMCs from patients and healthy controls were isolated from peripheral blood using 
Ficoll-Hypaque (PAA) density gradient centrifugation. Cells were washed, resuspended 
in 10% DMSO (Sigma-Aldrich) - AB human serum (BioWest) and frozen immediately 
at -80°C. After 24 hours, cells were stored in liquid nitrogen and kept until use. Serum 
samples were obtained after centrifugation of coagulated peripheral blood samples 
(2000RPM / 20min / room temperature), stored at -80°C and kept until use.  
 3.1.8 Spleen and lymph nodes samples 
Spleen and lymph nodes samples were obtained from cadaveric donors from spare 
material sent for cross monitoring to tissue typing laboratory. Samples were cut in 
pieces and mashed in gentleMAC C Tubes (Myltenyi Biotech) for 10 minutes. Cells 
were filtered twice, washed, resuspended in 10% DMSO (Sigma-Aldrich) - AB human 
serum (BioWest) and frozen immediately at -80°C. After 24 hours cells were stored in 
liquid nitrogen and kept until use.  
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3.1.9 B cell phenotypic analysis on PBMCs from kidney transplant patient and 
healthy controls 
PBMCs and cells obtained from spleen and lymph nodes were thawed from liquid 
nitrogen the same day of the staining. Cells were counted and 3x106 PBMCs, and 1x106 
cells from lymphoid tissues, were placed into 5ml polystyrene tube. To assess cell death, 
cells were stained with Live/Dead fixable yellow dead cell staining kit (Invitrogen) for 
10 minutes at 4°C. Then, cells were washed and stained with anti-CD19-AlexaFluor780 
(eBioscience), anti-CD20-AlexaFluor700 (eBioscience), anti-CD27-APC (eBioscience), 
anti-IgD-PE (BD), anti-IgM-PerCP-Cy5.5 (BD), anti-CD24-FITC (eBioscience) and 
anti-CD38-PECy7 for 30 minutes at 4°C. Stained cells were washed, resuspended in 
300ul of PBS and acquired on LSRFortessa (BD). LSRFortessa stability for patient 
samples was controlled with BD Cytometer Setup & Tracking Beads (CS&T) and 
application settings. Data was analysed using DIVA software (BD).  
3.1.10 B cell death and apoptosis measurement 
Standardisation of B cell death and apoptosis was performed in PBMCs, B cells and B 
cell subsets. 1x106 cells were stained with Live/Dead fixable yellow dead cell staining 
kit (Invitrogen) for 10 minutes at 4○C to assess cell death. Then, cells were washed and 
stained with anti-BAFFr-FITC (eBioscience) for 30 minutes at 4○C. Cells were washed, 
resuspended in 500ul of AnnexinV 1X Binding Buffer (eBioscience) and stained with 
AnnexinV-eFluor450 (eBioscience) for 10 minutes at 4○C; both staining were 
performed to assess apoptosis. Finally, cells were resuspended in 300ul of AnnexinV 
1X Binding Buffer (eBioscience) and acquired on LSRFortessa (BD). Data was 
analysed using FlowJo (Tree Star, Inc. Ashland, OR 97520. USA).  
Apoptotic B cells from kidney transplant patients were measured by surface staining 
with Live/Dead dye (Invitrogen) and anti-BAFFr-FITC (eBioscience). Finally, the 
viability of the B cell subsets from healthy volunteers was evaluated in the presence of 
tacrolimus (Sigma-Aldrich), mycophenolate mofetil (MMF) (CellCept, Roche) and 
steroids (SOLU-CORTEF, Pharmacia) in vitro. Cells were incubated in the presence of 
tacrolimus 0-25ng/ml, MMF 0-25ug/ml or steroids 0-500ng/ml overnight and 
Live/Dead dye and BAFFr staining were performed the next day to evaluate cell death 
and apoptosis. Cells were acquired on LSRFortessa (BD) and a minimum of 10.000 B 
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cell events were collected per sample. Data was analysed using FlowJo (Tree Star, Inc. 
Ashland, OR 97520. USA).      
3.1.11 CD20 and CD19 Median Fluorescence Intensity (MFI) analysis 
MFI of CD20 and CD19 (anti-CD20-AlexaFluor700 and anti-CD19-AlexaFluor780 
(eBioscience)) was obtained from statistical data extracted from the B cell panel 
described in Methods 3.1.9. B cell markers co-localisation was performed in PBMCs 
stained with anti-CD19-AlexaFluor780 (eBioscience), anti-CD20-AlexaFluor700 
(eBioscience), anti-CD27-APC (eBioscience), anti-IgD-PE (BD), anti-IgM-PerCP-
Cy5.5 (BD), anti-CD24-FITC (eBioscience) and anti-CD38-PECy7 for 30 minutes at 
4°C. Data was acquired on a FlowSight system equipped with four lasers, running with 
Inspire software, and analysed with IDEAS 3.0 software (all from AMNIS Corp, Seattle, 
WA, USA). Delta-centroid, polarisation and co-localisation of B cell markers were 
assessed with specific features/masks within IDEAS 3.0. A minimum of 100.000 B cell 
events were acquired per sample. 
 
3.1.12 B cell functional assays in response to CD40L and CpG activation measured 
in kidney transplant patient and healthy control’s PBMCs   
PBMCs and mouse L fibroblast (L cells) were thawed 24 hours before all functional 
assays. CD40L-transfected and non-transfected L cells were thawed, washed, 
resuspended in 1ml of complete media and X-ray irradiated for 30 minutes, receiving a 
total dose of 9045 cGy (RADS) (The Gammacell 1000, Elite). 0.5x105 CD40L-
transfected and non-transfected L cells were cultured in 48-well plates (Nunc, 
Langenselbold, Germany) overnight. Expression of CD40L in transfected and non-
transfected L cells was measured by surface staining using an anti-CD40L-PE 
(eBioscience) antibody. PBMCs from kidney transplant patients and healthy controls 
were thawed, washed and rested overnight in RPMI-1640 (Sigma) supplemented with 
2mM L-Glutamine (Gibco, Invitrogen), 100U/mL penicillin, 100mg/mL streptomycin 
(Gibco, Invitrogen) and 10% of Foetal Calf Serum (FCS) (SeraQ, Sussex, UK) in 24-
well plates (Nunc, Langenselbold, Germany) at 37°C 5% CO2. The day of the 
experiment, 1x106 PBMCs were cultured with and without 0.5x105 plate bound CD40L-
transfected L cells, 0.5x105 plate bound non-transfected L cells and CpG (1uM) (ODN 
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2006, InvivoGen) for 72hours. After 3 days, activation markers CD86-FITC 
(eBioscience), CD40-APC (eBioscience) and CD25-PE (eBioscience) were measured 
by surface staining in total, Memory and CD27- B cells after CD40 activation. TLR-9 
expression was measured in CpG-activated and non-activated B cells by intracellular 
staining using an anti-TLR-9-PE (eBioscience) antibody. Cytokine production (IL-10, 
IFN-γ and TNF-α) from CD40- and CpG-activated B cells was measured using 
intracellular staining and ELISA.  
3.1.13 Intracellular Staining 
Cells were activated with Phorbol 12-myristate 13-acetate (PMA) (50ng/mL, SIGMA), 
ionomicyn (1ug/mL, SIGMA), GolgiStop (1X, BD) and Brefeldin A (1X, BD) for 5 
hours in new culture media at 37°C 5% CO2. Cells were washed with PBS and stained 
with Live/Dead reagent for 10 minutes at 4°C. Cells were washed again and stained 
with anti-CD20-AlexaFluor780 (eBioscience) and anti-CD3-Pacific Blue for 30 minutes 
at 4°C. Cells were then fixed and permeabilised with FoxP3 Fix and Perm Kit (BD) 
before the intracellular staining with anti-IL-10-PE (BD), anti-IFN-γ-APC (eBioscience) 
and anti-TNF-α-PECy7 (eBioscience) for 30 minutes at 4°C. Samples were acquired on 
LSRFortessa (BD) within 24 hours and data was analysed using DIVA software (BD). 
3.1.14 ELISA 
Enzyme-linked immunosorbet assay (ELISA) (R&D) (eBioscience) was performed 
according to manufacturer’s instructions. Briefly, 96-well plates (NuncTM, Maxisorb, 
Thermo Scientific) were coated and incubated overnight with 100ul/well of mouse anti-
human IL-10 (eBioscience), mouse anti-human IFN-γ (R&D) and mouse anti-human 
TNF-α (R&D) at working concentrations. Plates were washed three times with 0.05% 
Tween 20 (Sigma) in PBS and blocked for 1 hour at room temperature with 300ul/ml 
freshly made filtered 1% bovine serum albumin (BSA) in PBS (w/v). Plates were 
washed and 100ul/well of standards and supernatant were added in triplicate for 2 hours 
at room temperature. Standard curves were prepared by serial two-fold dilutions from 
the maximum concentration recommended by the manufacturer (300pg/ml for IL-10, 
and 1000pg/ml for IFN-γ and TNF-α). 100ul/well of detection antibodies were added at 
the working concentrations for 2 hours at room temperature. Plates were washed and 
100ul/well of streptavidin-HRP (horseradish peroxidase) was added for 20 minutes at 
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room temperature. After final washes, plates were incubated with 100ul/well of 
tetramethylbenzidine (TMB) (eBioscience) for 10 minutes at room temperature and 
reaction was stopped adding 50ul/well of 2N sulphuric acid (H2SO4). Optical density at 
405nm was measured using Sunrise ELISA Reader (TECAN, UK). The concentration 
of each cytokine was calculated from standard curves using Magellan data analysis 
Software. 
3.1.15 CD40 and CpG activation in sorted B cell subsets 
CD40 and CpG activation functional assays in sorted B cell subsets were performed to 
analyse the IL-10 activation pathway in Memory, Naïve and Transitional B cells. 
Peripheral blood (cones) from healthy volunteers was used to obtain B cell subsets. 
Blood was incubated with Rosettsep Human B cell enrichment cocktail (STEM CELL) 
for 20 minutes at room temperature prior Ficoll-Hypaque density gradient centrifugation. 
After gradient separation, isolated B cells were obtained from the mononuclear layer 
(purity >70%). Cell viability was determined using trypan-blue exclusion. Cells were 
stained with anti-CD20-Pacific Blue (eBioscience), anti-CD27-APC (eBioscience), anti-
CD24-PerCP-Cy5.5 (BD), anti-CD38-PECy7 (eBioscience) and Live/Dead fixable 
yellow dead cell staining kit (Invitrogen) for 30 minutes 4°C. B cell subsets were sorted 
using ARIA II (BD). Memory B cells were selected as CD20+CD27+ (purity >95%), 
Naïve B cells were selected as CD20+CD27-CD24+CD38+ (purity >95%) and 
Transitional B cells were selected as CD20+CD27-CD24hiCD38hi (purity >95%) (Table 
4). 0.5x105 B cells subsets were cultured in complete media supplemented with IL-2 
(100ng/ml, R&D) with and without 1.0x104 CD40L-transfected L cells, 1.0x104 non-
transfected L cells or CpG (1uM) (ODN 2006, InvivoGen) for 72 hours at 37°C 5% 
CO2. After 3 days, IL-10 and TNF-α were measured using intracellular staining 




Table 4: B cell sort 
B cells were pre-enriched using CD20 Rosettsep. Isolated B cells were stained and Memory 
(CD20+CD27+), Naïve (CD20+CD27-CD24+CD38+) and Transitional (CD20+CD27-CD24hiCD38hi) B 
cells were sorted using ARIA II. Purity was checked using flow cytometry. B cell subsets presented >95% 









3.2 BCR signalling pathway activation and donor-specific response in 
kidney transplant patients. 
3.2.1 Measurement of phosphorylated proteins after BCR activation 
Phosphorylation of BTK, BLNK and ERK was assessed by phospho-flow (Picture 6). 
Isolated B cells from healthy volunteers were thawed and rested overnight in RPMI-
1640 (Sigma) supplemented with IL-2 (100ng/ml, R&D) at 37°C 5% CO2. Next day, 
1x106 cells were placed in 5ml polystyrene tubes and activated with anti-IgM 
(20ug/ml)/anti-IgG (20ug/ml) (Southern Biotech) antibodies and PMA (0.1uM, SIGMA) 
for 0, 5 and 10 minutes at 37°C. Cells were fixed with BD Cytofix buffer (BD) for 10 
minutes at 37°C. For BTK and ERK staining, cells were permeabilised with BD 
Phosflow Perm Buffer III (BD) for 30 minutes on ice, and then stained with anti-
ERK1/2 (pT202/pY204)-AlexaFluor488 (BD) and anti-BTK (pY551/ltk pY511)-PE 
(BD) for 30 minutes at 4°C. For BLNK staining, cells were permeabilised with BD 
Phosflow Perm/Wash Buffer I (BD) for 30 minutes at room temperature, and then 
stained with anti-BLNK (pY84)-AlexaFluor647 (BD) for 30 minutes at 4°C. Cells were 
acquired on an LSRFortessa (BD) within 24 hours. Data was analysed using FlowJo 
(Tree Star, Inc. Ashland, OR 97520. USA).      
3.2.2 Activation curve 
In order to identify the optimal activation period, isolated B cells from healthy 
volunteers were activated with anti-IgM (20ug/ml)/anti-IgG (20ug/ml) antibodies 
(Southern Biotech) and PMA (0.1uM, SIGMA) for 0, 10 and 30 minutes at 37°C. In 
order to test the effect of co-activation with CD40L, isolated B cells from healthy 
volunteers were activated with anti-IgM (20ug/ml)/anti-IgG (20ug/ml) (Southern 
Biotech) with and without 0.5x105 CD40L-trasnfected L cells for 10 minutes at 37°C. 
Cells were acquired on an LSRFortessa (BD) within 24 hours. Data was analysed using 
FlowJo (Tree Star, Inc. Ashland, OR 97520. USA).      
3.2.3 Inter and intra assay control  
Inter and intra assay controls were used to maintain the experimental settings stable 
over time. PBMCs from a healthy volunteer sample (control samples) were divided in 
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aliquots and stored in liquid nitrogen. Measurement of inter assay control was 
performed as follows: An aliquot from the control sample was thawed and rested in 
RPMI-1640 (Sigma) supplemented with IL-2 (100ng/ml, R&D) at 37°C 5% CO2 
overnight. Next day, cells were stained with CD20-Pacific Blue (eBioscience), CD27-
APC (eBioscience), CD24-PE (eBioscience), CD38-PECy7 (eBioscience) and 
Live/Dead fixable yellow dead cell staining kit (Invitrogen) for 20 minutes at 37○C 5% 
CO2. After the staining, PBMCs were divided in 6 5ml polystyrene tubes 
(1.0x106cells/tube) and activated with anti-IgM (20ug/ml)/anti-IgG (20ug/ml) (Southern 
Biotech) for 0 and 10 minutes at 37°C. Cells were stained for ERK-p and samples were 
acquired on an LSRFortessa (BD) within 24 hours. Data was analysed using FlowJo 
(Tree Star, Inc. Ashland, OR 97520. USA) and delta ERK-p was calculated for each 
subset. For intra assay control, an aliquot from the control sample was thawed, stained, 
activated and acquired every time an experiment with patients was performed. Delta 
ERK-p from patient samples was normalized with delta ERK-p from the control sample.  
3.2.4 B cell functional assays in response to BCR activation measured in kidney 
transplant patient and healthy control’s PBMCs   
PBMCs from patients and healthy controls were thawed and rested in RPMI-1640 
(Sigma) supplemented with IL-2 (100ng/ml, R&D) at 37°C 5% CO2 overnight. Next day, 
cells were stained with CD20-Pacific Blue (eBioscience), CD27-APC (eBioscience), 
CD24-PE (eBioscience), CD38-PECy7 (eBioscience) and Live/Dead fixable yellow 
dead cell staining kit (Invitrogen) for 20 minutes at 37○C 5% CO2. After the staining, 
3x106 PBMCs were divided in 4 5ml polystyrene tubes and activated with anti-IgM 
(20ug/ml)/anti-IgG (20ug/ml) (Southern Biotech) for 0, 10 and 30 minutes and with 
PMA (0.1uM, SIGMA) for 10 minutes at 37°C. Cells were fixed with BD Cytofix 
buffer (BD) for 10 minutes at 37°C, permeabilised with BD Phosflow Perm Buffer III 
(BD) for 30 minutes on ice and stained with anti-ERK1/2 (pT202/pY204)-
AlexaFluor488 (BD) for 30 minutes at 4°C. Cells were acquired on an LSRFortessa 
(BD) within 24 hours and data was analysed using FlowJo (Tree Star, Inc. Ashland, OR 
97520. USA). Delta ERK-p was calculated in total B cell and B cell subsets from 
healthy control and patient samples, and their data was normalized using delta ERK-p 
obtained from the control sample.  





Picture 6: BCR signalling pathway showing proteins measured by phospho-flow in red 
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3.2.5 Staining and isolation of membrane and cytosolic proteins  
PBMCs of interest were thawed from liquid nitrogen the same day of protein 
preparation. MHC expression was enriched removing CD2+ cells from PBMCs samples 
using anti-CD2 beads (Miltenyi). 20x106 PBMCs were incubated with 100ul of anti-
CD2 beads for 15 minutes at 4°C. Cells were washed, counted, and CD2- cells were 
stained with CFSE (5uM) for 20 minutes at 37°C. The reaction was stopped with 10ml 
of cold FBS for 5 minutes at 4°C and cells were washed two times with cold PBS. 
Stained cells were used to obtain proteins preparations. Membrane proteins from CFSE+ 
cells were extracted with Mem-PER Eukaryotic Membrane Protein Extraction Reagent 
Kit (PIERCE). 5x106 CFSE+ cells (per eppendorf tube) were washed and resuspended in 
150ul of Reagent A for 10 minutes at room temperature. Cells were washed and 
resuspended in 450ul of Reagent B/C for 30 minutes on ice vortexing every 5 minutes. 
Samples were centrifuged at 10,000xg for 3 minutes at 4°C and supernatants were 
removed and placed into new tubes for 10 minutes at 37°C to separate the membrane 
protein fraction. Samples were centrifuged again at 10,000xg for 2 minutes at room 
temperature to isolate the hydrophobic fraction containing membrane protein (bottom 
layer) from the hydrophilic fraction (top layer). The hydrophilic fraction was carefully 
removed and both fractions were collected in new tubes and stored at -80°C. The 
staining of membrane and hydrophilic proteins was checked by flow cytometry 
measuring the positive signal in the FITC channel. Membrane proteins (+100ul) were 
placed into Slide-A-Lyzer MINI Dialysis Devices, 10K MWCO (Thermo Scientific) for 
further dialysis. First, dialysis was performed during 3 hours at 4°C against 1000ml of 
0.5% CHAPS 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate 
(Biovision) dialysis buffer, then, dialysis buffer was changed and a second dialysis was 
performed overnight at 4°C. After dialysis, protein concentration was measured with 
Pierce BCA Protein Assay Kit (Thermo Scientific). 25ul of sample replicates and 
standard were placed into a 96-well plate (NuncTM, Maxisorb, Thermo Scientific). After 
adding 200ul of BCA Working Reagent (WR), samples were mixed for 30 seconds and 
plate was covered and incubated at 37°C for 30 minutes. Plate was cooled at room 
temperature and optical density at 562nm was measured using Sunrise ELISA Reader 
(TECAN, UK). Samples tubes were labelled and stored at -80°C. Control samples were 




3.2.6 Identification of CFSE+ membrane and cytosolic proteins by western blot 
In order to perform western blot, equal protein concentration was adjusted in all samples. 
20ug of proteins were mixed with 2X Laemmli Sample Buffer, and samples were boiled 
at 100°C for 5 minutes. Equal amount of proteins was loaded into the wells of the Mini 
Protean Precast Gels 4-15% gradient (BIO-RAD), including a molecular weight marker 
kaleidoscope pre-stained standard (BIO RAD). Electrophoresis was performed 2 hours 
at 100V in running buffer (Tris-Glycine/SDS: 25mM Tris-base (Fisher Scientific), 
190mM Glycine (Fisher Scientific) and 0.1% SDS (SIGMA)). Proteins were transferred 
to a nitrocellulose membrane (BIO RAD for 2 hours at 120V using transfer buffer 
(48mM Tris (Fisher Scientific), 39mM glycine (Fisher Scientific), 20% methanol 
(SIGMA) and 0.04% SDS (SIGMA)). Transfer efficiency was checked using Ponceau 
Red staining (Thermo Scientific). Membrane was blocked for 1 hour at room 
temperature using blocking solution (3g of Skimmed Milk in 100ml PBS). Membrane 
was incubated with a primary Anti-MHC class I (ab52922) diluted 1/1000 (Abcam) 
antibody or Anti-MHC class II antibody (ab55152) diluted 1/1000 (Abcam) in blocking 
solution overnight at 4°C or for 2 hours at room temperature. Membrane was washed, 
three times with PBS 5% Tween20 (Sigma) for 5 minutes each, and incubated with a 
secondary anti-mouse IgG conjugated to HRP diluted 1/20000 (GE Healthcare, Life 
Sciences) antibody in blocking solution at room temperature for 1 hour. Membrane was 
washed, three times with PBS 5% Tween20 (Sigma) for 5 minutes each, covered with 
2ml of Pierce ECL Western Blotting Substrate (Thermo Scientific) and wrapped in 
transparent film. Protein detection was performed exposing the membrane to a film 
(Amersham), and development was performed using Compact X4 Automatic X-ray 
Film Processor (Xograph). 
3.2.7 Positive controls for protein capture 
Two positive controls were used in the capture assay. The first control was a 
husband/wife pair sample in which the wife has been pregnant three times. In this case, 
the positive control corresponded to husband proteins recognised by wife B cells and 
the negative control corresponded to autologous wife proteins. CFSE+ B cells were 
analysed by flow cytometry and ImageStream. The second control pair sample was a 
kidney transplant patient with known anti−HLA antibodies. In this case, the positive 
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control proteins were prepared from samples with MHC recognised by recipient 
antibodies and negative control was prepared from samples with MHC not recognised 
by recipient antibodies. In the second samples, CFSE+ B cells and CFSE+ monocytes 
were analysed by flow cytometry. Cells were acquired on an LSRFortessa (BD) within 
24 hours. Data was analysed using FlowJo (Tree Star, Inc. Ashland, OR 97520. USA).       
3.2.8 Location of CFSE+ donor-proteins  
PBMCs from the first positive control were thawed and cultured overnight in complete 
media supplemented with IL-2 (100ng/ml, R&D) at 37°C 5% CO2 before activation. 
The next day, 0.5ug/ml of CFSE+ membrane and cytosolic proteins from the first 
positive controls (husband and wife) were cultured in the presence of 5x106 PBMCs 
from the positive control sample (wife), 24 hours at 37°C. Next day, cells were 
harvested and CFSE+ proteins were identified by flow cytometry and ImageStream. For 
flow cytometry, 1x106 PBMCs were stained with anti-CD20-eFluor450 (eBioscience), 
anti-CD27-APC (eBioscience), anti-CD24-PE (eBioscience), anti-CD38-PECy7 
(eBioscience) and Live/Dead yellow for 30 minutes at 4°C. Cells were acquired on an 
LSRFortessa (BD) within 24 hours. Data was analysed using FlowJo (Tree Star, Inc. 
Ashland, OR 97520. USA). Regarding ImageStream, 9x106 PBMCs were stained with 
anti-CD20-AlexaFluor780 (eBioscience), anti-HLA-DR-PE (eBioscience) and 
Live/Dead yellow for 30 minutes at 4°C. B cells were sorted as Live/Dead-CD20+HLA-
DR+ B cells using ARIA II (BD). Isolated B cell were analysed by ImageStream. Data 
was acquired on an ImageStreamX system equipped with three lasers and running with 
Inspire software (both AMNIS Corp, Seattle, WA, USA). IDEAS 3.0 software (AMNIS) 
was used for analysis. Intensity of CD20 and HLA-DR was masked in the cell surface 
and localisation with CFSE+ proteins was assessed using the internalisation feature 
between CFSE+ proteins and CD20+HLA-DR+ intensity masked in the cell surface. 
3.2.9 Identification of donor-proteins capture by recipient B cells from kidney 
transplant patients  
PBMCs from recipients were thawed and cultured overnight in complete media 
supplemented with IL-2 (100ng/ml, R&D) at 37°C 5% CO2 before activation. The next 
day, 0.1ug/ml of CFSE+ membrane and cytosolic proteins from donor or recipient 
samples were cultured with 2.5-5x106 PBMCs from the appropriate recipient samples 
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for 24 hours at 37°C. Next day, PBMCs were stained with anti-CD20-eFluor450 
(eBioscience), anti-CD27-APC (eBioscience), anti-CD24-PE (eBioscience), anti-CD38-
PECy7 (eBioscience) and Live/Dead yellow for 30 minutes at 4°C. Samples were 
analysed by flow cytometry to identify donor CFSE+ proteins in recipient B cells. Cells 
were acquired on an LSRFortessa (BD) within 24 hours. Data was analysed using 
FlowJo (Tree Star, Inc. Ashland, OR 97520. USA). 
3.2.10 CD4+ T cells antigen-specific activation mediated by B cells from kidney 
transplant patients and healthy controls 
IFN-γ/IL-10 dual-ELISPOT (R&D) was used to measure antigen-specific activation on 
CD4+ T cells elicited by autologous B cell subsets from kidney transplant patient. Cell 
preparation was performed as described below. PBMCs from recipients were thawed 
and cultured overnight in complete media supplemented with IL-2 (100ng/ml, R&D) at 
37°C 5% CO2 before activation. Next day, CD4+ T cells were obtained by positive 
selection using anti-CD4 beads (Miltenyi). B cells were enriched by negative selection. 
CD2+, CD3+ and CD14+ cells were removed from PBMCs samples using anti-CD2, 
anti-CD3 and anti-CD14 beads (Miltenyi). Enriched B cell samples from recipients 
were stained with anti-CD20-eFluor450 (eBioscience), anti-CD27-APC (eBioscience), 
anti-CD24-PerCP-Cy5.5 (BD), anti-CD38-PECy7 (eBioscience) and Live/Dead yellow 
(Invitrogen) for 30 minutes at 4°C. Cells were washed and B cell subsets from 
recipients were sorted using ARIA II (BD). Memory B cells were CD20+CD27+ 
(purity >95%), Naïve B cells were CD20+CD27-CD24+CD38+ (purity >95%) and 
Transitional B cells were CD20+CD27-CD24hiCD38hi (purity >95%).  
IFN-γ/IL-10 dual-ELISPOT plate (R&D) was blocked using 200ul of complete media 
for 30 minutes at room temperature. Plates were washed and 100ul containing 1x105 
recipient CD4+ T cells in complete media supplemented with IL-2 (100ng/ml, R&D) 
were added per well. 1.0x105 CD4+ T cells were cultured alone, with 0.5x105 
autologous Memory, Naïve or Transitional B cells with and without 0.1ug/ml of CFSE+ 
membrane and cytosolic proteins obtained from donor samples during 72 hours at 37°C 
5% CO2. After 3 days, cells were collected and CD25 and CD86 activation markers 
were measured in CD4+ T cell and CD20+ B cells, respectively, by surface staining 
using anti-CD25-PE (eBioscience) and anti-CD86-FITC (eBioscience) antobodies. Cells 
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were acquired on an LSRFortessa (BD) within 24 hours. Data was analysed using 
FlowJo (Tree Star, Inc. Ashland, OR 97520. USA).  
IFN-γ/IL-10 dual-ELISPOT plate was washed 3 times with 300ul/well of wash buffer, 
100ul/well of diluted detection antibody mixture was added, and the plate was incubated 
overnight at 4°C. Next day, the plate was washed and 100ul/well of diluted 
Streptavidin-AP was added for 2 hours at room temperature. Plate was washed again, 
and 100ul/well of BCIP/NBT chromogen was added for 1 hour at room temperature 
protected from light. BCIP/NBT chromogen was decanted and rinsed with deionised 
water. Plate was then inverted to remove excess water. 100ul/well of AEC chromogen 
solution was added for 20 minutes at room temperature protected from light. AEC 
chromogen solution was decanted and rinsed with deionised water. Plate was inverted to 
remove excess water and the flexible plastic under-drain was removed. After draying 
the plate at room temperature for 90 minutes, IFN-γ and IL-10 spots were counted using 
The AID iSpot reader system (AID, Oxford Biosystems Cadama).  
3.2.11 HLA antibodies detection 
Aliquots of frozen serum samples from kidney transplant patient were thawed just 
before the assay. Aggregates were removed from the serum by centrifugation (8,000- 
10,000G for 10 minutes) or filtration (0.2mm) prior to testing. LABScreen (One 
Lambda, Inc) beads were mix by gently vortexing or pipetting up and down several 
times prior to use. After mixing, 5ul of beads were incubated with 20ul of serum sample 
in a 96-well plate for 30 minutes in the dark at 25º C with gentle shaking. After 
incubation, plate was washed two times with 1X wash buffer. The plate was covered 
with tray seal (OLI Cat. #SSPSEA300), agitated and centrifuged 1,300G for 5 minutes 
to remove excess of wash buffer. 1X of PE-conjugated anti-human IgG (OLI Cat # LS-
AB2) was incubated in the dark for 30 minutes at 25º C. The plate was washed to 
remove the excess of PE-IgG and 80ul of PBS was added per well. The sample was 
ready for data acquisition and analysis. Data was acquired in a Luminex LX100 





3.3 The effect of B cell subsets as CD4+ T cells-activating cells. 
3.3.1 Cell culture media 
All cell cultures were grown using RPMI-1640 (Sigma) supplemented with 2mM L-
Glutamine (Gibco, Invitrogen), 100U/mL penicillin, 100mg/mL streptomycin (Gibco, 
Invitrogen) and 10% of Foetal Calf Serum (FCS) (SeraQ, Sussex, UK). 
3.3.2 Isolation of CD4+ T cell and CD20+ B cell from peripheral blood (cones) 
Peripheral blood (cones) from healthy volunteers was used to obtain CD4+ T cells and 
CD20+ B cells. Samples were diluted 1:2 with PBS 2% Bovine Serum Albumin (BSA) 
and 50ul/ml of RosettSep Human B cell enrichment cocktail and RosettSep Human 
CD4+ T cell enrichment cocktail (STEM CELL) was added to the corresponding sample 
for 20 minutes at room temperature. Samples were diluted again 1:4 with PBS 2% BSA 
and CD4+ T cells and CD20+ B cells were obtained directly from the mononuclear 
fraction obtained after Ficoll-Hypaque density gradient centrifugation. CD4+ T cells and 
CD20+ B cells were washed two times, counted and resuspended in PBS. 
3.3.3 Preparation of CD4+ T cell  
CD4+ T cells were stained with 1uM CellTrace Violet Cell Proliferation Kit (Invitrogen) 
for 20 minutes at 37°C protected from light. Unbound dye was quenched adding cold 
FCS for 5 minutes at 4°C. CD4+ T cells were washed two times, resuspended in 
complete media supplemented with IL-2 (100ng/ml, R&D) and placed in anti-CD3 
(1ug/ml, SIGMA) pre-coated plates. 1x106 of CD4+ T cells/well and 0.5x106 of CD4+ T 
cells/well were cultured 6 hours in anti-CD3 pre-coated plates before the addition of the 
B cell subsets. 
3.3.4 CD20+ B cell sorting 
B cells were counted and 60x106 cells were resuspended in 200ul of PBS. B cells were 
stained with anti-CD20-Pacific Blue (eBioscience), anti-CD27-APC (eBioscience), anti-
CD24-PerCP-Cy5.5 (BD), anti-CD38-PECy7 (eBioscience) and Live/Dead fixable 
yellow dead cell staining kit (Invitrogen) for 30 minutes 4°C. B cell subsets were sorted 
with ARIA II (BD). Memory B cells were CD20+CD27+ (purity >95%), Naïve B cells 
were CD20+CD27-CD24+CD38+ (purity >95%) and Transitional B cells were 
CD20+CD27-CD24hiCD38hi (purity >95%) (Table 4). 
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3.3.5 CD4+ T cell - B cell subsets co-cultures 
Large Scale experiment: 1x106 CD4+ T cells/well were cultured with and without 
0.5x106 sorted B cell, Memory, Naïve or Transitional B cells in 48 well-plates for 5 
days at 37°C 5% CO2. 1x106 CD4+ T cells/well were cultured with 0.5x106 B cell 
subsets in the presence or absence of 0.1ng/ml anti-IL-10R (R&D). 
Time Course experiments: 0.5x106 CD4+ T cells/well were cultured with and without 
0.5x106 sorted B cell, Memory, Naïve or Transitional B cells in 96 well-plates for 1, 3 
and 5 days at 37°C 5% CO2. 
After culture, CD4+ T cells and B cell subsets were collected and tested for CD4+ T cell 
proliferation, CD4+ T cell and CD20+ B cell activation, CD4+ T cell and CD20+ B cell 
cytokine production and CD20+ B cell viability.  
3.3.5.1 Flow cytometry: Proliferation  
CD4+ T cells were previously stained with CellTrace Violet Cell Proliferation Kit 
(Invitrogen). Cells from T cell - B cell co-cultures were stained with anti-CD20-
AlexaFluor780 (eBioscience) and anti-CD3-PerCP-Cy5.5 and Live/Dead fixable yellow 
dead cell staining kit (Invitrogen) for 30 minutes at 4°C. Cells were acquired on an 
LSRFortessa (BD) within 24 hours. Data was analysed using FlowJo (Tree Star, Inc. 
Ashland, OR 97520. USA).       
3.3.5.2 Flow cytometry: Activation markers 
Cells from T cell -B cell co-cultures were stained with anti-CD20-AlexaFluor780 
(eBioscience) and anti-CD3-PerCP-Cy5.5 (BD), anti-CD25-APC (eBioscience), anti-
CD69-FITC (eBioscience), anti-CD86-PE (eBioscience), anti-CD40L-PE (eBioscience) 
and Live/Dead fixable yellow dead cell staining kit (Invitrogen) for 30 minutes at 4°C. 
Cells were acquired on an LSRFortessa (BD) within 24 hours. Data was analysed using 
FlowJo (Tree Star, Inc. Ashland, OR 97520. USA).       
3.3.5.3 Flow cytometry: Cytokine Production 
Intracellular staining and ELISA were performed to measure IL-10, IFN-γ and TNF-α. 
Cells were activated with PMA (50ng/mL), ionomicyn (1ug/mL), GolgiStop (BD) and 
Brefeldin A (BD) for 5 hours in new culture media at 37°C 5% CO2. Cells were fixed 
and permeabilised with FoxP3 Fix and Perm Kit (BD) and stained with IL-10-PE (BD), 
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IFN-γ-APC (eBioscience) and TNF-α-PECy7 (eBioscience) for 30 minutes at 4°C. 
Cells were acquired on an LSRFortessa (BD) within 24 hours. Data was analysed using 
FlowJo (Tree Star, Inc. Ashland, OR 97520. USA).      
3.3.5.4 Flow cytometry: B cell viability 
Live/Dead fixable yellow dye up-take and expression of BAFFr were used to assess cell 
death and apoptosis in the B cell subsets. Cells from T cell - B cell co-cultures were 
stained with anti-CD20-AlexaFluor780 (eBioscience) and anti-CD3-PerCP-Cy5.5, anti-
BAFFr-FITC (eBioscience) and Live/Dead fixable yellow dead cell staining kit 
(Invitrogen) for 30 minutes at 4°C. Cells were acquired on an LSRFortessa (BD) within 




3.4 Genes differentially expressed in B cells from kidney transplant 
patients and healthy controls. 
3.4.1 B cells isolation from kidney transplant patients and healthy controls 
PBMCs samples were thawed from liquid nitrogen the same day of the staining. CD20+ 
B cells were enriched by negative selection with anti-CD3, anti-CD4 and anti-CD14 
beads (Miltenyi). Enriched B cell samples from recipients and healthy controls were 
stained with anti-CD20-eFluor450 (eBioscience) and Live/Dead yellow (Invitrogen) for 
30 minutes at 4°C. Cells were washed and live B cells were sorted using ARIA II (BD). 
CD20+ B cells purity was >95%. B cells were then washed with PBS two times and 
resuspended in 1ml of Trizol (BioLine). Vials containing kidney transplant recipients 
and healthy controls B cell samples in Trizol were shipped to Miltenyi Biotec on dry ice 
in two shipments. 
3.4.2 Quality control (QC) of total RNA 
RNA was isolated using standard RNA extraction protocols. RNA samples were 
quality-checked via the Agilent 2100 Bioanalyzer platform (Agilent Technologies). The 
results of the Bioanalyzer run were visualised in a gel image and an electropherogram 
using the Agilent 2100 Bioanalyzer expert software (data not shown). In addition to this 
visual control, the software generated an RNA Integrity Number (RIN) to check 
integrity and overall quality of total RNA samples. The RIN value was calculated by a 
proprietary algorithm that takes several QC parameters into account, for example, 28S 
RNA/18S RNA peak area ratios and unexpected peaks in the 5S RNA region. A RIN 
number of 10 indicated high RNA quality, and a RIN number of 1 indicates low RNA 
quality. According to published data and Miltenyi Biotec experience, RNA with a RIN 
number >6 is of sufficient quality for gene expression profiling experiments. 
3.4.3 Linear T7-based amplification of RNA 
For the linear T7-based amplification step, 20-50ng (depending on the available amount) 
of each total RNA sample was used. To produce Cy3-labeled cRNA, the RNA samples 
were amplified and labelled using the Agilent Low Input Quick Amp Labeling Kit 
(Agilent Technologies) following the manufacturer’s protocol. Yields of cRNA and the 
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dye-incorporation rate were measured with the ND-1000 Spectrophotometer (NanoDrop 
Technologies). 
3.4.4 Hybridisation of Agilent Whole Genome Oligo Microarrays 
The hybridisation procedure was performed according to the Agilent 60-mer oligo 
microarray processing protocol using the Agilent Gene Expression Hybridization Kit 
(Agilent Technologies). Briefly, 600ng Cy3-labeled fragmented cRNA in hybridisation 
buffer was hybridised overnight (17 hours, 65°C) to Agilent Whole Human Genome 
Oligo Microarrays 8x60K using Agilent’s recommended hybridisation chamber and 
oven. Finally, the microarrays were washed once with the Agilent Gene Expression 
Wash Buffer 1 for 1 minute at room temperature followed by a second wash with 
preheated Agilent Gene Expression Wash Buffer 2 (37°C) for 1 minute. The last 
washing step was performed with acetonitrile. 
3.4.5 Scanning results 
Fluorescence signals of the hybridised Agilent Microarrays were detected using 
Agilent’s Microarray Scanner System (Agilent Technologies).  
3.4.6 Image and data analysis 
The Agilent Feature Extraction Software (FES) was used to read out and process the 
microarray image files. The software determines feature intensities (including 
background subtraction), rejects outliers and calculates statistical confidences. Data 




3.5 Statistical analysis 
Statistical analysis tests were used according to the experimental design of each 
experiment, and further multiple comparison tests were performed to detect differences 
between variables.  
Non-parametric Kruskal-Wallis test with a Dunn’s multiple comparisons was 
used to analyse phenotypic studies and ERK phosphorylation in healthy controls and 
kidney transplant patient samples. This test was used because these experiments had one 
nominal variable (patients groups) and one measurement variable (percentages of 
populations), and the measurement variable was not normally distributed; * p<0.05 was 
considered significant.  
Wilcoxon matched-pairs signed rank test was used to measure differences in 
cytokine production from “Loss Tolerance” kidney transplant patient between non-
activated and activated samples. This test was use for the same reason than the Kruskal-
Wallis test, but in this case, only two groups were compared; * p<0.05 was considered 
significant. 
Non-parametric Friedman test with a Dunn’s multiple comparisons was used to 
analyse CD20 and CD19 MFI on B cells subsets from healthy controls and kidney 
transplant patient samples and IL-10 receptor expression on the B cell subsets. This 
statistical analysis was used to test continuous data when the variable was not normally 
distributed; * p<0.05 was considered significant.  
Two-way RM ANOVA test with Holm-Sidak, Sidak or Tukey’s multiple 
comparisons was used to evaluate differences between non-activated and activated 
samples from healthy controls and kidney transplant patient and differences between B 
cell subsets. This test was used because the same variable was investigated over two or 
more time points in the same group; * p<0.05 was considered significant.  
Data collection was carried out using Microsoft Excel (Microsoft) and tabulated 
data was transferred to Prism 6 (GraphPad Software, Inc). Data tables, statistical 




4 Phenotypical and functional characterisation of B cell 
subsets in kidney transplant patients 
	  
4.1 Introduction. 
 The role of B cells in kidney transplantation has been traditionally associated 
with the recognition of graft proteins by alloantibodies produced by B cell-differentiated 
Plasma cells (Mohan et al. 2012). These alloantibodies can adversely affect graft 
survival before and after transplantation. Before transplantation, the presence of pre-
existing alloantibodies can induce hyperacute rejection and accelerated acute rejection 
(Loupy et al. 2012); after transplantation, de novo alloantibodies can also trigger a 
detrimental immune response in chronic graft rejection, via donor-antigen recognition 
(Hidalgo et al. 2009). In addition, alloantibodies can compromise graft survival in early 
acute and chronic rejection, through the activation of the classical complement pathway 
(Csencsits et al. 2008). In summary, alloantibodies are recognised as negative indicators 
of graft survival, and their presence is predominantly associated with rejection.     
Alongside alloantibody production, B cells can also affect kidney transplantation 
success by acting as professional APCs. The role of these cells as APCs begins when 
protein from donor cells are first recognised by the BCR expressed on the cell surface of 
Naïve  B cells (Monroe 2006). Once the protein is bound and the BCR–protein complex 
is internalised, the cell machinery processes donor-proteins, which are then presented as 
peptides in the context of MHC class II (LeBien et al. 2008). Donor-antigens are 
recognised by alloantigen-specific CD4+ T cells from the recipient via MHC class II–
TCR interaction. This interaction, known as indirect recognition, occurs only when B 
and T cells share the same antigen-specificity. After MHC class II-TCR ligation, several 
activation proteins are up-regulated in both the B cell and T cell such as CD25, CD86, 
CD69 and so on (Clark et al. 1994). Interactions between these proteins induce 
activation of both cells. Finally, activated CD4+ T cells help Naïve B cells to become 
Memory or Plasma cells. Memory B cells are the more efficient APCs, because they 
exhibit high antigen specificity, compared to Naïve  B cells, and Plasma cells will 
produce donor-specific antibodies; both cells can participate in a rejecting immune 
response (Kimball et al. 2011). 
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As a consequence of their detrimental role in kidney transplantation, B cells 
have been targeted in depletion therapies, with the aim to improve kidney function and 
graft survival. Removal of B cells increases transplantation success by blocking the 
adverse effects produced by alloantibodies. While this has been demonstrated in some 
studies reporting an improvement in graft survival (Becker et al. 2004; Alausa et al. 
2005; Bagnasco et al. 2007), others have reported conflicting results (Clatworthy et al. 
2009). The effectiveness of CD20-depletion therapy therefore is still a controversial 
field and further study is required to clarify the benefits of targeting B cells as their role 
in transplantation tolerance remains unclear. 
Transplantation tolerance has been defined as long-term acceptance of 
transplanted organs without requirement for indefinite immunosuppression (Nickerson 
et al. 1994; Dong et al. 1999). Although the role of B cells in transplantation tolerance 
is unclear, several groups have now identified a link between B cells and kidney tolerant 
patients. These patients have been defined as transplant recipients that maintain a stable 
graft function without immunosuppressant therapy. Three independents studies (Newell 
et al. 2010; Pallier et al. 2010; Sagoo et al. 2010) demonstrated an expansion of B cells, 
and a high expression of B cell-related genes in tolerant recipients. These findings 
revealed that B cells cannot only be considered as a detrimental player in graft survival 
as previously described, they can also have a regulatory role in transplantation. 
Despite the fact that antibody production and antigen presentation are the main 
functions performed by B cells, a specific human B cell subset with anti-inflammatory 
properties has been reported and defined as Transitional or Regulatory B cells. These 
cells are the first population to emerge from the bone marrow, and can be found in 
peripheral circulation exhibiting a specific phenotype characterised by high expression 
of CD24 and CD38 molecules (Sims et al. 2005). Their main anti-inflammatory 
property is IL-10 production that is mediated through CD40-CD40L interaction (Blair et 
al. 2010).  
The identification of a B cell subset with regulatory properties is particularly 
relevant in humans and opens a new interest in the role of Transitional or Regulatory B 
cells in kidney transplantation tolerance. So far, our research group has reported an 
expansion of total B cells in peripheral blood, the absence of donor-specific antibodies 
in serum, and a differential expression of B cell-related genes in tolerant patients (Sagoo 
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et al. 2010). The first aim of this thesis was to quantify the B cell subsets, particularly 
Transitional B cells, in the peripheral blood samples from kidney transplant recipients 
and healthy controls. A clear expansion of specific B cell subsets in tolerant patients 
was not addressed at the beginning of this thesis since two contradictory sets of data 
were published. The first, from Brouard’s group, showed that Memory B cells were the 
main players in transplant tolerant patients (Pallier et al. 2010), while Newell et al. 
reported that Naïve  and Transitional B cells are the main regulatory cells (Newell et al. 
2010). The focus of this thesis was directed towards the characterisation of B cells using 
markers previously reported (Sims et al. 2005; Marie-Cardine et al. 2008; Palanichamy 
et al. 2009), specifically towards identified Memory, Naïve and Transitional B cells.  
In the same papers mentioned above, MS4A1, the gene that encodes the CD20 
molecule, was the only common gene up-regulated in tolerant patients. MS4A1 was the 
fifth gene differentially expressed in tolerant recipients in the IOT study (Sagoo et al. 
2010). It was up-regulated in tolerant patients from Brouard’s study (Brouard et al. 
2007; Pallier et al. 2010), and was also up-regulated in tolerant patients from the ITN 
study (Newell et al. 2010). Moreover, in the latter study, the CD20 transcript was the 
only gene significantly expressed at high levels in urine sediments from tolerant patients, 
compared to patients with stable function and healthy controls (Newell et al. 2010). 
Interestingly, Transitional B cells express a significantly higher CD20 MFI, compared 
to Naïve and Memory B cells (Cuss et al. 2006). Hence, the CD20 findings in tolerant 
recipients can be explained by an increase of Transitional B cells in tolerant recipients 
or by a potential, and as yet undiscovered, role of CD20 in transplantation tolerance. To 
answer this question, part of the phenotypic study was focused on the CD20 expression 
in B cells from healthy controls and transplant patients. 
The main difference between the groups of patients was the absence of 
immunosuppressants in tolerant recipients. To investigate whether the presence of 
immunosuppressive drugs in circulation could have affected the B cell signature, 
apoptosis induction and cell death was studied in samples from healthy volunteers 
cultured with the main immunosuppressive drugs used in kidney transplantation: 
tacrolimus, MMF and steroids.    
Finally, B cell activation and anti-inflammatory responses, ascertained by IL-10 
production, were evaluated in kidney transplant patients and healthy controls. CpG and 
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CD40L are the main stimuli to induce IL-10 production in human B cells. Whereas CpG 
activation induced IL-10 secretion from total B cells (Liang et al. 2010), CD40 
activation targeted Transitional (Blair et al. 2010) and Naïve cells (Duddy et al. 2004; 
Iwata et al. 2011).  
In summary, B cells in kidney transplantation are not only predecessors of 
antibody-producing cells and professional APCs; their contribution as cytokine-
producing cells is also relevant when describing their role in transplantation tolerance. 
Since IL-10 is the main cytokine in peripheral tolerance and Transitional B cells are the 
main IL-10-producing B cells after CD40 activation (Blair et al. 2010), the first 
hypothesis to cover was: 
• Transitional B cells are expanded in peripheral blood of tolerant kidney 
transplant recipients. 
To address this hypothesis, the percentage of the B cell subsets was measured in kidney 
transplant recipients and healthy controls. Once B cell subset distribution was 
established, the second hypothesis was considered: 
• Transitional B cells from tolerant patients modulate an anti-inflammatory 
response and therefore participate in the state of tolerance. 
To answer the second hypothesis, expression of B cell activation markers and cytokine 
production, after CD40L and CpG interaction, was measured in kidney transplant 
patients and healthy controls to establish if tolerant recipients were exerting an IL-10-




4.2 Phenotypic characterisation of B cell subsets in kidney transplant 
patients. 
4.2.1 B cell phenotype and the identification of B cell subsets 
In order to identify the B cell profile in the different groups of patients, an 8-
colour flow-cytometry panel was developed to analyse B cell subsets within PBMCs 
from frozen samples. Age and gender-matched healthy controls were used as a 
reference for normal B cell subset distribution.  
The flow panel was developed using antibodies for selected B cell surface 
markers and BCR components based on several publications (Sims et al. 2005; Marie-
Cardine et al. 2008; Lee et al. 2009; Palanichamy et al. 2009). The purpose of the 
staining was to identify Memory, Naïve and Transitional B cells with high precision.  
Anti-CD20 and anti-CD19 antibodies were used to perform a double staining to 
identify B cells within PBMCs (Fig1 A). From the CD20+CD19+ population, a specific 
antibody for the CD27 molecule was used to separate Memory B cells (CD27+) from 
CD27- B cells (Fig1 B) (Agematsu et al. 1997; Agematsu et al. 1998). From the CD27- 
fraction, IgM/IgD double positive cells were selected (Fig1 C) because Transitional B 
cells have been previously described as cells expressing high levels of IgD and IgM 
(Sims et al. 2005). Finally, specific antibodies for CD24 and CD38, two markers highly 
expressed in Transitional B cells, were used to identify three CD27- B cell subsets (Fig1 
D). Transitional B cells were identified through their characteristic elongated triangle 
distribution due to their linear co-expression of CD38 and CD24 (Cuss et al. 2006; Lee 
et al. 2009; Blair et al. 2010). According to the maturation process, Naïve B cell, 
identified as CD24+CD38+, lose the high expression of CD24 and CD38, but maintain a 
positive signal for both markers. Finally, CD24+CD38- Mature B cells completely lose 
CD38 but maintain CD24 expression.  
Without forgetting the role as antibody-producing cells, the levels of pre-Plasma 
cells in circulation were measured. To achieve this, CD20-CD19+CD27+CD38hi pre-




Figure 1: B cell subset identification. 
Samples were obtained from frozen PBMCs separated from the mononuclear fraction of whole blood 
after gradient centrifugation. Samples were thawed on the same day of the experiment and stained with 
the 8-colour flow-panel. Fortessa settings were maintained stable during three years of study using 
Cytometer Setup and Tracking Beads (CS&T), application settings and an internal assay control, which 
was prepared and acquired at the same time than patient samples. B cells were identified as CD20+CD19+ 
cells by a double staining for CD20 and CD19 (A). From the CD20+CD19+ population, Memory B cells 
were identified as CD27+ B cells (B), and from the CD27- population, IgD+IgM+ B cells were then 
selected (C). From the CD27-IgD+IgM+, Transitional B cells were identified as CD24hiCD38hi, Naïve  B 
cells were identified as CD24+CD38+ and Mature B cells were identified as CD24+CD38- (D). From the 
CD20-CD19+ population (E) pre-Plasma cells were identified as CD27+CD38hi.            
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4.2.2 Distribution of B cell subsets in peripheral blood, spleen and lymph nodes 
Transitional B cells are the first population that emerge from the bone marrow 
and enters into circulation. Once in the periphery, Transitional B cells have the potential 
to become Naïve B cells and continue their maturation process, hence, peripheral blood 
should be the main source for locating these cells. However, it is not clear if this 
population can migrate into immune organs, like spleen or lymph nodes, to play a role 
as an independent regulatory population.  
In order to find the main location of Transitional B cells and the remaining B 
cell subsets, the B cell panel was performed in three different tissues: peripheral blood, 
spleen and lymph nodes (Fig 2). In Figure 2A, within the lymphocyte population, the 
percentage of B cell was 10-15% in peripheral blood, 50-60% in spleen and 40-50% in 
lymph nodes (Fig2 A). In terms of the different subsets, only Memory B cells were 
significantly increased in spleen (***p<0.0001) compared to peripheral blood. No 
significant difference was observed in the rest of the subsets between the tissues (Fig2 
B).  
Interestingly, even when the percentage of total B cells was three times as high 
in the spleen and lymph nodes when compared to circulation, the percentage of 
Transitional B cells was always higher in peripheral blood. Percentages of Transitional 
B cells in circulation were around 10-12%, whereas in spleen and lymph node they did 
not exceed 2% (Fig2 B). 
Unlike Transitional B cells from spleen and lymph nodes, cells obtained from 
peripheral blood exhibited a clear and distinctive phenotype (described in Fig1 D), 
characterised by high expression of CD24 and CD38. The shape of this phenotype was 









Figure 2: B cell subset distribution in peripheral blood, spleen and lymph nodes. 
Ten frozen cells from peripheral blood samples of healthy volunteers, and six spleen and two lymph 
nodes samples from cadaveric donors were thawed and stained (as described in Fig 1) to identify B 
lymphocytes (A) and their subsets (B). Two-way RM ANOVA test with a Tukey’s multiple comparisons 
test was used; * p<0.05 was considered significant. Examples from Transitional B cells in peripheral 
blood, spleen and lymph node are shown in counter plots (C). 
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4.2.3 Tolerant recipients exhibited higher percentages of Transitional B cells 
compared to non-tolerant recipients 
Having established how to identify B cell subsets in samples from healthy 
volunteers, the distribution of the same subsets was then analysed in peripheral blood 
samples from kidney transplant patients (tolerant, stable, monotherapy, chronic rejector) 
and age-gender matched healthy controls.  
The first analysis was performed to evaluate total B cells and the distribution of 
B cell populations in the different patient groups. The percentages of total B cells from 
healthy controls (*p=0.0140) and tolerant patients (**p=0.0017) were both significantly 
increased compared to B cells from stable patients (Fig3 A). Despite previous 
publications reporting a decreased number of B cells in chronic rejector, compared to 
tolerant and healthy controls, no differences in percentages were observed between 
these groups in this study. The difference in the results could be explained by the fact 
that the previous studies compared B cell numbers, whereas this study compared B cell 
percentages, between patients. No differences in percentages of total B cells were 
observed between healthy controls and tolerant patients (p>0.05); this result suggests 
that B cells are not “expanded” in tolerant recipients, compared to healthy controls.  
B cell subsets (Memory, Naïve, Transitional, Mature and pre-Plasma B cells) 
were then analysed. The percentage of CD27+ Memory B cells in the peripheral blood 
was around 20%, and no significant differences were observed between groups (Fig3 B). 
Naïve or CD27-CD24+CD38+ B cells were the largest B cell population in the peripheral 
blood, but again, no difference between the percentages of total Naïve B cells amongst 
the patient groups was found (Fig3 C).  
Although Transitional B cells were the smallest population within the B cell 
subsets, significant differences were found between patient groups. Transitional B cells 
were significantly expanded in tolerant patients, compared to stable patients 
(**p=0.0037) and chronic rejector (****p<0.0001) (Fig3 D).  
Transitional B cells were also expanded in healthy volunteers in comparison to 
stable patients (**p=0.0032) or chronic rejector (****p<0.0001), but again, no 
difference in percentages of Transitional B cells between healthy volunteers and tolerant 
patients were observed (p>0.05).    
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Mature B cells, an interesting population usually absent in samples from healthy 
volunteers, was increased in peripheral blood from stable patients in comparison to 
healthy controls (*p=0.0341) and tolerant patients (*p=0.0305) (Fig3 E). Pre-Plasma 
cells were also increased in stable patients when compared to chronic rejector 
(*p=0.0468) (Fig3 F). 
In summary, similar percentages were observed between healthy controls and 
tolerant patients. In fact, no significant differences were found in any B cell subset 
between these two groups. These results demonstrate that the percentages of B cells and 
their subsets were not greatly expanded in tolerant patients. However, percentages of 
Transitional B cells were increased in tolerant recipients, compared to patients with 
triple immunosuppressive therapy and chronic rejector. These results naturally led the 
direction of the investigation towards the potential effects of immunosuppressive drugs 






Figure 3: B cells subsets distribution in kidney transplant patients. 
Percentages of total B cells (A), Memory (B), Naïve (C), Transitional (D), Mature (E) and pre-Plasma 
cells (F) were measured in PBMCs from healthy control (HC) tolerant (Tol), stable (Sta), monotherapy 
(Mon) and chronic rejector (CR) (described in Table 3) by surface staining. Kruskal-Wallis test with a 
Dunn’s multiple comparisons test was used, * p<0.05 was considered significant.           	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4.2.4 Effects of drugs on B cell viability 
Having shown that the percentage of Transitional B cell was higher in tolerant 
patients and healthy controls when compared to the other groups under 
immunosuppressive therapy, a possible detrimental influence of these drugs in B cell 
viability or apoptosis was studied. Percentages of apoptotic B cells in healthy controls 
and kidney transplant patients were evaluated to identify any failure in the B cell 
survival. The aim of this experiment was to dismiss the possibility that 
immunosuppressive drugs were producing a specific decrease in the Transitional 
population in non-tolerant recipients.  
An assay was developed to measure dead and apoptotic cells using a Live/Dead 
dye, AnnexinV and BAFFr. Firstly, live cells were identified as Live/Dead-, whereas 
dead cells were identified as Live/Dead+ (Fig4 A). Then, from the live population, 
apoptotic cells were identified as AnnexinV+ BAFFr- (Fig4 B). It was demonstrated that 
down-regulation of BAFFr was a specific indicator of B cell apoptosis because 
apoptotic B cells, or AnnexinV+ cells, were also BAFFr- (Fig4 B). Once the staining 
was set up, expression of BAFFr was evaluated in samples from healthy controls and 
kidney transplant patients. Results revealed that B cells from healthy controls exhibited 
a higher expression of BAFFr, compared to B cells from stable patients (*p=0.0280) 
and chronic rejector (*p=0.0404) (Fig4 C). Therefore, it can be suggested that apoptotic 
B cells were increased in these two patient groups.  
The effect of tacrolimus, MMF and steroids in cell viability and apoptosis 
induction was measured using the same parameters mentioned above. The concentration 
range used started from drug concentrations found in patients’ circulation, 0-10ng/ml 
for tacrolimus, 0-10ug/ml for MMF and 0-50ng/ml for steroids, to exceeding the 
therapeutic concentrations of patients, >10ng/ml for tacrolimus, >10ug/ml for MMF 
and >50ng/ml for steroids. Cell death was evaluated in total B cells (Fig5 A), Memory 
(Fig5 C), Naïve (Fig5 E) and Transitional B cells (Fig5 G). At the same time, apoptosis 
was also measured in total B cells (Fig5 B), Memory (Fig5 D), Naïve (Fig5 F) and 
Transitional B cells (Fig5 H). 
The results obtained demonstrated that high concentration of steroids induced 
cell death mainly in Memory B cells (Fig5 C), whereas apoptosis occurred 
predominantly in Naïve (Fig5 F) and Transitional B cells (Fig5 H). No differences in B 
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cell viability were observed with tacrolimus or MMF. 
Due to the effects observed with steroids, cell death was evaluated in the B cell 
subsets from samples treated with and without steroids (Fig6 A). Results showed that at 
high-drug concentrations, Memory B cells were the main population affected by this 
drug. Apoptosis was then measured in the B cell subsets (Fig6 B & C), and at 500ng/ml 
of steroids, Naïve and Transitional, but not Memory B cells, increased significantly 
their apoptotic cell percentages.  
In conclusion, tacrolimus, MMF and steroids had no effect on cell viability or 
apoptosis induction at physiological concentration. On the other hand, when steroids 
were used at non-physiological concentrations, cell death or apoptosis was induced in 




Figure 4: Measurement of B cell viability and apoptosis in kidney transplant patients. 
Samples from healthy volunteers were used to identify dead B cells as Live/Dead+ , using flow 
cytometry (dot-plot and histogram) (A). From the Live/Dead- population observed in Figure A, two dot-
plots and one histogram were used to identify apoptotic B cells. The first dot-plot identified apoptotic B 
cells as AnnexinV+Live/Dead- . These AnnexinV+ Live/Dead- cells were then plotted in an 
AnnexinV/BAFFr dot-plot, and images showed that apoptotic AnnexinV+ B cells were also BAFFr– cells. 
Finally, a histogram showed AnnexinV+BAFFr–  or apoptotic cells in orange (B). Expression of BAFFr 
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was measured in healthy control (HC) tolerant (Tol), stable (Sta), monotherapy (Mon) and chronic 




















Figure 5: The effects of immunosuppressive drugs in B cell viability and apoptosis in vitro. 
Left column shows live B cells, defined as Live/Dead-CD20+, and the right column shows apoptotic B 
cells, defined as Live/Dead-CD20+ BAFFr-. Identification of live (A) and apoptotic (B) B cells; live (C) 
and apoptotic (D) Memory B cells; live (E) and apoptotic (F) Naïve B cells; live (G) and apoptotic (H) 
Transitional B cells are shown after treatment with immunosuppressive drugs. Tacrolimus, MMF and 
steroids were added to PBMCs cultures for 24 hours at concentrations showed in the X axes. Live/Dead 
and BAFFr expression was analysed by flow cytometry. Two-way RM ANOVA test with a Tukey’s 






Figure 6: Steroids effect in cell viability and apoptosis in B cell subsets in vitro. 
Cell viability in B cell subsets was measured as the difference between live B cell treated with and 
without different concentration of steroids (A). Apoptosis was measured as Live/Dead-CD20+BAFFr- 
within B cell subsets and percentages of apoptotic cells were compared between B cell subsets (B) and 
between steroid concentrations (C). Two-way RM ANOVA test with a Tukey’s multiple comparisons test 
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4.2.5 Transitional B cells exhibited the highest median CD20 expression. 
As previously mentioned in the introduction, MS4A1 is the encoding gene for 
CD20, one of the main B cell markers. This was the only common up-regulated gene in 
tolerant recipients from the IOT study (Sagoo et al. 2010), Brouard’s study (Brouard et 
al. 2007; Pallier et al. 2010) and the ITN study (Newell et al. 2010). Interestingly, 
Transitional B cells express higher levels of CD20, compared to Naïve and Memory B 
cells (Cuss et al. 2006). In this study, protein expression of the CD20-encoding gene, 
MS4A1, on Transitional B cells from patient groups and healthy controls was 
investigated.  
To address if CD20 was higher in tolerant recipients and whether or not it was 
due to the presence of Transitional B cells, a specific flow cytometry analysis was used, 
in which MFI estimated the amount of CD20 molecules expressed per cell. Once this 
analysis was standardised, the MFI of CD20 was investigated for all B cells subsets 
from patient samples and healthy controls, using CD19 as a control.  
It was observed that the median expression of CD20 was higher in Transitional 
B cells, compared to IgM+/IgD+ (*p=0.0391), Naïve (****p<0.0001) and Mature cells 
(****p<0.0001) (Fig7 A), whereas CD19 MFI was lower in Transitional B cells, 
compared to Memory B cells (*p=0.0120) (Fig7 B). The difference of CD20 MFI 
between total and Transitional B cells in each patient group was studied, and an 
increased CD20 MFI of Transitional B cells was observed in healthy control 
(****p<0.0001), tolerant (****p<0.0001), stable (*p<0.0285) and chronic rejector 
(***p<0.0003) (Fig7 C). Conversely, although no difference in the levels of the 
expression of CD19 between total and Transitional B cells was observed between 
patients groups, CD19 MFI from these two populations was significantly decreased in 
chronic rejector (*p<0.05) (Fig7 D). 
Addressing a potential function of CD20 in tolerance was difficult as the role of 
the CD20 signalling pathway in the B cells remains unknown. There are only few 
reports regarding the function of this protein in humans, but none was linked to 
tolerance. Therefore, it was necessary to find any preliminary evidence to explain the 
high expression of this marker in Transitional B cells. The expression and the 
localisation of CD20 in the B cells subsets was studied, followed by evaluation of any 
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possible co-localisation with the rest of the phenotypic markers expressed by these cells. 
The aim was to evaluate if CD20 was interacting with more proteins, specifically in 
Transitional B cells, and if these potential interactions were important for Transitional B 
cell function and survival.   
Expression and localisation of the same markers used in the B cell flow panel 
were this time measured by ImageStream. Results confirmed that Transitional B cells 
(pink dots) showed the highest CD20 expression in a CD20/CD19 dot-plot (Fig7 E), as 
previously observed using MFI in Figure 7A.  
The distribution of CD20 was then evaluated using the delta centroid (Fig7 F). 
This parameter measures the difference of CD20 distribution between the cell centre 
and any polarised zone in the cell. Proteins equally distributed exhibit the highest 
fluorescent zone in the centre of the cell; therefore when markers are equally distributed, 
delta centroid values are close to 0. On the other hand, when markers are polarised, 
delta centroid increase between the cell centre and the polarised zone, and values are > 0. 
CD20 distribution was not polarised and the expression of this marker was equally 
distributed in the B cells. Delta centroid was then used to identify the location and 
polarisation of all B cell markers used in the B cell panel in Memory, Naïve and 
Transitional B cells from a healthy volunteer (Fig7 G). Although differences in the 
expression of the markers were observed between B cell subsets, no differences were 
exhibited regarding protein polarisation.  
 Finally, co-localisation between CD20 and B cell markers were analysed using 
Inspire software. An example of co-localisation between CD20 and CD24/CD38 in 
Transitional B cells is shown in Figure 7F. Equal distribution was found for CD20 and 
the rest of the B cell markers, and no specific co-localisation was observed between 
markers; delta centroid values for all surface markers were close to 0 (data not shown). 
In conclusion, high expression of CD20, previously found in tolerant recipients, 
could be explained by the high expression of this protein found in Transitional B cells. 
Although Transitional B cells from all patient groups exhibited higher CD20 MFI, 
compared to other B subsets, percentages of Transitional cells were only augmented in 
tolerant patients. However, the role of CD20, if any, in tolerance remains unclear. No 
evidence of CD20 interaction with other surface markers was observed, the protein was 






Figure 7: CD20 and CD19 MFI. 
CD20 (A) and CD19 (B) MFI was measured in B cell subsets from healthy volunteers. CD20 (C) and 
CD19 (D) MFI was measured in total B and Transitional B cells from healthy control (HC), tolerant (Tol), 
stable (Sta), monotherapy (Mon) and chronic rejector (CR). Friedman test with a Dunn’s multiple 
comparisons test was used, * p<0.05 was considered significant. Transitional B cells (pink dots) within B 
cells (yellow dots) were identified in a CD20/CD19 dot-plot analysed by ImageStream (E). The 
distribution of the CD20 molecule within the B cells was measured using delta centroid (values close to 0 
demonstrate equal distribution). Co-localisation of the CD20 molecule with CD24/CD38 expression was 
analysed using delta centroid (values close to 0 demonstrate equal distribution) (F). The distribution of all 
B cell markers in Memory, Naïve and Transitional B cells were displayed in a gallery pictures obtained 


















4.3 Functional characterisation of B cell subsets in kidney transplant 
patients. 
4.3.1 B cells from kidney transplant patients up-regulated CD25 and CD86 after 
cognate CD40 activation 
Once the B cell subset distribution and phenotypic characteristics were clearly 
defined in each patient group, an investigation was carried out into the capacity of B cell 
subsets to secrete IL-10, a known key cytokine produced by regulatory B cells. 
However before testing this, the question of whether all the different B cell subsets 
could be activated by different stimuli was evaluated. CD40 activation of B cells was 
the first stimulus studied because this activation has been shown to induce regulatory 
properties in Transitional B cells by CD80/CD86 activation and IL-10 production (Blair 
et al. 2010). Firstly, the relationship between B cell activation markers and tolerance 
was studied, followed by the measurement of IL-10-producing B cells from the different 
patient groups. 
Co-stimulatory molecules have different roles in B cell activation; for example 
after B cell activation, CD80/86 are up-regulated and induces T cell activation via CD28 
interaction (Tu et al. 2008), or anergy via CTLA-4 (Clark et al. 1994). Other co-
stimulatory signal is the B-T cell CD40-CD40L interaction. This activation has an 
important role in the development and class-switching of the B cells (Agematsu et al. 
1998), and genetic absence of CD40L in human results in hyper IgM syndrome whereby 
B cells are unable to class switch to IgG (Agematsu et al. 1998). Another molecule up-
regulated after B cell activation is the alpha-chain of the IL-2 receptor, CD25. This 
activation has an important role in survival signalling (Schultz et al. 2001). For all these 
reasons, the focus of the study moved towards CD86, CD40 and CD25 expression on B 
cell subsets. 
Since CD40 stimulation was critical for the regulatory B cell activation (Duddy 
et al. 2004; Jamin et al. 2008), different methods were used to obtain optimal CD40 
activation. In a first attempt, soluble anti-CD40 antibody was tested to emulate CD40-
CD40L interaction, but no evidence of B cell activation was observed (data not shown). 
In a second attempt, L cells transfected with CD40L were used to replicate the 
interaction between CD40 and CD40L. These cells were kindly donated by Dr. Case 
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Van Kooten to Professor Giovanna Lombardi. CD40L expression was evaluated in both 
non-transfected and CD40L-transfected L cells, using an anti-CD40L antibody. 
Histogram showed a positive CD40L expression in transfected cells, whereas no 
positive signal was identified in non-transfected cells (Fig8 A).  
Up-regulation of co-stimulatory molecules in CD20+ cells was analysed to 
ensure B cell activation after stimulation with CD40L-transfected cells. CD86 and 
CD25 expression was measured in B cells within PBMCs. Histogram showed an up-
regulation of CD86 and CD25 after CD40-mediated B cell activation in a healthy 
volunteer (Fig8 B).  
Once the expression of CD25 and CD86 molecules were correctly up-regulated 
after cell activation in healthy volunteers, the B cell response in samples from kidney 
transplant patients, compared to results from healthy controls was evaluated. To 
perform the experiments, patient samples were activated with CD40L-transfected L 
cells, using non-transfected L cells as a control.  
Expression of CD25 and CD86 molecules were measured in total B cells from 
healthy controls and kidney transplant patients. The first findings demonstrated that B 
cells from all groups up-regulated CD25 (Fig8 C) and CD86 (Fig8 D) molecules 
following CD40 activation. These results suggest that B cells from all patient groups 
were capable to respond to CD40-CD40L interaction, and that immunosuppressive 
drugs did not affect the B cell response after activation. Although a significant 
difference was observed for CD25 up-regulation in tolerant patients compared to 
patients in monotherapy (*p=0.0138), no significant differences were observed in the 
expression of CD86 molecule between patient groups. Because B cell activation in 
tolerant recipients did not display clear differences in the expression of this molecule 
compared to other patient groups, it is difficult to support the idea that up-regulation of 
CD86 is linked to transplantation tolerance.        
Expression of CD25 (Fig8 E) and CD86 (Fig8 F) were then measured in 
Memory B cells from healthy controls and kidney transplant patients. Although 
activation in this subset was ascertained by up-regulation of both molecules in all 
patients groups after CD40 activation, no significant differences in activated B cells 
were observed between groups.  
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 Finally, expression of CD25 (Fig8 G) and CD86 (Fig8 H) was measured in 
CD27- B cells (Naïve and Transitional), and again, CD25 and CD86 were up-regulated 
in B cells from all patients groups after CD40 activation. No significant differences in 
percentages CD86+ B cells were found between groups, however, CD25 was 
differentially expressed in B cells from tolerant patients compared to patients in 
monotherapy (*p=0.024) and chronic rejector (*p=0.040). These differences were also 
observed between the last groups and healthy controls. 
CD40, the protein that interacts with CD40L, was also measured in total B cells 
(Fig9 A), Memory (Fig9 B) and CD27- (Fig9 C) B cells, but no significant differences 
were found between activated samples or between groups.  
In conclusion, up-regulation of CD86 was not specific for tolerant recipients and 
activation of B cell responses after CD40 ligation was observed in all patient groups, 
independently of the immunosuppressive drug treatment. CD25 expression was 
specifically increased in CD40-activated CD27- B cells from tolerant patients; following 
on from these results, it would not be far-fetched to suggest that when CD25 is up-
regulated in these cells, there may be an increase in IL-2 capture, as CD25 is part of the 
IL-2 receptor. Taking this into consideration, if the IL-2 signalling pathway is triggered 
in activated Naïve and Transitional B cells, survival genes will be transcribed. If this 
does occur, cells from tolerant recipients will respond better to CD40 activation than B 
cells from other patient groups, and will therefore secrete more IL-10 as they support 















Figure 8: Expression of activation molecules in kidney transplant patients. 
The expression of CD40L was measured in 1.0x106 unstained CD40L-transfected L cells , CD40L-PE-
stained non-transfected L cells  and CD40L-PE-stained CD40L-transfected L cells  (A). The 
expression of CD86 and CD25 molecules on CD20+ B cells was measured by surface staining after 3 days 
of activation with 0.5x105 non-transfected L cells  and CD40L-transfected L cells  (plate-bound) (B). 
Expression of CD25 (C) and CD86 (D) from total B cells, expression of CD25 (E) and CD86 (F) from 
Memory B cells and expression of CD25 (G) and CD86 (H) from CD27- B cells was measured by surface 
staining in 1.0x106 PBMCs from healthy control (HC) tolerant (Tol), stable (Sta), monotherapy (Mon) 
and chronic rejector (CR) after 3 days of activation with 0.5x105 non-transfected L cells and CD40L-
transfected L cells (plate-bound). Two-way RM ANOVA test with a Sidak’s multiple comparisons test 







Figure 9: Expression of CD40 on B cell subsets. 
Expression of CD40 from total B cells (A), Memory B cells (B) and CD27- B cells (C) was measured by 
surface staining in 1.0x106 PBMCs from healthy control (HC) tolerant (Tol), stable (Sta), monotherapy 
(Mon) and chronic rejector (CR) after 3 days of activation with 0.5x105 non-transfected L cells and 
CD40L-transfected L cells (plate-bound). Two-way RM ANOVA test with a Sidak’s multiple 




















4.3.2 B cells from kidney transplant patients up-regulated TLR-9 after CpG 
activation 
The second stimulus used to activate B cells was CpG, cytosine-guanine DNA 
regions (Liang et al. 2010). CpG, like CD40 ligation, has previously been shown to 
induce optimal stimulation of IL-10 production by total B cells (Liang et al. 2010). This 
activation occurs through TLR-9, an intracellular toll like receptor that recognises 
specific unmethylated CpG oligonucleotide (ODN) sequences from microbial DNA. 
CpG-TLR-9 activation was used to ensure that the IL-10 signalling pathway was 
not affected in recipients by the effect of immunosuppressive drugs, and since CD40 
activation preferentially targeted Transitional B cells, it was also used to induce a 
regulatory response from all the B subsets.      
Since up-regulation of CD86 and CD25 molecules confirmed CD40 activation 
(prior to IL-10 secretion), TLR-9 expression was used to confirm CpG activation. Thus, 
TLR-9 expression was studied in unstimulated and CpG-stimulated samples from 
healthy controls and kidney transplant patients using intracellular staining. Histograms 
(Fig10 A) and dot-plots (Fig10 B) showed an increase of TLR-9 expression in CpG-
activated B cells (blue) compared to unstimulated B cells (black).  
TLR-9 expression was then measured in B cells from kidney transplant patients 
and healthy controls, with and without CpG activation (Fig10 C). Differences in TLR-9 
expression, between non-activated and activated samples, were observed in B cells from 
healthy controls (**p=0.0062), tolerant (**p=0.0015), stable (*p=0.0460) and 
monotherapy (**p=0.0060) patients. No difference between CpG-activated samples 
between groups was observed.  
B cells from all patient groups, except chronic rejector, responded to CpG 
activation via TLR-9 expression. Interestingly, because chronic rejector was the only 
group not responding to this stimulus, it was important to determine in the following 
experiments whether IL-10 production was also affected. Finally, because stable and 
monotherapy patients up-regulated TLR-9 expression, the study confirmed that 




Figure 10: Expression of TLR-9 after CpG activation. 
Expression of TLR-9 from B cells was measured in unstimulated  and 1uM CpG-stimulated  samples 
using a histogram (A) or a dot-plot (B) after 3 days of culture. Expression of TLR-9 from unstimulated 
and 1µM CpG-stimulated  B cells was measured by intracellular staining in 1.0x106 PBMCs from 
healthy control (HC) tolerant (Tol), stable (Sta), monotherapy (Mon) and chronic rejector (CR) samples 
after 3 days of culture (C). Two-way RM ANOVA test with a Sidak’s multiple comparisons test was used, 
* p<0.05 was considered significant.             
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4.3.3 Transitional B cells produced the highest levels of IL-10 after CD40 
activation 
    Having demonstrated that in transplant recipients and healthy controls, 
ligation of CD40 and CpG up-regulated activation markers and TLR-9, respectively, a 
study into whether the same stimuli can induce IL-10 production by B cells was 
undertaken. The focus of the study was on IL-10 production due to the important role 
this cytokine plays in immune regulation (Blair et al. 2010; Liang et al. 2010; Iwata et 
al. 2011). 
Particularly relevant to this study, Transitional B cells have been shown to 
control the immune responses through IL-10 production. (Blair et al. 2010). Claudia 
Mauri’s group revealed a down-regulation of the Th1 response and observed lower 
percentages of CD4+IFN-γ+ and CD4+TNF-α+ cells when Transitional B cells were 
present in culture. This regulatory property was diminished when the IL-10 pathway 
was blocked, revealing that IL-10 was one of the mechanisms of immune regulation 
used by these cells. In this study, tolerant patients exhibited higher percentages of 
Transitional B cells than other patient groups. IL-10 production after CD40 activation 
was then studied, to understand if Transitional B cells were participating in tolerance 
through IL-10 regulation. Since CD40 activation targeted mainly Naïve and Transitional 
B cells (Duddy et al. 2004; Duddy et al. 2007; Blair et al. 2010), the potential 
regulatory role of Memory B cells in tolerant transplant patients was evaluated using 
CpG stimulation.    
IL-10 production was measured in kidney transplant patients by intracellular 
staining and ELISA. The first method allowed the measurement of IL-10 specifically 
produced by B cells, and the second allowed the measurement of total levels of cytokine 
after three days of culture. Both methods were evaluated in PBMCs and isolated B cells, 
but only PBMCs were used due to the difficulty to isolate B cells from patient samples 
and the decrease of cell viability observed when isolated B cells were cultured. 
Intracellular staining was used to identify IL-10-producing cells, especially in 
the Transitional population. However, this approach was not optimal in the 
identification of the different B cell subsets. Unfortunately, after three days of culture 
and the use of PMA and ionomycin, the high expression of CD24 and CD38 was 
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completely lost, therefore the identification of Transitional B cells by this method was 
not possible. Because of this, sorted Memory, Naïve and Transitional B cells from 
healthy volunteers were used, to determine how CD40 and CpG activation were 
affecting each B cell subset, and to then apply this principle to patient samples. IL-10 
production in CD40 or CpG-activated B cell subsets was measured in the form of 
CD20+IL-10+ cells, using intracellular staining (Fig11 A) and ELISA.  
The results obtained demonstrated that CD40-activated Transitional B cells 
triggered a specific and distinctive IL-10 response. After three days of culture, an 
increment of CD20+IL-10+ cells was mainly observed in the Transitional population 
(**p=0.0049) after CD40 activation (Fig11 B). Although IL-10 secretion was also 
observed in the Transitional population using ELISA, no significant differences were 
found between non-activated and CD40-activated samples (Fig11 C).  
Conversely, the Memory B cell subset was the main population targeted by CpG 
activation. Although IL-10+ cells were increased in Memory (****p>0.0001), Naïve 
(**p=0.0025) and Transitional (***p=0.0005) B cells (Fig11 D) after CpG activation, 
protein levels were only significantly increased in the supernatants from Memory B 
cells (**p=0.0076) (Fig11 E). Altogether CpG-activated Memory B cells were the 
higher responders compared with the other two subsets, shown by intracellular staining 
and ELISA. 
From these results, it was concluded that CD40 activation targets mainly 






Figure 11: IL-10 production by B cell subsets from healthy volunteers (cones). 
Sorted B cell subsets were stimulated with and without 1.0x104 non-transfected L cells, 1.0x104 CD40L- 
transfected L cells (plate-bound), or 1uM CpG during 3 days, and representative dot-plots of CD20+IL-
10+ B cells were displayed to demonstrate the quality of the intracellular staining (A). IL-10 was 
measured in cultures of 0.5x106 B cell subsets stimulated with 1.0x104 non-transfected L cells, or 1.0x104 
CD40L-transfected L cells (plate-bound) after 3 days using intracellular staining (B) and ELISA (C). IL-
10 was also measured in cultures of 0.5x106 B cell subsets stimulated with or without 1uM CpG after 3 
days using intracellular staining (D) and ELISA (E). Two-way RM ANOVA test with a Sidak’s multiple 





4.3.4 B cells from tolerant recipients produced higher levels of IL-10 and lower 
levels of TNF-α  than B cells from chronic rejector  
IL-10 production was measured in CD40- or CpG-activated samples from 
kidney transplant patients and healthy controls. The aim of this part of the study was to 
determine if IL-10 was differentially produced by B cells from tolerant recipients.  
To address this question, PBMCs from patients and healthy controls were 
stimulated for three days with and without non-transfected L cells, CD40L-transfected L 
cells or CpG. Although the cytokine of most interest evaluated was IL-10, TNF-α 
production was also analysed to evaluate whether this pro-inflammatory cytokines was 
also secreted during the two activations methods. Whereas intracellular staining was 
used to identify IL-10-producing B cells, ELISA was used to measure IL-10 and TNF-α 
in supernatants. Results were analysed with two multiple comparisons. The first 
multiple comparison test analysed significant differences between non-activated and 
CD40- or CpG-activated samples in each patient group, and the second multiple 
comparison test analysed significant differences in CD40- or CpG-activated samples 
between patient groups. For a better understanding, and because both statistical analysis 
are displayed in the graphs, first analysis is shown in grey and second analysis is shown 
in black. 
IL-10 expression by B cells (Fig12 A), and IL-10 production in the supernatants 
(Fig12 B) were measured in CD40-activated patient samples. Although differences in 
CD20+IL-10+ cells between non-activated and activated samples were observed only in 
tolerant patients (****p>0.0001) and healthy controls (**p=0.0111), protein levels were 
significantly increased in all groups except chronic rejector. These findings revealed 
that IL-10-producing B cells were mainly present in groups with high percentages of 
Transitional B cells. They also suggested that immunosuppressive drugs did not block 
IL-10 production in general, as IL-10 was observed in supernatants from stable and 
monotheraphy patients. Results also suggest that IL-10 production is affected in 
rejection as this cytokine was not significantly different in CD40-activated B cells or in 
the supernatant from chronic rejector. Differences between patient groups were 
analysed as well, and it was observed that CD20+IL-10+ cells B cells were increased in 
tolerant patients compared to patients in monotherapy (**p=0.023) and chronic rejector 
(**p=0.0080) at day 3, but no differences between groups were observed when IL-10 
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was measured in supernatants. Again this result supports the idea that B cells from 
tolerant recipients were the main IL-10 producing-cells.  
At the same time, CpG activation was studied in transplant patients and healthy 
controls. The percentages of CD20+IL-10+ B cells (Fig12 C), and IL-10 levels in the 
supernatant (Fig12 D) were measured in non-activated and CpG-activated PBMCs. 
Unlike CD40L, differences in IL-10 production by B cells, between non-activated and 
activated samples, were observed in all patients groups, except chronic rejector. 
However, IL-10 levels in supernatants were increased in tolerant patients (***p=0.0006) 
and chronic rejector (*p=0.0145). In conclusion and similar to CD40 activation, B cells 
from tolerant recipients exhibited high expressions of IL-10 in CpG-activated samples. 
However, it is still unknown whether the high-levels of IL-10 observed in some 
supernatants from chronic rejector, came specifically from B cells, as no increase of 
CD20+CD10+ cells was observed after activation in this group compared to tolerant 
(***p=0.0006) and stable (*p=0.0452) patients. Because of this, it is possible that other 
PBMCs were participating in IL-10 secretion from the chronic rejector samples.  
Finally, TNF-α secretion was measured in supernatants from transplant patients 
and healthy controls after 3 days of activation with CD40L (Fig12 E) or CpG (Fig12 F). 
Only samples from chronic rejector had significantly increased levels of TNF-α after 
CD40L (**p=0.0013) and CpG (*p=0.0113) activation.   
As a general conclusion it can be stated that B cells from tolerant recipients are 
the main IL-10 producing cells, independent of the type of activation. CD40 activation 
targeted Transitional B cells; therefore groups with high percentages of these cells 
exhibited high percentages of CD20+IL-10+ cells. Although healthy controls and 
tolerant patients were the main CD40L responders, B cells from other patients groups 
also responded to CD40 activation with IL-10 production, but at lower levels. This 
means that IL-10 is not impaired in non-tolerant recipients; hence, results suggest that 
differences in CD20+IL-10+ percentages are directly proportional to Transitional B cells 
percentages found in patient samples. In addition, it is suggested that 
immunosuppressive drugs were not blocking the IL-10 signalling pathway in B cells.  
Memory B cells were the predominant responder B cell population activated by 
CpG. All groups exhibited high percentages of CD20+IL-10+ cells, and no differences in 
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percentages were found between patient samples after activation, except in chronic 
rejector. Because of this, it can be stated that CpG activation affected equally all B 





Figure 12: IL-10 production by B cell subsets from kidney transplant recipients 
IL-10 and TNF-α production was measured in CD40- and CpG-activated PBMCs from healthy control 
(HC), tolerant (Tol), stable (Sta), monotherapy (Mon) and chronic rejector (CR). 1.0x106 PBMCs were 
stimulated with 0.5x105 non-transfected L cells or 0.5x105 CD40L-transfected L cells (plate-bound), and 
after 3 days of culture, IL-10+Bcells (A) and secreted IL-10 in supernatants (B) were measured by 
intracellular staining and ELISA, respectively. PBMCs were also activated with and without 1uM CpG 
during 3 days of culture. IL-10+Bcells (C) and secreted IL-10 in supernatants (D) were measured by 
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intracellular staining and ELISA, respectively. Finally, levels of TNF-α in the supernatants of 1.0x106 
PBMCs activated with 0.5x105 non-transfected L cells or 0.5x105 CD40L-transfected L cells (plate-bound) 
(E), and with or without 1uM CpG (F) were measured after 3 days of culture. Two-way RM ANOVA test 
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4.3.5 “Loss Tolerance” kidney transplant recipients reduced Transitional B cells 
and the capacity to produce IL-10 over time    
If IL-10 is participating in the process of transplantation tolerance, patients that 
lost their tolerant state should display alterations in this pathway over time. Three “Loss 
Tolerance” patients were recruited from Sheffield, Czech Republic and Switzerland at 
three time points separated between six months. Sample quality was not optimal due to 
long distance and period of sample transportation. Cells were stained with the B cell 
panel (Fig1) and changes in the B cell subsets were studied over time. Loss Tolerance 
recipients presented different percentages of CD20+CD19+ B cells, but the percentages 
were not affected over time (Fig13 A). In terms of the Memory B cells, whereas all 
patients maintained invariable Memory B cell percentages between Time Point 1 and 2, 
two of three exhibited an increase in the number of Memory B cells at Time point 3 
(Fig13 B). Percentages of Naïve B cells did not show any particular changes over time 
(Fig13 C). Interestingly, Transitional B cells from all patients decreased over time 
(Fig13 D). Examples of this loss of Transitional B cells are shown in Dot plots (Fig13 
E).  
Samples activated with CD40L (Fig13 F&H) and CpG (Fig13 G&I) were tested 
for IL-10 and TNF-α production using intracellular staining and ELISA. Both 
techniques were performed to identify all cytokines, but only ELISA was useful in 
determining cytokine production because poor cell quality resulted in low numbers of 
PBMCs after intracellular staining. Although B cells from two patients increased IL-10 
production after CD40 and CpG activation, levels of IL-10 were very low compared to 
activated-samples from tolerant patients (Fig13 F&G). A similar result was observed 
with TNF-α after CD40L activation. No particular changes were observed in TNF-α 
production after CpG activation.            
In summary, in samples from patients that lost tolerance, the percentages of 
Transitional B cells and the ability to produce IL-10 after CD40 and CpG activation was 









Figure 13: “Loss Tolerance” kidney transplant recipients. 
Percentages of total B cells (A), Memory (B), Naïve (C) and Transitional B cells (D) were measured in 
“Loss Tolerance” kidney transplant recipients by surface staining using panel described in Figure 1. 
Examples of dot-plots of Transitional B cells at time point 1, 2 and 3 from one “Loss Tolerance” kidney 
transplant recipient (E). Secretion of IL-10 was measured in cultures of 1.0x106 PBMCs from “Loss 
Tolerance” kidney transplant recipients, stimulated with 0.5x105 non-transfected L cells or 0.5x105 
CD40L-transfected L cells (plate-bound) (F), and with or without 1uM CpG (G), after 3 days of culture 
using ELISA. Secretion of TNF-α was measured in cultures of 1.0x106 PBMCs from “Loss Tolerance” 
kidney transplant recipients, stimulated with 0.5x105 non-transfected L cells or 0.5x105 CD40L-
transfected L cells (plate-bound) (H), and with or without 1uM CpG (I), after 3 days of culture using 






















4.4 Discussion.    
	  
4.4.1 Overview 
The phenotypic and functional characterisation of the B cell subsets in kidney 
transplant recipients studied in this thesis allowed a better understanding of the role of B 
cells in transplantation tolerance.  
The link between Transitional B cells and transplantation tolerance is based on 
the data showing that tolerant patients exhibited the highest percentages of Transitional 
B cells compared to the other patient groups maintained with immunosuppressive drugs. 
Because immunosuppressive drugs were the main difference between non-tolerant and 
tolerant recipients, the effects (specific induction of apoptosis and cell death) of 
tacrolimus, MMF and steroids on B cells were studied. Then, the phenotype of B cells 
was studied, and Transitional B cells were found to exhibit the highest expression of 
CD20. After phenotypic characterisation, B cell activation was studied measuring up-
regulation of activation markers and cytokine production in B cells from different 
groups of kidney transplant patients.  
4.4.2 B cell phenotype and the identification of the B cell subsets 
The distribution of B cell subsets was studied in peripheral blood to identify 
mainly the Transitional population within PBMCs. The B cell panel used in this study 
was more accurate than the flow panel used by the ITN and the IOT (Newell et al. 2010; 
Sagoo et al. 2010), and was designed based on data from Sims and colleagues (Sims et 
al. 2005; Palanichamy et al. 2009).  
The B cell flow panel was optimised to obtain the best phenotypic 
characterisation. A double positive staining using CD20 and CD19 was performed to 
identify total B cells. Although CD19 and CD20 are both markers fully expressed on all 
B cells, initial results demonstrated that discrimination of B cells using only CD19 was 
quite poor. On the other hand, CD20 exhibited a better separation of CD20+ cells from 
non-B cells, but because Transitional B cells were the main point of interest, the subset 
selection strategy used was very stringent and it was decided the study would start with 
a double staining to avoid any possible contamination with non-B cells in the further 
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downstream analysis.  
Once B cells were identified, CD27 was used to separate Memory B cells. 
Despite the fact that CD27- B cells are smaller with very little cytoplasm, and CD27+ B 
cells are larger cells with a more abundant cytoplasm (Agematsu et al. 1997; Nagumo et 
al. 1998), there are not many markers that help to differentiate one from the other; 
CD27 was the best available marker found. Published data support the idea that CD27 is 
present only in Memory B cells because CD27+, but not CD27- B cells, are rapidly 
activated and can produce higher levels of IgA, IgM, IgG and IgG subclasses 
(Agematsu et al. 1997). Another study demonstrated that CD27+ B cells were absent in 
adult patients suffering from X-linked hyper-IgM syndrome (Agematsu et al. 1998). 
The only definitive marker of Memory B cells is the presence of somatically mutated 
high-affinity antigen receptors. Single-cell studies performed demonstrated that the 
majority of IgD+CD27+ B cells carry mutated V-region genes in comparison with 
IgD+CD27- B cells (Klein et al. 1998). Contrasting data reported the existence of 
CD27−IgG+ B cells in peripheral blood, but the low frequency of somatic mutation 
found in these cells suggests that they could represent just a first wave of Memory B 
cells (Fecteau et al. 2006). In summary, CD27 was the best option for Memory B cell 
discrimination.  
After identification of Memory B cells as CD27+, the characterisation continued 
from the CD27- population with the selection of double positive IgD+IgM+ cells. Based 
on previous studies that described high expression of both surface immunoglobulins in 
Transitional B cells, a double staining was used to improve the identification of these 
cells by phenotypic enrichment (Palanichamy et al. 2009).  
Finally, Transitional and Naïve B cells were identified from the IgD+IgM+ 
population using CD24 and CD38. The selection of CD24 and CD38 was based on 
characterisation studies of Transitional B cells in human samples (Cuss et al. 2006; 
Palanichamy et al. 2009; Blair et al. 2010). Other important surface markers such as 
CD10, CD5 and CD1d (Lee et al. 2009; Yanaba et al. 2009) were not included since the 
aim of this characterisation was to identify of Transitional B cells within PBMCs from 
patient samples rather than a full phenotypic characterisation of these cells. Transitional 
B cells were then identified as CD24hiCD38hi, and Naïve B cells were identified as 
CD24+CD38+. The percentage of Naïve B cells was always the highest within the B cell 
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subsets (50-80%), while the percentage of Transitional B cell was the lowest (10% 
within B cells).      
The population identified as CD24+CD38- “Mature” B cells was an interesting 
population because it was mainly found in patient samples rather than in healthy 
controls. One explanation could be that because Memory B cells are localised in the 
same zone in the flow analysis, “Mature” cells could be Memory B cells with a low or 
absent expression of CD27. The terminology “Mature” was used because B cells were 
positive for IgD and IgM and thus maturation process was implicit, but also to 
distinguish this population from the Naïve and Transitional population (as CD24 and 
CD38 expression was different as well). This terminology did not imply that Naïve and 
Transitional B cells are not part of the mature repertoire of B cells. Finally, pre-Plasma 
cell precursors identified as CD20-CD19+CD27+CD38hi (Harada et al. 1996; Arce et al. 
2001) was a small population predominant in some patient, but absent in healthy 
controls. 
In summary, the B cell panel designed allowed the identification of all the 
relevant B cells subsets present in peripheral blood (Sims et al. 2005). The staining of 
the flow panel was maintained stable during the three years of the study using CS&T 
beads, application settings (control for the flow cytometer variation) and an internal 
sample (control the surface staining/cell preparation variation). 
4.4.3 B cell subset distribution observed in samples from peripheral blood, spleen 
and lymph nodes 
In order to understand the role of Transitional B cells in tolerance, the location 
of these cells was identified in different human tissues associated with an 
immunological function. 
Transitional B cells are the first population that emerge from the bone marrow 
into peripheral blood. Several groups have described a full phenotype in both tissues 
demonstrating how the B cells undergo a maturation process (Sims et al. 2005; Lee et al. 
2009; Palanichamy et al. 2009).  
Although B cells from bone marrow exhibited high percentages of 
CD24hiCD38hi cells, they still remained immature and unable to leave bone marrow in 
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normal conditions, therefore a direct participation in kidney or systemic tolerance is 
unlikely. Furthermore, bone marrow sampling is unpleasant, expensive, requires certain 
surgical elements and it was not ethically justifiable to obtain B cells from kidney 
transplant recipients with stable function.  
The presence of Transitional B cells was evaluated in peripheral blood, lymph 
nodes and spleen from healthy volunteers and cadaveric donors to establish which tissue 
exhibited the highest percentages of Transitional B cell. Results demonstrated that the 
highest percentages of Transitional B cells were found in peripheral blood. Cuss and 
colleagues evaluated CD19+CD24hiCD38hi cells in spleen and lymph nodes and like the 
results obtained in this thesis, both tissues exhibited a low presence of Transitional B 
cells. On the other hand, they found high percentages of Transitional B cells in cord 
blood, but not in peripheral blood (Cuss et al. 2006; Lee et al. 2009). Of note, their 
average percentage was 2.6% of CD19+CD24hiCD38hi B cells in peripheral blood 
samples, whereas this study found a range between 0.5-15% of CD20+CD19+CD27-
CD24hiIgM+CigD+CD38hi Transitional B cells in healthy control and patient samples. 
The differences found can be due to the different gating strategies used to identify all B 
cells subsets, especially Transitional B cells.  
Peripheral blood was the best source to evaluate Transitional B cells in kidney 
transplant recipients, not only because of the higher percentages exhibited compared to 
other tissues, but also because it was the least invasive source from which to obtain 
samples.     
4.4.4 Tolerant recipients exhibited higher percentages of Transitional B cells than 
non-tolerant patients 
B cell subsets, especially Transitional B cells, were measured in peripheral 
blood samples from healthy controls and kidney transplant patients. Tolerant patients 
exhibited the highest percentages of Transitional B cell compared to other patient 
groups.  
B cells and kidney transplantation tolerance was linked for the first time in 2010 
by Brouard’s group (Brouard et al. 2007; Pallier et al. 2010). They defined drug-free 
long-term graft function (DF) patients as patients with long-term acceptance of 
mismatched kidney allografts, after immunosuppressive drug withdrawal, following 
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kidney transplantation. They found that tolerant patients displayed a high number of 
peripheral B cells, particularly Memory B cells, and that these B cells exhibited an 
inhibitory and survival profile.  
During the same year, two large-scale studies focused on identifying a signature 
of tolerance in kidney transplant patients, one from Europe led by Robert Lechler 
(Sagoo et al. 2010) and one from the USA led by Vicki L. Seyfert-Margolis (Newell et 
al. 2010), were published together in the Journal of Clinical Investigation. Both studies 
revealed an expansion of peripheral blood B cells, mainly the Naïve and Transitional 
population, and an increased	  expression of multiple B cell-related genes.  
One year later, Cohelo’s group identified a rare group of kidney-transplanted 
individuals, defined as operational tolerance (OT), able to maintain normal graft 
function with an immunocompetent immune system after the complete withdrawal of 
immunosuppressive drugs. They found that tolerant patients displayed preserved 
numbers of B cells, Naïve B cells and Bregs (defined as CD19+CD24hiCD38hi). Tolerant 
patients also displayed preserved BCR diversity, and a preserved CD40/STAT3 
signalling pathway in Bregs (Silva et al. 2012).  
Data from the study presented in this thesis was obtained from a selected group 
of patients chosen from the GAMBIT study. 12 newly identified tolerant recipients and 
three tolerant recipients included in the IOT study were recruited for the GAMBIT 
study and used in this research project. After three years of B cell subset phenotypic 
analysis, only partial confirmation of what was described by the previous studies could 
be made. Even when results from this thesis agreed with other studies regarding the 
expansion of B cells (in particular Transitional B cells) in tolerant recipients, results 
regarding the Memory or Naïve populations differed from the findings in previous 
studies. Discrepancies in the results can be explained because previous groups evaluated 
numbers of B cells rather than percentages.  
In conclusion, the number and percentages of Transitional B cells were different 
in tolerant recipients compared to patients maintained with immunosuppressive therapy, 
however, no difference was observed between tolerant recipients and healthy control. 
These results opened several questions regarding why Transitional B cells were 
maintained in tolerant patient but not in other patient groups, what was the 
immunological effect of the cells in graft function and whether the immunosuppressive 
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drugs had an effect on Transitional B cell survival.        
4.4.5 The effect of immunosuppressive drugs in B cell viability in vitro 
Because Transitional B cells percentages between tolerant and healthy control 
samples did not exhibit any significant difference, a possible detrimental effect of 
immunosuppressive drugs was evaluated in B cell survival in vitro.  
The detrimental effect of immunosuppressive drugs in B cell survival was 
measured as apoptosis induction and cell death. The expression of BAFFr was linked to 
apoptosis induction. The main reason for doing this is that this particular receptor and 
its ligands have a crucial role in survival signalling and maintenance of mature B cells 
(Craxton et al. 2005; Li et al. 2012). Furthermore, defects in BAFFr expression impairs 
B cell development and prevents the formation of follicular and marginal zone B cells 
(Rauch et al. 2009).  
Results from this thesis showed that down-regulation of BAFFr was a specific 
indicator of apoptosis in the B cells, for this reason, the expression of this receptor was 
measured on B cells from kidney transplant recipient. Stable and chronic rejector 
recipients exhibited a lower expression of BAFFr compared to healthy controls, but 
tolerant recipients did not exhibit any difference compared to healthy volunteers; this 
indicated that B cells from stable and chronic rejector were more sensitive than B cells 
from tolerant patients. Pallier et al. reported that drug-free long-term graft function (DF) 
patients exhibited a transcriptional profile favouring B cell survival. These patients 
displayed an increased BAFFr/BAFF ratio compared to patients with stable graft 
function, healthy individuals, and patients with chronic rejection (Pallier et al. 2010). 
This study’s findings matched those of Pallier et al., showing differential survival 
signals between tolerant patients and stable and rejector patients, but unlike Pallier et al., 
no differences between tolerant patients and healthy individuals were found.  
BAFFr expression in stable and chronic rejector was lower than in B cells from 
healthy control. A possible reason for this could have been the toxic effect of 
immunosuppressive drugs in B cell viability. The effect of tacrolimus, MMF and 
steroids was evaluated, but no clear pattern was found that could explain or associate 
these drug levels with B cell death.  
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Literature reported different effects of these three drugs, for example, Beattly 
and colleagues evaluated the effect of tacrolimus on EBV-infected B cells and found 
that tacrolimus promoted EBV-infected B cells growth through protection from cell 
death. In addition, they demonstrated that tacrolimus inhibited Fas-mediated apoptosis 
(Beatty et al. 1998). This report agrees with the results shown before, as no difference 
was observed in B cells cultured with tacrolimus.   
Another example is the Ganschow study, which demonstrated for the first time 
that using the immunosuppressive drug MMF resulted in MMF-induced B-cell 
dysfunction and depletion in clinical transplantation. They presented the case of a 9-yr-
old girl with primary hyperoxaluria type 1 and systemic oxalosis. The post-operative 
immunosuppression consisted of cyclosporine, prednisolone, and MMF. Four weeks 
post-transplant, serum IgG concentration and B cell count were critically low but this 
effect was reversed when MMF was stopped (Ganschow et al. 2001). In this thesis, 
results in vitro did not demonstrate any difference in viability when MMF was added in 
B cell cultures, but interaction with other drugs in vivo could cause the detrimental 
effect observed by this group.    
Finally, Lill-Elghani’s group found in humans that glucocorticoid induced 
apoptosis of CD10+CD19+ early B cells in the bone marrow, whereas IgD+ mature B 
exhibited glucocorticoid resistance (Lill-Elghanian et al. 2002). Studies of B cell 
subsets in lung transplant recipients treated with steroids, tacrolimus, and MMF showed 
a lack of differences in the absolute number of B cell subsets within the first year of 
follow-up (San Segundo et al. 2012). Kathryn Wood’s group demonstrated that in B cell 
repopulation after Alemtuzumab induction, a transient increase of Transitional and 
Naïve B cells could be seen, and this was not affected by treatment with 
immunosuppressive therapy consisting of tacrolimus, MMF and steroids (Heidt et al. 
2012). In this thesis, B cell viability and apoptosis was severely affected by steroids, but 
again these tests were performed only in vitro, therefore no real drug effect can be 
concluded using this method.   
4.4.6 CD20 and CD19 protein expression in B cells subsets 
CD20 and CD19 molecules are B cell markers that allowed the identification of 
the B cell population within PBMCs. CD19 is one of the earliest cell surface molecules 
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related to B cell lineage differentiation and has been shown to provide a co-stimulatory 
signal for activation through the BCR (Horvath et al. 1998). CD20 is another early B 
cell differentiation antigen identified and CD20-specific monoclonal antibodies are 
commonly used for the treatment of B cell malignancies and autoantibody-mediated 
autoimmune diseases. Despite that, the role of CD20 in human B cell physiology 
remains elusive (Kuijpers et al. 2010).  
The CD20-codifing gene, MS4A1, was one of the genes found in the IOT study 
(Sagoo et al. 2010) to be differentially expressed in tolerant recipients compared to 
other patients groups. This gene was also found up-regulated in tolerant patients from 
the ITN study (Newell et al. 2010) and in the study from Brouard et al  (Brouard et al. 
2007). MS4A1 was the only common gene found in these studies. Moreover, only the 
CD20 transcript from urine sediments was significantly higher in tolerant patients 
compared to patients with stable function and healthy controls (Newell et al. 2010).  
Transitional B cells express significantly higher levels of CD20 compared to 
Naïve and Memory B cells (Cuss et al. 2006). This was confirmed by the current study 
and it was also found that CD20 density in cell membrane was higher in Transitional B 
cells compared to other B cell subsets. Despite CD20 being higher in tolerant recipients, 
no suggestion of a direct relationship between CD20 and tolerance can be made, due to 
the lack of knowledge of CD20 function in the B cell population. The only evidence of 
a human case without CD20, demonstrated that CD20 has a central role in the 
generation of T cell-independent (TI) antibody responses, but not in B cell proliferation, 
activation or survival (Kuijpers et al. 2010).   
Unlike MS4A1, CD19 encoded-gene, CD19, was found in position 489 in the 
IOT study (Sagoo et al. 2010); this is interesting because even when both markers are 
fully expressed on B cells, only CD20 was increased in tolerant recipient. This result 
opens a new approach about the potential unknown role of CD20 in transplantation 
tolerance.  
The clinical use of Rituximab, a chimeric monoclonal antibody against CD20 
used to deplete B cells in haematological (Maloney et al. 1997) and autoimmune 
(Virgolini et al. 2004) diseases, and more recently in transplantation (Salama et al. 
2006), was another important aspect to consider. Because Transitional B cells express 
the highest levels of CD20, these cells are probably the most sensitive population to be 
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affected by Rituximab. This suggests that Rituximab is not only destroying harmful 
predecessors of antibody-producing cells, it is also destroying, (with high efficiency) B 
cells with immunoregulatory properties.  
Studies from Alausa and colleagues presented the case of a 49 years old 
Caucasian male with early acute kidney allograft rejection that was refractory to high 
doses of steroids and thymoglobulin. This patient was treated with Rituximab and 
Muromonab (anti-CD3ε) and after 9 months post-transplantation, he remained rejection 
free with a serum creatinine of 1.7 mg/dL (Alausa et al. 2005), suggesting that 
Rituximab in combination with an anti-CD3ε delayed graft rejection.  
Faguer and colleagues did a pilot study in eight renal-transplant patients 
presenting acute humoral rejection. They assessed the efficacy of Rituximab (375 
mg/m2 weekly) for 3 to 5 consecutive weeks, in addition to plasma exchange, steroids, 
MMF, and tacrolimus. After a follow-up of 10 months (range 7–23), patient and graft 
survival was 100% and 75%, respectively. Renal function improved in six cases (levels 
of creatinine was decreased), graft loss occurred in two cases, and four patients had 
infectious complications. At the final follow-up, DSA had disappeared or decreased in 
four cases. They concluded that Rituximab therapy, in addition to plasma exchange, 
might be beneficial in renal transplant patients presenting acute humoral rejection 
(Faguer et al. 2007).  
On the other hand, Tyden and colleagues reported a 3-years study of ABO-
incompatible renal transplant patients in which forty-four received Rituximab and forty-
seven received placebo. They concluded that a tendency was seen toward fewer and 
milder rejections during the first 6 months in the Rituximab group, but after the 3-year 
follow-up, they did not find a significant difference in the development of donor-
specific antibodies. There was also no difference in the number of graft losses between 
the groups, but there was a statistically significant difference in the mortality, as eight 
deaths were found in the Rituximab study group versus none in the placebo group 
(Tyden et al. 2012).  
Clatworthy et al. planned to recruit hundred and twenty patients in their clinical 
trial, comparing Rituximab versus Daclizumab (anti-CD25 monoclonal antibody) as 
induction therapy in patients undergoing renal transplantation, but the study was 
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suspended after recruitment of the first thirteen patients, owing to an excessive 
incidence rate of acute cellular rejection in the Rituximab group. Patients who received 
Rituximab had a rate of acute rejection that was not only higher than the rate in the 
control group (83% vs. 14%), but also higher than that previously observed among 
patients who had not received induction therapy (35%) (Clatworthy et al. 2009), 
suggesting that Rituximab was an unsuccessful induction therapy. 
Differences and contradictions of Rituximab clinical trials in transplantation, 
such as the ones mentioned above, do not clarify the effectiveness of Rituximab in 
improving graft survival or reducing acute or chronic rejection. In turn, the B cell role in 
renal transplantation is also not clarified, and the understanding of a potential role of 
regulatory B cell in graft survival is fundamental to address this question.  
4.4.7 B cells from kidney transplant patients up-regulated CD25 and CD86 
expression after cognate CD40 activation 
After the phenotypic characterisation, a functional characterisation was 
performed in B cells from healthy controls and patients, measuring up-regulation of 
activation molecules and cytokine production after CD40 and CpG activation. 
    Up-regulation of activation molecules is an important indicator of cell 
activation. This parameter was measured by comparing non-simulated with stimulated 
B cells in PBMCs samples from healthy volunteers and kidney transplant patients.  
No differences in CD86 expression were found between healthy controls and 
patient samples in this study; B cells from all patient groups up-regulated CD86 after 
CD40L activation. Pallier et al. found that total non-activated B cells of tolerant patients 
displayed significantly higher levels of CD80, CD86, CD40, and CD62L compared to 
other transplant patients. They proposed that B cells from tolerant patients expressed an 
activated-memory phenotype with a positive expression of co-stimulatory molecules, 
but when B cells from patients were activated for different lengths of time using 
different stimuli (CD40L, CD40L+anti-IgM, CD40L+CpG), no significant difference 
between activation molecules was observed (Pallier et al. 2010). Newell et al. also 
found that non-activated CD86+CD19+ B cells were significantly higher in samples 
from tolerant patients compared to healthy controls (Newell et al. 2010), but because all 
percentages were no higher than 5% of positive cells, it does not seem plausible to argue 
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that these cells were generally activated.  
Although no differences were observed in CD86 up-regulation, the CD25 
molecule was significantly increased in B cells from tolerant recipients. When the 
expression of this molecule was studied in B cell subsets, CD27- (Naïve and 
Transitional) B cells were the main population responsible for the differential 
expression. The high expression of CD25 in human IL-10-competent B cells was 
observed by Tedder et al. (Iwata et al. 2011). However, Pallier et al. did not find any 
significant differences of CD25 expression in activated B cells (CD40L, CD40L+anti-
IgM, CD40L+CpG) from patients or healthy controls samples (Pallier et al. 2010). 
Different findings from the latter study might be explained by the use of an anti-CD40 
antibody, while in the study presented here, CD40L-transfected cells were used for B 
cell activation since activation with transfected cells was always higher compared to the 
soluble antibody (data not shown). Tedder et al. tested a recombinant CD40L and a 
soluble anti-CD40 monoclonal antibody, and they observed 3.2% and 1% of IL-10+ 
CD19 cells after activation, respectively. They used recombinant CD40L in 
combination with LPS or CpG, obtaining percentages of 12.1% and 9.3% of IL-10+ 
CD19 cells, respectively, suggesting that the recombinant CD40L and a soluble anti-
CD40 monoclonal antibody were not enough stimuli for IL-10 production in their study 
(Iwata et al. 2011).   
In conclusion, results from this thesis suggested that the expression of CD25 by 
B cells is important in tolerance. CD25 is part of the IL-2 receptor, and IL-2 induces 
survival signals in B cells. Since B cell survival was decreased in stable and chronic 
rejector but not in tolerant recipients, and high expression of CD25 was observed only 
in CD27- B cells from tolerant recipients after CD40L activation, it is suggested that 
high expression of the IL-2 receptor by B cells may indicate better B cell viability. 
Since CD27- B cells from tolerant recipients exhibited better viability and endure better 
CD40 activation, these cells may produce more IL-10 than B cells from stable and 
chronic rejector, contributing thereby in the tolerant state.   
4.4.8 B cells from kidney transplant patients up-regulate TLR-9 after CpG 
activation 
TLR-9 expression was measured on B cells by intracellular staining to ensure 
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that these cells were responding to CpG activation. This staining was difficult to 
standardise as TLR-9 is not express on the cell surface after activation. In spite of this, 
using a modified intracellular staining method and a second blocking step, the staining 
of TLR-9 expression was detected; unfortunately these results could not be compared 
with published data as gene expression, and not protein expression, has been used to 
measure TLR-9 expression.  
Liang et al., using RT-PCR, described that human B cells from patients with 
chronic lymphocytic leukaemia expressed high levels of TLR-9 when cells were CpG 
ODNs activated. They also found that CpG ODN induced IL-10 production, which in 
turn, induced STAT-1 phosphorylation and B cell apoptosis (Liang et al. 2010).  
In this thesis, IL-10 production and TLR-9 expression after CpG activation were 
measured in B cells within PBMCs and a correlation between both parameters was 
observed (data now shown), demonstrating that IL-10 production and TLR-9 expression 
were both induced by CpG activation.  
4.4.9 Transitional B cells secrete IL-10 after CD40 activation, and Memory B cells 
secrete IL-10 after CpG activation 
Transitional B cells, Regulatory B cells or IL-10-competent B cells are different 
definitions for IL-10-producing B cells. The importance of IL-10 production lies in the 
role of IL-10 as an anti-inflammatory cytokine in the immune system. The next question 
that this thesis addressed was whether this cytokine was differentially secreted by B 
cells from tolerant patients. 
In humans Duddy et al. reported that B cells secreted IL-10 after CD40 
stimulation. Interestingly, when CD40 stimulation was performed together with BCR 
activation, instead of IL-10, B cells produced more TNF-α, LT, and IL-6 (Duddy et al. 
2004). Further investigation by Tedder’s group revealed that CD40L activation induced 
IL-10+ B cells, but dual stimulation of CD40 and CpG for 48 hours induced even higher 
frequencies and numbers of IL-10+ B cells. The phenotype of these IL-10-competent B 
cells was similar to the phenotype exhibited by Transitional B cells (Iwata et al. 2011). 
In summary, CD40 and CpG activations were the main stimuli to obtain IL-10 from B 
cells, whereas CD40 targeted Transitional (Blair et al. 2010) and Naïve cells (Iwata et al. 
2011), and CpG induced IL-10 secretion from all B cells (Liang et al. 2010).  
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Intracellular staining was the first technique used to evaluate IL-10 production 
by B cell subsets after CD40L and CpG activation, but after several attempts it was 
discovered that it was impossible to identify Transitional B cells because their specific 
markers were down-regulated after three days of culture plus PMA activation. IL-10 
production in sorted B cell subsets from healthy individuals was evaluated to understand 
which activation was stimulating which B cell subset, for further extrapolation of these 
data into patient samples results. Results demonstrated that Transitional B cells were the 
main population responding to CD40-CD40L interaction, which concurred with 
published data, but it was also found that predominantly Memory B cells responded to 
CpG activation.  
From the results obtained from the sorted B cell subsets, CD40L and CpG were 
used separately in patient samples in order to measure IL-10 secretion produced by 
Transitional B cells, as this population was responding specifically to CD40L and was 
the main population increased in tolerant patients. The initial idea was to use CpG as a 
positive control for IL-10 secretion and expression, but based on the results that were 
obtained, CpG activation was used to evaluate possible immune-regulatory mechanisms 
related to Memory B cells via IL-10 production.    
4.4.10 B cells from tolerant recipients produced higher levels of IL-10 and lower 
levels of TNF-α  than B cells from chronic rejector 
After all the required standardisations, IL-10 was measured in patient samples; a 
significant increase of IL-10-producing B cells was found in tolerant patients compared 
to chronic rejector, after CD40 or CpG activation. This means that both Transitional and 
Memory B cells from tolerant recipients were producing IL-10 after activation.    
The results on IL-10 production observed in patient samples showed several 
discrepancies with published data. For instance, Pallier et al., measured cytokine 
secretion in the supernatants of B cell non-stimulated or stimulated with CD40L, 
CD40L/CpG, or CD40L/anti-IgM after 40  hours of activation, but they did not observe 
any difference in IL-10, IL-6, and TNF-α levels between the different groups of patients 
(Pallier et al. 2010). In this thesis, early attempts to activate B cells using soluble CD40 
antibody were invariably unsuccessful. It seems that in Pallier’s study they were not 
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activating B cells either, as they could not find evidence up-regulation of activation 
molecule after their different activation methods.   
Newell’s data reported a statistically significant increase in IL-10+CD38+CD24+ 
Transitional B cells in the tolerant group relative to the stable or healthy control, after 
activation with PMA and ionomycin. Although the differences measured were 
statistically significant, they recognised that the overall percentages were extremely low, 
with many samples lacking any IL-10–producing cells, and with a large overlap of IL-
10 expression between groups. They suggested that this could be caused by the 
stimulation conditions that were limited in length and intensity in order to maintain the 
phenotype of the subsets. In this thesis, PMA and ionomycin did not specifically 
increase IL-10 production in total B cells, and high intensity stimulation down-regulated 
CD24 and CD38. Unlike the current study, Newell’s study did not confirm the 
intracellular data measuring protein levels from the supernatants.    
Sagoo et al. also evaluated production of TGF-β, IL-10 and IFN-γ by 
intracellular staining, after in vitro stimulation of PBMC with PMA and ionomycin. 
Interestingly, using the same activation protocol than Newell’s group, B cells from 
tolerant patients expressed higher percentages of CD20+TGF-β+ B cells, but not IL-10+ 
or IFN-γ+ cells (Sagoo et al. 2010). While the IOT found higher percentages of 
CD20+TGF-β+ B cells, the INT found higher percentages of CD20+IL-10+ B cells in 
tolerant recipients after PMA and ionomycin activation. The discrepancies between 
those studies and the results in this thesis are possibly due to the differences in the 
length and kind of activation. As the aim of this study was to specifically target IL-10 
pathway, activation lasted 72 hours, using CD40L cognate interaction and CpG.  
Data presented in Coelho’s study demonstrated IL-10 expression on Bregs after 
48 hours of activation with mouse anti-human CD40 monoclonal antibody and soluble 
CD40L. CD19+IL-10+ B cells were measured by intracellular cytokine staining. 
Interestingly, they did not measure IL-10 production in patient sample; data presented 
was obtained from only four healthy controls. In this thesis, IL-10 was measured not 
only by intracellular staining, but also in supernatants to confirm the validity of the 
results obtained by intracellular staining data in each kidney transplant recipient.  
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In terms of IFN-γ and TNF-α, unusual intracellular staining was observed in 
both cases. Staining of IFN-γ was strangely increased in B cells, but because ELISA did 
not exhibit any significant value, it was decided that the staining was due to changes in 
size scatter when B cells were activated. TNF-α was also difficult to measure in B cells 
from PBMCs samples; whereas differences in the levels of this cytokine were found 
between supernatants from activated and non-activated samples, the intracellular 
staining showed no differences between samples, showing all B cells (activated and 
non-activated) as positive for TNF-α. These results led to the conclusion that TNF-α 
was positive because of the effect of PMA and ionomycin rather than the activation with 
CD40L or CpG. For these reasons, only the data obtained from ELISA for this pro-
inflammatory cytokine is presented in this thesis.    
In conclusion, IL-10 was differentially secreted by B cells from tolerant patients 
compared to chronic rejector. In addition, B cells from chronic rejector secreted TNF-α 
instead of IL-10. This change in the secretion profile by B cells could be a consequence 
of the immunological responses exhibited in the different patient groups.   
4.4.11 “Loss of Tolerance” kidney transplant recipients 
The fact that some transplanted patients can obtain good graft function in the 
absence of immunosuppression is still puzzling. A number of questions regarding this 
clinical response are immediately raised such as how long does it last, can it be induced, 
is it stable overtime, and so on. In order to answer these questions, three patients that 
had lost their tolerant state were identified and studied to try to understand more this 
unusual phenomenon. This is the first time such group of patients has been evaluated 
and no previous records in the literature have been found. In patients from this group, 
the tolerant state was not permanent, but what cause the lost of graft function is still 
unknown.  
In this study, it was found that although total B cell percentages remained 
without variation after losing tolerance, the percentages of Transitional B cells 
decreased over time. Loss of tolerance, accompanied by loss of Transitional B cells, 
supports the idea that Transitional B cells are participating in the tolerant state. 
Unfortunately, the quality of the samples did not allow for all the sets of experiments (to 
evaluate cytokine production or BCR activation) originally planned to be performed, but 
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when a comparison of IL-10 secretion between this group and tolerant recipients was 
made, it was observed that IL-10 secretion was absent in the “Loss Tolerance” group 
after CD40 and CpG activation.  
These results further support a clear relation between tolerance and Transitional 
B cells as “Loss of Tolerance” patients have a decreased percentage of Transitional B 




5 BCR signalling pathway and donor-specific response in 
kidney transplant patients 
	  
5.1 Introduction. 
 The immune response in kidney transplant recipients is commanded by the 
innate and the adaptive immune system (He et al. 2003). The innate response is a non-
specific response, antigen independent, immediate, and exposure to antigen results in no 
immunological memory (Murphy et al. 2012). The adaptive response, on the other hand, 
is antigen-dependent and antigen-specific. There is a lag time between exposure and 
maximal response, and exposure to antigen results in immunologic memory (Murphy et 
al. 2012). Although both responses can participate or mediate rejection in kidney 
transplantation, the donor-specific response is still the most critical response involved.  
The donor-specific response is principally initiated when gene products encoded 
in the MHC region from the donor cells are recognised as foreign by immune cells from 
the recipient (Halloran et al. 1986; Eremin et al. 2011; Murphy et al. 2012). Genes from 
the MHC region are highly polymorphic (Snell 1948) and were initially identified 
because of their presence in rejection of transplanted tissues (Snell 1951; Snell et al. 
1951).  There are two main classes of MHC molecules, Class I and II: 
• Class I molecules are expressed in all nucleated cells. They are 
recognised by CD8 T cells, and three major loci, B, C and A, as well as 
other undefined minor loci are contained in their genetic complex (Sun et 
al. 1995).  
• Class II molecules are only expressed on APCs such as DCs, 
macrophages and B cells. They are recognised by CD4+ T cells; and the 
class II genetic complex also contains three loci, DP, DQ and DR (Bach 
et al. 1967; Mehra et al. 2003; Eremin et al. 2011).  
Donor-MHC molecules can be identified by direct, indirect and semi-direct 
recognition. Direct recognition is when MHC molecules expressed on the surface of 
donor cells are directly recognised as foreign by recipient T cells (Warrens et al. 1994). 
Indirect recognition is when donor MHC proteins are recognised, internalised, 
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processed and presented as peptides by recipient APCs to recipient T cells, in a self-
MHC restricted manner (Lechler et al. 1982). Finally, semi-direct recognition is when 
recipient APCs capture whole membrane blocks from donor cells, and immune cells 
from the recipient recognise donor MHC proteins contained in these membrane blocks 
through the direct pathway, together with indirect recognition of donor MHC antigens 
(Herrera et al. 2004). 
The indirect pathway in kidney transplantation consists of the presentation of 
donor-antigenic peptides by self-MHC, in a self-restricted manner (Lechler et al. 1982; 
Shoskes et al. 1994). It has been associated with chronic rejection due to the long-term 
response triggered after donor-antigen recognition, internalisation and presentation by 
recipient APCs. B cells are also professional APCs because they present peptides in the 
context of the MHC class II. Unlike other APCs, B cells recognise donor-proteins with 
high specificity, due to the specificity exhibited by the BCR immunoglobulin to the 
foreign protein, therefore the recognition by the BCR is the first step in the indirect 
response induced by B cells (Lanzavecchia et al. 1985; Steele et al. 1996).   
The B cell Receptor (BCR) is a transmembrane protein formed by both 
immunoglobulin and CD79 (Igα/Igβ). While the membrane-bound immunoglobulin is 
located in the outer surface of the cell and recognises foreign proteins, the heterodimer 
CD79 contains immunoreceptor-tyrosine-based activation motif (ITAM), in the 
intracellular tails, and they are responsible for the downstream signal activation 
(Murphy et al. 2012). 
 Activation of the BCR complex induces recruitment and activation of the 
protein tyrosine kinase Syk, which in turn, promotes BTK phosphorylation and PLCγ, 
Shc and Vav activation. Then, the BLNK adaptor protein continues the BCR activation 
downstream, resulting in the activation of the intermediate signalling protein Ras. Ras 
finally activates the MAP kinases, ERK, JNK and p38. These last proteins activate 
multiple signalling cascades, involving kinases, GTPases, and transcription factors that 
can change the cell metabolism, gene expression and cytoskeletal organisation. The 
complexity of BCR signalling allows triggering of different cell functions including 
survival, anergy, apoptosis, proliferation, and differentiation into antibody-producing 
cells or Memory B cells. This complexity deepens according to: maturation of the cell, 
the nature of the antigen, the magnitude and duration of BCR signalling, and signals 
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from other receptors such as CD40 or BAFFr. Therefore, the participation of B cells in 
the immune response is directly related to the different responses triggered after BCR 
activation (Sproul et al. 2000; Hasler et al. 2001). 
B cells play a double role in donor-specific responses; through the BCR, they 
can recognise donor MHC molecules as antigens and then present them as donor-
derived peptides in the context of MHC class II (Sproul et al. 2000), and they can 
differentiate into antibody-producing Plasma cells (Calame 2001; Calame et al. 2003). 
Evidence of clear participation of B cells in kidney transplant allorecognition is 
predominantly evident after the appearance of IgG donor-specific antibodies in the 
serum of the recipient. Presence of donor-specific antibodies indicates the existence of 
Memory B cells with BCRs (Ig) sharing the same specificities of the IgG donor-specific 
antibodies.  
According to the third hypothesis in this thesis:  
• Transitional B cells are able to modulate active allogeneic responses and 
therefore play a key role in inducing donor-specific tolerance. 
Donor-specific response driven by B cells and their subsets, were evaluated in 
kidney transplant recipients. In order to answer this question, this chapter was divided in 
two aims:   
Aim 1: Evaluation of the BCR signalling pathway, with a non-specific stimulus 
in patient samples and healthy controls.  
Aim 2: Donor-specific antigen capture, internalisation and further antigen 
presentation by B cells to CD4+ T cells. The idea was to measure BCR activation, 
donor-specific B cells, donor-proteins internalisation and the CD4+ T cell response in 




5.2 BCR signalling pathway activation in kidney transplant patients. 
5.2.1 BCR activation was quantified using ERK-p 
The BCR signalling pathway was studied in healthy controls and patient samples 
after non-specific activation. Three proteins from the BCR signalling pathway were 
selected (BTK, BLNK and ERK) and phosphorylation of each protein was measured 
after activation by phospho-flow. BTK and BLNK were discarded from patient assays; 
the first protein because the BCR activation was not as optimal as expected, and the 
histogram did not show a well defined activation peak, and the second protein because it 
required specific buffers incompatible with those already used. Functional and technical 
complications, as well as the inconsistency of the staining made the measurement of 
these two proteins incompatible with the assay. ERK, on the other hand, showed a very 
stable staining with the highest separation between the negative and the positive control 
(Fig14 A).  
A 6-colour phospho-panel was developed to measure the MFI of ERK-p in each 
B cell subset. Standardisation of this protocol was initiated by performing a time course 
to detect the maximum MFI difference between non-activated and activated samples. 
PMA was used as a positive control of ERK-p and 10 minutes was the minimum time 
required for maximum phosphorylation signal (Fig14 B). After 10 minutes, a plateau in 
the activation pattern was observed. The effect of CD40L as a co-activator of the BCR 
pathway was also measured, but no additive effect was found when both activations 
were performed together (Fig14 C). CD40L activation was then discarded from patient 
samples.  
▲MFI was defined as the difference between the MFI of a 10-minutes 
stimulated sample  with the MFI of a 0-minutes stimulated (or non-stimulated) 
sample  (Fig14 D). A control sample was used to perform an inter-assay and intra-
assay control. For the intra-assay control, three aliquots of the control sample were 
prepared and acquired at the same time; results in ▲ERK-p did not present significant 
differences (Fig14 E). For the inter-assay control, a control sample was acquired every 




Figure 14: ERK phosphorylation. 
BTK-p, BLNK-p and ERK-p were measured in 1.0x106 PBMCs from healthy volunteers after BCR-
activation with anti-IgM (20ug/ml)/anti-IgG (20ug/ml) during 0, 5 and 10 minutes at 37○C using 
phospho-flow. (A). A time course of ERK-p was measured in 1.0x106 PBMCs from healthy volunteers 
after BCR-activation with anti-IgM (20ug/ml)/anti-IgG (20ug/ml) during 0, 10 and 30 minutes at 37○C 
using 0.1uM PMA 10 minutes as a positive control (B). The effect of CD40L as a co-stimulatory 
molecule was evaluated in ERK-p adding 0.5x105 CD40L-transfected L cells into 1.0x106 BCR-activated 
PBMCs (C). Difference in ▲ERK-p MFI between 1.0x106 non-activated PBMCs and 1.0x106 activated 
PBMCs with anti-IgM (20ug/ml)/anti-IgG (20ug/ml) for 10 minutes at 37○C was displayed in a histogram 
(D). 1.0x106 PBMCs from the inter assay control were activated with anti-IgM (20ug/ml)/anti-IgG 
(20ug/ml) during 0 and 10 minutes at 37○C;▲ERK-p MFI was measured in total B cells and B cell 
subsets (E). 	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5.2.2 ERK phosphorylation detection by phospho-panel in B cell subsets 
BCR activation was determined by phosphorylation of the downstream protein 
ERK. Although this biological change allowed the development of an effective method 
to quantify BCR activation, the real challenge was to quantify this activation in each B 
cells subset. A 6-colour phospho-panel was designed to measure ERK-p in different B 
cell subsets after BCR activation.  
The gating strategy began with the selection of the live population in PBMCs 
(Fig15 A). This population was very important to measure because the activation at 
37°C, the intracellular staining protocol and the buffers used in the phospho-panel were 
very detrimental for B cell viability. The final protocol resulted in more than 80% of 
PBMCs viability. Then, from the live population, B cells were identified as CD20+ cells 
(Fig15 B) and Memory B cells as CD20+CD27+ cells (Fig 15 C). Finally, from the 
CD27- population, Naïve and Transitional B cells were identified as CD24+CD38+ and 
CD24hiCD38hi, respectively (Fig15 D). Even with all the difficulties of the methodology 
used in the phospho-panel, the detection of each B cell subset was possible (with an 
acceptable separation and definition), in order to continue with the measurement of 
ERK-p. Delta ERK-p was then measured in total B cells, Memory, Naïve and 












Figure 15: Phospho-panel gating strategy. 
1.0x106 PBMCs were stained for 20 minutes at 37○C before activation with anti-IgM (20ug/ml)/anti-IgG 
(20ug/ml). Live cells were defined as Live/Dead- (A).  B cells were defined as CD20+ (B). Memory B 
cells were defined as CD27+ (C) and from the CD27- population Naïve B cells were identified as 
CD24+CD38+ and Transitional were identified as CD24hiCD38hi (D). ▲ERK-p MFI was identified in 
total B cells, Memory, Naive and Transitional B cells as the difference between ERK-p MFI from non-
activated samples (white histogram) and ERK-p MFI from samples activated with anti-IgM 
(20ug/ml)/anti-IgG (20ug/ml) for 10 minutes at 37○C (colour histogram) using phospho-flow (E). 
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5.2.3 Distribution of IgM- and IgG-expressing cells in PBMCs from healthy control 
and kidney transplant patients 
IgM percentages, and therefore IgG percentages indirectly, were measured in 
Memory and CD27- B cells from patient samples to ensure that the stimulus used in the 
BCR activation experiments were targeting Memory, Naïve and Transitional B cells 
(Agematsu et al. 1997; Agematsu et al. 1998).  
The frequencies of IgM+IgD- (Fig16 A), IgM+IgD+ (Fig16 B), IgM-IgD- (Fig16 
C) and IgM-IgD+ (Fig16 D) cells, within CD27- B cells, were measured by surface 
staining. At the same time, the frequency of IgM+IgD- (Fig16 E), IgM+IgD+ (Fig16 F), 
IgM-IgD- (Fig16 G) and IgM-IgD+ (Fig16 H) cells, within Memory B cells, were 
measured by surface staining in healthy controls and patient samples. 
 These tests found that CD27- cells were mainly IgD/IgM double positive (Fig16 
B), while CD27+ were divided in IgM+IgD+ B cells (un-switched class-Memory B cells) 
(Fig16 F) and IgM-IgD- B cells (switched class-Memory B cells) (Fig16 G).  
Because of this mixture of IgM+ with IgM- cells, a combination of anti-IgM/ 





Figure 16: IgM/IgD distribution in CD27- and CD27+ B cells from kidney transplant patients. 
From the CD27- population (described in Fig1 B) IgM+IgD- (A), IgM+IgD+ (B), IgM-IgD- (C) and IgM-
IgD+ (D) populations were identified, and from the CD27+ population (described in Figure 1 B) IgM+IgD- 
(E), IgM+IgD+ (F), IgM-IgD- (G) and IgM-IgD+ (H) populations were identified in PBMCs from healthy 
controls and patient samples using surface staining. Kruskal-Wallis test with a Dunn’s multiple 
comparisons test was used, * p<0.05 was considered significant.            
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5.2.4 B cell subsets from tolerant recipients displayed defective ERK 
phosphorylation after BCR activation compared to healthy volunteers 
PBMCs from healthy controls and patient samples were used to study the BCR 
activation in CD20+ B cells and subsets. In order to activate all the B cell subsets at the 
same time, a combination of anti-IgM and anti-IgG activating antibodies were used. 
Previous tests had defined CD27- B cells as mainly IgM+ cells (Fig16 B), while CD27+ 
Memory B cells were both, IgM+ (Fig16 F) and IgM- (Fig416 G). Therefore, this dual 
stimulation allowed the activation of the BCR from Memory, Naïve and Transitional B 
cells simultaneously.  
Results show that phosphorylation of ERK, after BCR activation, was reduced in 
CD20+ cells from tolerant recipients (**p=0.0055) compared to CD20+ cells from 
healthy control (Fig17 A). Regarding subsets, Memory B cells (Fig17 B) (**p=0.0049) 
and Naïve B cells (Fig17 C) (**p=0.0040) from healthy controls exhibited a higher 
BCR activation compared to samples from tolerant recipients only. Even when tolerant 
patients exhibited the same tendency of BCR activation in the Transitional population, 
the difference did not reach statistical significance (p=0.1277) (Fig17 D).  
Using the same results, a different comparison between samples was performed; 
this time instead of comparing delta ERK-p between patient groups, delta ERK-p 
between B cell subsets from each patient group was compared. Within group 
comparison, healthy controls exhibited a higher activation in the Memory B cell subset 
compared to Transitional B cells (***p=0.0008) (Fig18 A). This tendency was lost in 
tolerant (Fig18 B), stable (Fig18 C) and monotherapy patients (Fig18 D), but was 
recovered in chronic rejector (*p=0.0361), in a lower scale (Fig18 E). 
These results indicate that B cells and B cell subsets from tolerant recipients, 
exhibited a certain degree of anergy or unresponsiveness to general BCR activation, as 




Figure 17: BCR activation measured in B cells subsets from kidney transplant patients. 
PBMCs from control, healthy control and patient samples was thawed and rested in RPMI-1640 (Sigma) 
supplemented with IL-2 (100ng/ml, R&D) at 37°C 5% CO2 overnight. Next day, 3.0x106 PBMCs from 
control, healthy control (HC), tolerant (Tol), stable (Sta), monotherapy (Mon) and chronic rejector (CR) 
were stained for 20 minutes at 37○C with the panel described in Figure 15, to identify ▲ERK-p in total B 
cells (A) Memory (B), Naïve (C) and Transitional (D) B cells. After surface staining, PBMCs were 
divided in three aliquots, and 1.0x106 cells were activated with anti-IgM (20ug/ml)/anti-IgG (20ug/ml) or 
0.1uM PMA (not shown) for 0 and 10 minutes at 37○C. ERK-p was identified using phospho-flow, and 
▲ERK-p was calculated as the difference in ERK-p between non-activated samples and BCR-activated 
samples (described in Figure 14 D). Kruskal-Wallis test with a Dunn’s multiple comparisons test was 





Figure 18: BCR activation measured between B cells subsets from kidney transplant patients. 
▲ERK-p was compared between B cell subsets in PBMCs samples obtained from healthy control (A), 
tolerant (B), stable (C), monotherapy (D) and chronic rejector (E) using the same protocol described in 
Figure 17. Kruskal-Wallis test with a Dunn’s multiple comparisons test was used, * p<0.05 was 




5.3 Donor-specific response in kidney transplant patients. 
In terms of non-specific BCR activation, it was found that B cells from tolerant 
recipients exhibited a lower BCR activation compared to healthy volunteers. The next 
step was then to measure BCR activation and immune responses driven by B cells after 
specific activation, in this case with donor-specific antigens. The following section will 
describe the role of B cells as APCs for the alloresponse in different groups of kidney 
transplant patients.  
5.3.1 Donor-proteins preparation 
Donor-specific B cells can be identified by the ability of the BCR to bind donor-
proteins; following on from this, an assay was developed to detect and measure donor-
protein capture by recipient B cells. The challenge of this assay was to achieve protein 
fluorescent labelling, to then identify and locate these proteins, within recipient B cells.  
Protein preparation started with the enrichment of MHC class II+ donor cells. 
For this reason, CD2+ cells were removed from the PBMCs using positive selection 
with magnetic-beads. After the enrichment, donor cells were stained with CFSE, and 
proteins from the membrane and cytosol were isolated by centrifugation cycles with 
hydrophobic buffers. After the separation, histograms exhibited a CFSE+ staining for 
donor-proteins obtained from the membrane fraction (Fig19 A) and from the cytosolic 
fraction (Fig19 B) of the cell. CFSE+ protein samples  were compared to unstained 
protein samples  (Fig19 A&B).  
The optimisation of the solvent in which both fractions were contained was 
performed after protein isolation. While the cytosolic fraction was resuspended in a 
low-dose detergent solvent, the membrane fraction was resuspended in a high-dose 
detergent solvent. Cell toxicity is associated with high detergent concentrations; 
however, detergent can be removed using two methods; detergent-removal columns and 
dialysis. Detergent removal column protocols concentrated proteins in the samples, but 
also maintained high concentration of detergent in the protein preparations. On the other 
hand, dialysis halved the concentration of the proteins, but samples remained low levels 
of detergent (Fig19 C). Due to the toxicity produced by high detergent concentration, 
dialysis was used despite the fact that the concentration of the proteins was lower than 
the other method. 
165	  
	  
Once donor-proteins were in the appropriate solvent, MHC conformation was 
evaluated by western blot. MHC class I and II were found in both protein fractions 
(Fig19 D). Whereas higher concentrations of MHC class were found in the membrane 
fraction, MHC class II exhibited better definition in the cytosolic fraction.  
Optimal protein concentration was established by measuring cell death from 
cultures at different donor-protein concentrations. More than 80% of live cells were 
observed when membrane protein concentration was between 0-0,5ug/ml (Fig19 E); 
therefore, this concentration range was used, as the viability was quite acceptable. 
Optimal culture conditions were also tested because the volume contained and the cell 
concentration strongly influenced the cell viability after protein addition. Then, 12 
(Fig19 F) and 48 (Fig19 G) well-plates were used with 2.5, 5 and 10x106 of PBMCs. 
Best culture conditions were found to be in 12 well-plate at 5x106 PBMCs/4ml of media, 








Figure 19: Donor-protein isolation. 
Histograms were used to demonstrate the FITC+ staining in unstained  and CFSE+  protein samples 
from the membrane (A) and cytosolic (B) fraction of the cell after protein isolation. Four different 
methods were used to remove detergent from protein samples without drastically affecting protein 
concentration. Spin removal detergent columns, dialysis and combinations were tested to measure protein 
concentration after detergent removal (C). After isolation and dialysis of proteins preparations, western 
blot was performed to identify MHC class I and class II molecules using 20ug of protein per sample (D). 
Lymphocytes viability was measured after adding different concentrations of the CFSE+ protein using a 
Live/Dead dye, and optimal viability was found when protein concentration was between 0 - 0,5ug/ml (E). 
Using the same technique, lymphocytes viability was measured after adding 0.5-1ug/ml of CFSE+ 
proteins in 12 (4ml) (F) and 48 (2ml) (G) well-plate. Best condition was obtained when 0.5ug/ml of 
CFSE+ proteins were cultured with 5.0x106 PBMCS in a 12 well-plate with 4ml of complete media/well. 
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5.3.2 Donor-specific activation assays in two control samples 
Before performing patient assays, the experiments were controlled with two 
control samples. The first control corresponded to a husband/wife pair sample in which 
the wife had become pregnant three times by her husband. It has been demonstrated that 
female transplant recipients who received an organ from their husband, with a single 
previous pregnancy, had a high graft survival rate, comparable to those with more than 
one pregnancy (Suzuki et al. 1997). It has been shown that a history of pregnancy 
induces high sensitisation in female recipients.  
Based on this, proteins, prepared from MHC+ class II cells from the husband, 
were tested with PBMCs from the wife. Autologous (wife) and allogeneic (husband) 
proteins were prepared and 0.5ug/ml of each preparation was added in PBMC cultures 
from the wife, to then measure the donor-protein specific B cells by flow cytometry. B 
cells were identified as CD20+ cells from the live PBMC population cultured with 
autologous (Fig21 A) and allogeneic (Fig21 B) proteins; B cells were close to 3% in 
both samples. From the B cell population, CFSE+ B cells that recognised autologous 
(Fig21 C) or allogeneic (Fig21 D) proteins were identified. Results revealed that 
incubation with allogeneic proteins exhibited a 0.416% of CFSE+ cells compared to 
0.035% of CFSE+ cells from autologous proteins. The first control sample demonstrated 
specificity in the identification of donor-specific B cells despite the low number of 
events.  
The second control pair sample was a kidney transplant recipient with known 
anti-HLA antibodies. “Negative’’ proteins were prepared from CD2- allogeneic PBMCs 
in which the allogeneic HLA proteins were not recognised by known recipient 
antibodies. “Positive” proteins were prepared from CD2- PBMCs that expressed HLA 
molecules recognised by known recipient antibodies.  
B cells were identified as CD20+ cells and monocytes as CD14+ cells. 
Monocytes were used as a positive control for protein internalisation because these cells 
capture proteins by phagocytosis in a non-specific manner. B cells were cultured alone 
(Fig22 A), with “negative” (Fig22 B) or “positive” (Fig22 C) HLA proteins. From the 
same sample, CD14+ cells were evaluated without proteins (Fig22 D), and with either 
the “negative” (Fig22 E) or the “positive” (Fig22 F) HLA protein preparations. A faint 
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but consistent difference was observed between the negative and the positive B cell 
samples (Fig22 B), but no difference was observed in the monocytes. Negative (Fig22 E) 
and positive (Fig22 F) samples within monocytes presented a similar percentage of 
protein capture. 
In conclusion, the second control sample demonstrated specificity in the 
identification of donor-specific B cells, but it also demonstrated clear differences 
between two APCs exhibiting different internalisation processes. Whereas monocytes 
capture non-specific CFSE+ proteins via phagocytosis, B cell internalise mainly donor-













Figure 20: Control sample 1. 
To perform the assays, 0.5ug/ml of autologous (A) and allogeneic (B) CFSE+ proteins were cultured for 
24 hours with 5.0x106 PBMCS in a 12 well-plate with 4ml of complete media/well. Then, CD20+ FITC+ 








Figure 21: Control sample 2. 
To perform the assays, CFSE+ proteins were cultured for 24 hours with 5.0x106 PBMCS in a 12 well-plate 
with 4ml of complete media/well. FITC+ B cells were identified in samples with 0ug/ml (A), 0.5ug/ml of 
negative/autologous (B) and 0.5ug/ml of positive/allogeneic (C). FITC+ CD14 monocytes were identified 












5.3.3 Donor-protein internalisation 
After protein sample preparation, a time course was performed to define the 
minimum incubation time required to identify the donor-proteins inside recipient B cells. 
CFSE+ cells were studied within monocytes and B cells from the control sample 
(described in 5.3.2) at 1, 2, 4, 8 and 24 hours after donor-protein addition. Both cells 
exhibited CFSE+ cells after 24 hours (Fig20 A), hence the following assays were all 
performed after 24 hours of culture. 
To confirm that CFSE staining found by flow cytometry corresponded to protein 
internalisation and not just a membrane bound protein, ImageStream images were used 
to identify the localisation of donor-proteins within the B cells, using the control 
samples (described in 5.3.2). Recipient PBMCs were cultured with CFSE+ donor-
proteins overnight. CD20+ B cells were then sorted by staining with CD20 and MHC II 
markers for ImageStream acquisition. Single B cells were identified with brightfield 
area close to 100, and aspect ratio close to 1 (Fig20 B). Focused cells were selected up 
to 60 brightfield gradient (Fig20 C). Double intensity of HLA and CD20 defined the B 
cell population (Fig20 D) and the intensity of donor-protein CFSE+ cells were evaluated 
in the HLA-DR aspect ratio positive cells (Fig20 E).  
After the population analysis, a cell-based analysis of positive images was 
performed. The surface of the cell was defined using the brightfield image. Then, CD20 
(pink) and HLA-DR (red) molecules were identified on the surface of the B cells using 
both the intensity feature (for CD20 and HLA-DR together) and the brightfield image. 
Once the cell surface was delimitated by CD20 and HLA-DR intensity from their 
respective fluorescence channels, CFSE+ donor-proteins, presenting a positive intensity 
in the FITC channel, were identified inside of the CD20+/MHC class II+ B cell (Fig20 
F). To detect donor-proteins inside of the B cells, the image of the intensity of the 
CFSE+ proteins was overlapped with the image of the intensity of CD20+/MHC class II+. 
A positive CFSE signal inside the B cells was observed, along with vesicle appearance, 
and these were found to be closer to the inner side of the membrane (Fig20 F). Cells 
incubated with autologous-proteins did not exhibit a CFSE signal (-) (Fig20 G) 





Figure 22: Donor-protein internalisation. 
A protein-capture time course assay was performed after 1, 2, 4, 8, and 24 hours, to identify CFSE+ cells 
within monocytes and B cells, when 0.5ug/ml of CFSE+ proteins were cultured with 5.0x106 PBMCS in a 
12 well-plate with 4ml of complete media/well. (A). CFSE+ B cells were enriched from the PBMCs and 
CD20+HLA-DR+ B cells were sorted before ImageStream analysis. Then, single cells were identified 
from the sorted population (B), focused cells were identified from the singles (C), B cells were identified 
from the focused cells (D) and FITC+ B cells were identified from the B cell population (E). Images of 
bright field, CD20 , HLA-DR , and CFSE+ donor-proteins  from sorted B cells were obtained using 
ImageStream (F). Negative (-) and Positive (+) controls of protein internalisation displayed by 
ImageStream images (G).	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5.3.4 Donor-specific B cell presentation assays demonstrated a positive response in 
chronic rejector but not in tolerant and stable patients 
 The first aim of this experiment was to evaluate antigen capture by B cells from 
kidney transplant recipients by measuring CFSE+ donor-protein internalisation by 
recipient B cells, using B cells as APCs and donor-proteins as allogeneic antigens. 
Allogeneic proteins (donor) and autologous proteins (recipient) were prepared and 
incubated with recipient PBMCs for 24 hours at 37°C. For each patient, the autologous 
protein capture (○—) and the allogeneic donor-proteins capture (—●) by CD20+ B cells 
was measured using flow cytometry (Fig23 A). Firstly, only recipient B cells from 
chronic rejector exhibited a significant increase in protein recognition and 
internalisation of allogeneic donor-proteins (*p=0.0428). Secondly, donor-protein 
capture in B cells from chronic rejector was significantly higher than those from tolerant 
(***p=0.0002) and stable (****p<0.0001) patients.  
The second aim of this assay was to analyse effector responses by measuring 
donor-specific T cell activation. Recipient CD4+ cells were cultured with autologous B 
cell subsets loaded with donor-proteins. After 3 days of activation, CD4+ T and CD20+ 
B cells were harvested, CD25 expression was measured in CD4+ T cells and CD86 was 
measured in CD20+ B cell subsets, in order to study their expression after donor-antigen 
presentation. Surprisingly, CD25 expression by CD4+ T cells was increased in tolerant 
patients (Fig23 B). All B cell subsets from all recipients expressed CD86 with equal 
intensity (Fig23 C).   
After donor-specific activation, the CD4+ T cell response was measured in an 
IFN-γ/IL-10 dual-ELISPOT assay. This method allowed the measurement of two 
cytokines at the same time in CD4+:CD20+ co-cultures activated with donor-proteins. 
The idea was to evaluate the Th1 response and the role of IL-10, in donor-specific 
activation. Background cytokine production from CD4+:CD20+ co-cultures without 
donor-proteins and from CD4+ cultures with donor-proteins (without B cells) was 
subtracted from the cytokine production from donor-specific CD4+:CD20+ co-cultures. 
In healthy controls responses, background subtraction was exclusively from CD4+ T cell 
cultures without B cells. IFN-γ and IL-10 spots were calculated per 100.000 CD4+ T 
cells from the CD4+:CD20+ co-cultures.   
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  Regarding the Th1 response, IFN-γ production by CD4+ T cells (Fig23 D) 
induced by all B cell subsets was absent in tolerant samples. All stable samples secreted 
IFN-γ, but Naïve and Transitional subsets were the highest inducers. CD4+ T cells from 
chronic rejector secreted IFN-γ, mainly from the sample activated by Memory B cells; 
Naïve B cells induced half of the amount present when CD4+ T cells were co-cultured 
with Memory B cells, and Transitional B cells did not induce any IFN-γ production in 
this patient group.  
IL-10 secretion by CD4+ T/CD20+ cells (Fig23 E) was higher in healthy controls 
than patient samples, but no differences were observed between B cell subsets, although 
T cell cultures with Transitional B cells exhibited the highest frequency of IL-10 
production. In tolerant and stable patients, cells did not secrete considerable amounts of 
IL-10. Interestingly, chronic rejector co-cultures secreted more IL-10 that other 
recipient samples, but all B cell subsets induced the same levels of this cytokine. It is 
unknown if the IL-10 secretion was coming from the B cell subsets or from the CD4+ T 
cell population.   
IFN-γ  and IL-10  spots from the IFN-γ/IL-10 dual-ELISPOT were plotted 
together to evaluate any relationship between the secretion of these two cytokines in 
healthy controls (Fig23 F) and kidney transplant patients (Fig23 G).  
In healthy controls, both cytokines were identified in CD4+ T cell co-cultures 
with all B cell subsets. In this group, IL-10  secretion was more than doubled 
compared to IFN-γ , and while Memory B cells induced higher levels of IFN-γ, 
Transitional B cells induced the highest levels of IL-10 (Fig23 F). CD4+ T cells from 
tolerant patients failed to produce any IFN-γ despite clear evidence of CD4+ T cell 
activation, whereas CD4+ T cells from stable patients mainly secreted IFN-γ. CD4+ T 
cells from chronic rejector secreted IFN-γ mainly from samples cultured with Memory 
B cells, and slightly less in T cells cultured with Naïve B cells. Interestingly, CD4+ T 
cells cultured with Transitional B cells did not produce any IFN-γ (Fig23 G). 
In conclusion B cells from tolerant recipients did not induce a Th1 response with 
any B cell subset, revealing a potential role for B cells in controlling the allogeneic-
specific response to the graft. In chronic rejector, the groups with the highest protein 
capture, Memory B cells induced the higher Th1 response, followed by Naïve B cells, 
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which produced a median response. Interestingly, Transitional B cells did not induce 
IFN-γ production. The last result supports the idea that Transitional B cells do not 








Figure 23: Donor-specific antigen response 
Internalisation of 0.1ug/ml of autologous ○— and allogeneic —● CFSE+ proteins by 5.0x106 CD20+ B 
cells from kidney transplant recipients after 24 hours of culture, measured as CD20+CFSE+ B cells by 
flow cytometry (A). Two-way RM ANOVA test with a Sidak’s multiple comparisons test was used, * 
p<0.05 was considered significant. An IFN-γ/IL-10 dual-ELISPOT was performed to measured antigen-
specific activation on CD4+ T cells elicited by autologous B cells subsets from kidney transplant 
recipients. 1.0x105 CD4+ T cells were co-cultured with and without 0.5x105 sorted autologous B cells 
subsets from healthy control (HC), tolerant (Tol), stable (Sta) and chronic rejector (CR) for 72 hours, with 
and without 0.1ug/ml of autologous or allogeneic CFSE+ proteins. After 3 days, CD4+ T cells and CD20+ 
B cell subsets from the co-cultures were collected, and the expression of CD25 on CD4+ T cells (B) and 
CD86 on the B cell subsets (C) were measured in the different groups of kidney transplant recipients 
using surface staining. IFN-γ (D) and IL-10 (E) production by CD4+ T cell/CD20+ B cell subsets co-
cultures was measured using an IFN-γ/IL-10 dual-ELISPOT. Spots per 105 cells were calculated in each 
well after background deduction. Combined IFN-γ/IL-10 production was plotted in sample from healthy 
controls (F) and kidney transplant recipients (G). Two-way RM ANOVA test with a Tukey’s multiple 

















5.3.5 Donor-specific antibodies were more prevalent in serum samples from 
chronic rejector  
 HLA matching plays a fundamental role in the outcome of transplanted patients, 
particularly from deceased donors. Large national transplant databases clearly show that, 
in spite of improving immunosuppression, the higher the number of HLA antigen 
matches, the better the outcome following kidney transplantation, particularly in 
deceased donor transplants (Eremin et al. 2011). 
In practice, renal transplant donors and recipients are matched in order to 
increase graft survival (Eremin et al. 2011). Three of the HLA loci are usually typed 
and matched in kidney transplantation: HLA-A, HLA-B, and HLA-DR. However 
nowadays, immunosuppressive drugs can mitigate the effect of HLA mismatching 
maintaining stable graft function even when more than one mismatch is present in the 
transplanted organ (Halloran 2004).  
In this section, the relationship between HLA mismatches and the outcome in 
the different patients groups was investigated (Table 3). Interestingly, tolerant recipients 
had the lowest HLA mismatches; less than 50% for HLA-A, HLA-B and HLA-DR. 
More than the 70% of the stable patients presented at least one HLA mismatch in each 
locus. Patients in monotherapy varied; 50% had HLA-class I mismatch and less than 20% 
had HLA class-II mismatch. Chronic rejector were the group with the highest numbers 
of HLA mismatch, more than the 80% of the patients presented HLA differences with 
the donor, around 25% presented two mismatches and the rest presented only one 
mismatch (Table 3).   
Donor-specific anti-HLA class-I and anti-HLA class-II antibodies were 
identified in serum samples from transplanted samples (Fig24). The number of total 
patients positive for DSA , patients with HLA-I DSA , patients with HLA-II DSA 
,	  and with both  were plotted. In the tolerant group, two patients presented HLA 
class-I DSA, and one patient HLA class-II DSA. The only stable patient positive for 
DSA had only one HLA class-I antibody. In the chronic rejector group, two patients 
presented HLA class-I DSA, four patients presented HLA class-II DSA, and a further 
five patients presented both.  
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In summary, chronic rejector were the patients with the highest number of 
DSAs. This suggests that the presence of these antibodies correlates with low graft 
survival and bad prognosis. However, two tolerant recipients also exhibited DSAs 
without any sign of chronic rejection, suggesting that DSAs may not be a reliable 
indication of graft lost. Conversely, this result may indicate that these tolerant patients 
are close of losing their graft and their tolerant state. Specificities in DSAs did not show 

















Figure 24: Donor-specific antibodies. 
DSA were obtained from serum samples from healthy controls and kidney transplant patients. The total 
number of patients positive for total DSA ; the total number of patients positive for HLA-I DSA ; 
the total number of patients positive for HLA-II DSA ;	  and total number of patients positive for HLA-I 





The second chapter was designed to evaluate the BCR signalling pathway and 
the donor-specific responses elicited by B cells from the different patient groups. The 
first aim was to evaluate the function of the phosphorylation cascade of B cells from 
different patient groups by measuring phosphorylated proteins from the BCR signalling 
pathway after non-specific activation. Then, donor-specific assays and the measurement 
of anti-donor HLA antibodies were performed to understand the role of B cells as APCs 
in antigen-specific responses. 
5.4.2 BCR activation 
The BCR engagement is the main activation in the B cell population; when it 
binds the specific antigen it transduces the signal downstream through the BCR 
signalling cascade. In this pathway, several proteins are phosphorylated after BCR 
activation, one of which is ERK. The staining for ERK-p was very stable and was used 
as an indicator of general BCR activation in Memory, Naïve and Transitional B cells.  
Irish et al. from Nolan’s group studied the BCR-mediated signalling via 
phosphorylation of BTK, Syk, ERK1/2, and p38 in tumour B cells from follicular 
lymphoma samples (Irish et al. 2006; Irish et al. 2006). They found that p-ERK1/2 
exhibited the highest activation signal after 8 minutes of activation with 10ug/ml of 
anti-IgM and anti-IgG F(ab′)2 fragments in CD20+ cells within PBMCs. The same 
stimulus and kinetics of ERK and BTK reported by Nolan’s group were used to design 
the activation protocol and the phospho-flow staining for this study.  
Nolan’s data reported that αIgM/αIgG was the best stimulus to activate the BCR 
in total B cells; to confirm this, IgM+ and IgM- B cells were studied in healthy controls 
and kidney transplant patient samples (Fig16). As expected CD27- B cells expressed 
high levels of IgM, and CD27+ B cells exhibited both IgM+ and IgM- B cells. It was 
assumed that CD27+IgM- B cells found in peripheral blood correspond to IgG 
expressing-B cells. A combination of anti-IgM/ anti-IgG was then used to activate both 
subsets at the same time. Concentration of anti-IgM/ anti-IgG was also a critical point in 
the experiments, as such, several concentrations of antibodies were tested and 20ug/ml 
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was found to be optimal for activation in all groups of patients.   
Three proteins from the BCR pathway were evaluated in this study, BTK, 
BLNK and ERK, but only ERK was stable enough to be measured in patient samples. In 
addition, several time points were evaluated, and it was found that 10 minutes was 
sufficient to identify ERK-p with a fair separation between the activated and the non-
activated sample. Nolan’s group also reported a shorter time of activation and a lower 
intensity in BTK-p compared to ERK-p, a result that was also found in this study during 
the standardisation; however this result is explained by the fact that BTK-p appears 
much earlier than ERK-p in the BCR signalling cascade.  
ERK-p levels were studied after BCR, CD40 and BCR/CD40 activation, but 
only BCR activation induced a positive response. Even when both activations (BCR and 
CD40) were performed together, CD40-CD40L interaction decreased BCR activation 
instead of promoting a higher response. Contrary to the data from this thesis, Ying et al. 
examined whether CD40 ligation activated the BCR signalling pathway (Ying et al. 
2011). They stimulated BALB/c splenic B cells with anti-IgM F(ab′)2, anti-CD40, or 
both, and blotted with phospho-antibodies against Lyn, Syk, and BLNK. They found 
that CD40 stimulation induced phosphorylation of Syk and BLNK, whereas BCR and 
CD40 co-stimulation resulted in a synergistic activation of Syk, but not Lyn. Their 
results suggest that CD40 activation shares components of the BCR signalling pathway, 
and because of that, CD40 may quantitatively enhance BCR-mediated signalling. They 
also found that BTK-p and ERK-p were enhanced by CD40 co-stimulation in BCR-
mediated signalling (Mizuno et al. 2005; Ying et al. 2011); interestingly B cells were 
activated first via CD40, and then by using anti-IgM (Mizuno et al. 2005). The main 
differences between Ying’s study and this thesis were the origin of the cells and the 
technique used to detect phosphorylation; this study used PBCMs and a phospho-flow, 
and they used BALB/c splenic B cells and western blot. They also added an anti-mouse 
CD40 activating antibody, while CD40L-transfected L cells were used in this study. 
Possible reasons for these discrepancies include: western blot is more sensitive than 
phospho-flow to detect phosphorylation signals; CD40L-transfected L cells were not 
added at the right concentration; B cells from the spleen responded better to CD40 
activation than B cells from peripheral blood, a different proportion of Naïve and 
Memory in the sample; or simply because as PBMCs already presented the CD40 
stimulus needed to activate B cells, the addition of CD40L-transfected L cells was 
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irrelevant in the activation system, and they only interfere with the BCR engagement 
due their large size.  
Finally, Duddy et al. demonstrated that B cells exhibited different responses, 
depending on the activation received (CD40, BCR, BCR+CD40) (Duddy et al. 2004). 
Whereas CD40 activation induced an anti-inflammatory response, BCR activation 
induced a pro-inflammatory response that was enhanced with the CD40-CD40L 
interaction. These results suggests that in human B cells, BCR and CD40 activation 
trigger different signalling pathways, and that BCR activation can be boosted by CD40 
co-stimulation.  
In conclusion, ERK-p evaluation allowed the measurement of BCR activation in 
Memory, Naïve and Transitional B cells. This activation was short, non-specific, and 
controlled by several factors. The main benefit of this technique was the possibility of 
measuring BCR activation in different B cell subsets within PBMCs.     
5.4.3 ERK-p was detected in the B cell subsets by phospho-flow 
Phospho-flow was used to identify ERK-p in B cell subsets within PBMCs. The 
challenge was to distinguish Memory, Naïve and Transitional B cells, get a fair viability 
and avoid complex sample preparation. PBMCs were used because, after several tests, it 
was ascertained that B cells maintained a better viability when they were not isolated, as 
isolated or sorted B cells exhibited a low survival rate (data not shown).  
Regarding the use of phospho-flow panels in transplantation, Silva et al. found 
significantly higher levels of STAT3-p in B cells from kidney transplant tolerant 
recipients after CD40 activation (Silva et al. 2012). The same technique was used 
before by Claudia Mauri’s group to study the IL-10 pathway after CD40-CD40L 
interaction (Blair et al. 2010). The results demonstrated a relationship between tolerance 
and IL-10 signalling. Both groups identified that the main STAT-3-p expressing cells 
were within the Transitional B cells. 
Although identification of the link between tolerance and the Transitional 
population through STAT3-p was of interest, the phospho-panel was used in this 
chapter to study the BCR activation and donor-specific responses rather than CD40 




5.4.4 B cell subsets from tolerant recipients displayed a defective BCR signalling 
pathway compared to healthy volunteers 
BCR activation was measured in total B cells and B cell subsets from healthy 
controls and kidney transplant patients. These experiments generated two important 
results: total B cells and B cell subsets from tolerant recipients failed to phosphorylate 
ERK after BCR activation, and Transitional B cells exhibited lower ERK-p than 
Memory and Naïve B cells.  
DeFranco’s group established that BCR activation varies depending on the 
maturation state of the cell and on the additional signals that the cell receives (DeFranco 
2000). They proposed that antigen-BCR interaction in immature mouse B cells typically 
causes them to enter into an anergic state or undergo apoptosis. In contrast, mature B 
cells coming into contact with antigens enter the G1 phase of the cell cycle and up-
regulate many proteins involved in adhesion and antigen presentation. Strong BCR 
stimulation can also induce differentiation of B cells into antibody-secreting Plasma 
cells by providing cell-cell contact signals via CD40, and by releasing cytokines such as 
IL-4 and IL-5 (DeFranco 2000; Richards et al. 2001). These different responses can be 
associated with the ERK-p observed in B cell subsets from this thesis, as Transitional B 
cells had lower responses than Memory and Naïve B cells.  
Another group reported in a mouse model that BCR ligation on immature B cells 
induced apoptosis, whereas on mature B cells induced cell activation and growth 
(Koncz et al. 2002). They compared the kinetics of ERK activation in transitional 
immature and mature B cells and found that in immature B cells, ERK was transiently 
phosphorylated, while in mature cells, ERK phosphorylation was sustained up to 2 
hours. The lack of sustained ERK activation in immature B cells suppressed the 
transcription factors necessary for proliferation signals (Koncz et al. 2002).  
Another study also reported the role of ERK in B cell survival by comparing 
BCR with BAFF activation. They found that although BCR cross-linking induced rapid 
activation of ERK within 30 minutes, ERK activation subsequently declined below 
basal levels within 16 hours and remained low. On the other hand, BAFF induced 
delayed but sustained stimulation of ERK. Their results suggested that BAFF inhibited 
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death by sustained ERK activation (Craxton et al. 2005), as a consequence, they 
consider ERK activation as an indicator of better B cell viability.  
A case report showed that T1 and T2 B cells in mice were more sensitive to 
BCR stimulation than mature follicular B cells for BCR-induced ERK phosphorylation. 
This phenomenon was explained by the absence of Lyn (a kinase that phosphorylates 
ITAMs on the BCR Igα/Igβ chains following antigen binding) in the immature 
population. Then, while the B cell signalling was greatly enhanced in mature B cells, 
the B cell signalling was minimally affected in the immature cells (Gross et al. 2009). 
These results in mouse models suggest that mature B cells responded better than 
immature B cells to full BCR activation.  
In studies with human cells, Ha et al. compared BCR activation in B cell subsets 
from cord blood, bone marrow, and peripheral blood. First, they investigated the 
activation of ERK and p38 in B cells following stimulation with anti-IgM or anti-CD40 
antibodies. Then, they identified different B cell subsets with IgD, CD27, CD24 and 
CD38 markers, and finally they measured ERK and p38 phosphorylation in these well-
defined B cell subsets. They found that B cells in cord blood contained an increased 
proportion of CD24-expressing B cells and a low proportion of CD27-expressing B 
cells. In addition, a minimal CD40-mediated activation of ERK and p38 was observed 
in these cells (Ha et al. 2008), implying that Transitional B cells were not responding to 
BCR activation.  
In the study presented in this thesis, B cells from tolerant recipients failed to be 
activated via BCR compared to B cells from healthy controls. This result was important 
because for the first time a difference was observed between B cells from tolerant 
patients and healthy controls. This result suggests that B cells from tolerant recipients 
revealed a certain degree of anergy or unresponsiveness; interestingly, this effect was 
also observed in Memory and Naïve B cells from tolerant recipients. This could imply 
that total B cells from tolerant recipients enter into a non-responsive state after BCR 
activation.  
Looking at the different B cell subsets, it was observed that in healthy controls, a 
clear pattern could be established in which Memory B cells were the main responders to 
BCR activation, Naïve B cells were intermediate and Transitional B cells were the 
lowest responders. This pattern was lost in all patients groups except in chronic rejector. 
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All these data together suggest that B cells could contribute to tolerance via failure in 
the BCR activation. 
5.4.5 Donor-specific responses overview 
Several reports support the idea that whereas direct recognition plays a dominant 
role in acute rejection, indirect recognition is the main pathway involved in chronic 
allograft failure (Mason et al. 1996; Hornick et al. 2000; Baker et al. 2001; Baker et al. 
2001). This is because T cells require co-stimulatory signals from specialised APCs to 
get activation. In the case of direct recognition, within hours/weeks of transplantation, T 
cells are activated by the recognition of intact foreign MHCs on the surface of donor 
APCs from a transplanted organ, particularly DCs. After few weeks from 
transplantation, DCs of donor origin are depleted, therefore the occurrence of direct 
recognition is unlikely (Game et al. 2002). In the case of indirect recognition, when 
donor MHC are internalised, processed, and presented as peptides by host APCs, a 
permanent activity is observed after transplantation due to a continual trafficking of 
recipient APCs through the graft (Game et al. 2002).  
Pathways of allorecognition also have implications in transplantation tolerance. 
In order to obtain clinical tolerance, an induction of specific tolerance in T cells with 
indirect allospecificity is required to control the recipient immune response (Game et al. 
2002). B cells are professional APCs; they express MHC class II and can therefore elicit 
indirect responses through donor-peptide presentation in the context of MHC class II. 
One of the aims of this thesis was to evaluate the induction of indirect alloresponses by 
T cells, induced by donor-specific B cell and their subsets. The final goal was to find a 
relationship between these cellular responses and the clinical responses in kidney 
transplanted patients.  
5.4.6 Donor-protein preparation and internalisation 
To develop donor-specific assays, a new method was set up to obtain soluble 
proteins from donor cells. This protocol has evolved from protocols previously reported 
(Baker et al. 2001; Bestard et al. 2008; Nickel et al. 2009). The aim of this part of the 
project was to measure donor-proteins inside of the B cells, thus the first goal was to 
obtain stained soluble donor-proteins identifiable by flow cytometry. MHC molecules 
conjugated with fluorescent proteins were available (as the ones used to identify donor-
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specific antibodies by Luminex kits), however, the cost was very high and it was 
impossible to obtain them separately. Furthermore, even if common HLA-A/B/C and 
HLA/DR molecules were used, DQ, DP, mH and other relevant proteins would still be 
missing in the assay. For all these reasons, a new method was set up using a CFSE 
staining in the donor CD2- cells before the membrane and cytosolic protein extraction. 
This technique allowed obtaining a variety of CFSE+ donor-proteins, identifiable by 
flow in the FITC channel, from several donor samples. 
5.4.7 Control samples used in donor-specific activation assays 
Two samples were used as controls, the first sample derived from a woman that 
had three pregnancies with the same partner. It is known that mammalian reproduction 
poses an immunological paradox because foetal alloantigens encoded by genes inherited 
from the father, should provoke responses by maternal T cells leading to foetal loss 
(Mellor et al. 2000). One of the hypotheses to explain foetal tolerance proposed that the 
foetus is not recognised as foreign by the mother; however, women who have several 
children with the same partner usually make alloantibodies recognising the partner 
MHC mismatched molecules. Indeed, this has been recognised as the best source of 
antibodies for human MHC typing (Murphy et al. 2012). The existence of antibodies 
indicates the existence of paternal specific B cells.  
In 1997, Susuki et al. reported pooled results of spousal donor transplants 
performed at 97 centres in the USA. The data was gathered from 250 centers in the 
USA in the UNOS Registry between October 1987 and December 1996, and analysed 
by Kaplan-Meierb survival curves. The authors of the study investigated the effect of 
pregnancies on transplant outcome (Picture 7) and found that wives with a single 
previous pregnancy had a high graft survival rate comparable to those with more than 
one pregnancy. Based on these results a spouse/wife (with three pregnancies) was used 
to increase the possibility of identifying donor-specific B cells. 
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Picture 7: Effect of pregnancy in graft survival  
Figure extracted from “Unrelated living donor kidney transplants” (Suzuki et al. 1997). 
 
When the B cells from the former control sample and the second control sample 
(that corresponded to a kidney transplant recipient with known HLA alloantigens 
recognised) were incubated with CFSE labelled “donor” proteins, a high background in 
the staining was observed in positive samples compared to the unstained samples. 
Therefore, a sample without CFSE+ proteins was not the proper negative control to 
obtain percentages of CFSE+ B cells. The problem was solved using as a sample of self-
CFSE+ proteins as a negative control (knowing no history of autoimmune disease in 
both cases).  
Although this data showed CFSE-proteins+ B cells, and a difference between the 
negative and positive control, protein internalisation was not proven because donor-
antigens are recognised by the BCR, therefore the signal obtained could have 
corresponded to a surface location instead of an internal one. ImageStream was used to 
confirm the location of CFSE+ donor-proteins inside the B cells.  
Finally, it was concluded that protein recognition and internalisation was 
assessed with this method and the next step was to measure both parameters in patient 
samples.         
5.4.8 Donor-specific activation exhibited by kidney transplant patients 
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Recipient B cells were cultured with protein preparations from recipient and 
donor samples to identify antigen recognition and internalisation in different patient 
groups. Results demonstrated that B cells from chronic rejector internalised more donor-
proteins compared to tolerant and stable patients.  
The donor-specific indirect response was then observed using recipients CD4+ T 
cells as responders, donor-proteins as antigens, and B cell subsets as APCs. The main 
idea of this experiment was to evaluate the contribution of each B cell subset to donor-
antigen presentation.  
Chung et al. investigated the ability of murine Transitional B cells to process 
and present antigens to CD4+ T cells, and to elicit protective signals in the absence of 
CD86 up-regulation. They reported that Transitional B cells processed and presented 
antigens as peptide:MHC class II complexes, but their ability to activate T cells and 
provide help to CD4+ T helper cells was compromised (compared to Mature B cells) 
unless exogenous T cell co-stimulation was provided. Their data suggest that during an 
immune response, Transitional B cells may be able to sustain the responses of pre-
activated CD4+ T cells, but are unable to initiate activation of Naïve T cells (Chung et al. 
2003). This report demonstrated the functional role of Transitional B cells as APCs due 
to their ability to process and present donor-antigens.  
In this thesis, results obtained from the control samples exhibited antigen 
internalisation in all B cell subsets, including Transitional B cells (data not shown). 
However, B cells from tolerant recipients did not show any CFSE+ B cells within any of 
the B cell subsets analysed. The fact that tolerant recipients had more HLA-matches 
with their respective donors compared to stable patients and chronic rejector, could 
possibly have affected the percentage of B cells capable of capturing donor-proteins. 
This could be due to a lower diversity of proteins present in preparations from donors of 
tolerant recipients; data from dual-ELISPOT support this result as IFN-γ was not 
secreted by responders CD4+ T cells co-cultured with B cell subsets from tolerant 
recipients.  
In contrast, B cells from chronic rejector demonstrated a positive donor-protein 
capture and a positive antigen-presentation to CD4+ T cells, as demonstrated in the dual-
ELISPOT results. Interestingly, in this patient group, Memory B cells were the best 
APCs in the induction of the Th1 response, whereas Naïve B cells demonstrated a lower 
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potential in the induction of IFN-γ. Transitional B cells did not induce any IFN-γ 
production by CD4+ T cells.  
B cells from stable patients did not show a clear capture pattern, and Naïve and 
Transitional B cells induced more Th1 response than Memory B cells.  
In conclusion, only data obtained from the analysis of chronic rejector agreed 
with Chung’s suggestion that Transitional B cells are unable to activate T cells. 
Regarding the results in tolerant recipients, Haynes et al. investigated the role of the 
donor-specific indirect responses from T cells in renal transplant tolerance using trans-
vivo delayed-type hypersensitivity (tvDTH). They found that the indirect pathway was 
active in tolerant, steroid-monotherapy, standard immunosuppression and chronic 
rejection patients, but not in identical twin recipients. Although they found responses in 
all patients groups, distinct intergroup differences were evident and they corresponded 
to the clinical status (Haynes et al. 2012) They found that tolerant recipients exhibited 
the lowest response, followed by patients in monotheraphy, then stables, and finally, 
chronic rejector. These findings concur with the results obtained from tolerant recipients 
in this thesis, as they did not induce a pro-inflammatory response. Haynes et al. also 
tested blocking antibodies in their tvDTH model to evaluate the participation of IFN-γ, 
TGF-β, IL-17 and IL-10. Whereas anti-IFN-γ and anti-IL-17 antibodies significantly 
blocked the indirect pathway of T effector cell responses to donor-antigens in the 
chronic rejector patients, antibodies against TGF-β blocked the suppressive response 
observed in tolerant recipients. In contrast, IL-10 did not appear to contribute to the 
anti-donor cell response, as neutralising IL-10 did not affect the footpad swelling to 
donor-antigen. The results of this thesis did not demonstrate any clear involvement of 
IL-10 in antigen-specific responses. IL-10 was mainly produced during co-cultures of B 
and T cells obtained from chronic rejector, but no differences between B cell subsets 
was observed within this group. Finally, they demonstrated the activity of B cells in the 
tvDTH assay. They depleted B cells from one stable and one tolerant patient and they 
measured the inhibitory response to allo-peptides. Neither patient’s inhibitory response 
was affected by depletion or reintroduction of B cells. Even when no clear B cell 
participation in tolerant patients was identified, a link between tolerance and B cells was 
suggested, as two of the three tolerant patients with the lowest regulation to donor-
antigen also had the lowest number of B cells. 
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In summary, like T cells, B cells cannot be considered as cells with one specific 
function. Similar to T cells that can have effector, regulatory and cytotoxic functions, B 
cell subsets also seem to have different responses and roles in the immune system.  
Transitional B cells have been the main B cell population related to tolerance in 
humans; for example, patients with severe immunodeficiency exhibited an increment of 
circulating immature/transitional B cells with a noticeable reduction of circulating 
memory B cells (Martinez-Maza et al. 1987; De Milito et al. 2001; Cuss et al. 2006). 
Blair et al demonstrated the importance of Transitional B cells in human autoimmune 
disease, showing that patients with systemic lupus erythematous were refractory to 
CD40 stimulation, and therefore, the suppressive capacity of the B cells was impaired 
when IL-10 pathway was blocked (Blair et al. 2010). Finally, a new intriguing role of 
Transitional B cells in kidney transplantation was revealed since tolerant recipients 
exhibited an expansion of B cells, especially Transitional B cells in peripheral blood 
(Newell et al. 2010; Sagoo et al. 2010; Silva et al. 2012). All these clinical data support 
the idea that Transitional B cells exhibit a specific regulatory role able to modulate 
different immunological processes via different mechanisms.        
5.4.9 Donor-specific antibodies were more prevalent in serum samples from 
chronic rejector 
Although several studies reported the prevalence of donor-specific antibodies 
(DSAs) in chronic rejection (Kimball et al. 2011; Loupy et al. 2012; Mohan et al. 2012; 
Page et al. 2012) the role of DSAs in mediating chronic allograft injury is not fully 
understood. Hidalgo reported that in addition to the detrimental effect of pre-existing 
DSAs in the outcome of the transplant, de novo antibodies, emerging at any time after 
transplantation, could also negatively affect graft survival (Hidalgo et al. 2009).  
Hidalgo also reported that DSAs have different pathogenicity. Recent 
observation supported the idea that de novo DSAs are mainly specific to donor MHC 
class II; interestingly, DSAs against MHC class II are associated with a worse prognosis 
than DSAs against MHC class I (Hidalgo et al. 2009). In this study a mixture of MHC 
class I and II DSAs were found in all kidney transplant recipients, except in 
monotherapy. These results suggest that MHC class I and II are not only participating in 
the immunological response in transplantation during rejection.    
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Incidence of DSAs was clearly higher in patients with chronic rejection. This 
was not only found in the numbers of patients positive for DSAs, it was also seen in the 
number of antigenic specificities shown by recipients from this group. This observation 
supports the results from the antigen capture assays where the percentages of CFSE+ B 
cells from chronic rejector were higher compared to tolerant and stable recipients. 
Interestingly, two tolerant recipients also presented DSAs without any clinical signs of 
possible rejection. 
In summary the role of antibodies in transplantation tolerance is not fully 
understood with this small numbers of samples. It was concluded that because DSAs are 
prevalent in chronic rejection, they contribute to this clinical state, however it was 
observed that the presence of DSAs does not always induce rejection, since two tolerant 




6 The effect of B cell subsets as CD4+ T cell-activating cells 
6.1 Introduction. 
The cross-talk between B and T cells, that involves specific antigen recognition, 
and protein-protein interaction, can lead to cell activation and cytokine production 
(Clark et al. 1994). The TCR and the MHC are the main players in cognate recognition. 
The TCR recognises specific self-restricted peptides in the context of the MHC 
molecules. Although TCR:peptide-MHC complex is an important interaction, 
participation of co-stimulatory molecules is essential to induce cell survival and/or to 
lead to different activation pathways. Co-stimulation molecules induce different 
responses: CD80/CD86-CD28 induces T cell activation, CD40-CD40L induces B cell 
survival and maturation, and CD86-CTLA-4 induces anergy (Dong et al. 1999). 
Cytokines also play an important role in the cross-talk between cells; they can induce 
cell survival, proliferation, activation, differentiation or suppression depending of the 
type of cytokine released.  
In the following set of experiments, the incidence of B cells in the induction of 
proliferation, activation and cytokine secretion by CD4+ T cell was evaluated. B cell 
subsets were isolated from peripheral blood samples (healthy volunteers), and co-
cultured with autologous CD4+ T cells to evaluate for each subset, the potential role as 
CD4+ T-activating cells.  
Memory, Naïve and Transitional B cells not only exhibit a specific phenotype, 
they also express a different array of co-stimulatory molecules, distinct cytokine 
secretion profiles, and different survival properties. These differences between the 
subsets are the main causes of the variety of, and sometimes opposite, effects in CD4+ T 
cell proliferation, activation and cytokine secretion.  
In summary, this chapter was designed mainly to answer the last hypothesis in 
this thesis:  
• Transitional B cells exhibit an anti-inflammatory response compared to 




6.2 CD4+ T cell activation by B cell subsets. 
6.2.1 Memory, but not Transitional B cells induced CD4+ T cell proliferation after 
five days of co-culture 
In order to understand the potential role of B cells as CD4+ T-activating cell, 
CD4+ T cell proliferation induced by autologous B cell subsets was studied. T and B 
cells were obtained from healthy volunteer’s blood samples. B cell subsets were then 
isolated to study their distinctive T cell-activating effects. CD4+ T cells were activated 
with an anti-CD3 antibody in order to up-regulate CD40L expression on the T cell 
surface, and to consequently activate the B cells through CD40-CD40L interaction. 
Expression of CD40L was measured on the T cell surface after 12 and 24 hours of anti-
CD3 activation, and maximal CD40L expression was obtained between 6 and 12 hours 
of activation (Fig25 A). To increase chances of CD40-CD40L interaction, B cells were 
then added after 6-8 hours of CD4+ T cell activation (when CD40L expression was at 
the highest level). To allow this interaction, CD4+ T cells were activated while B cell 
subsets were isolated by flow sort, allowing both cells to be ready at the same time 
before the five-day co-culture.   
After T and B cells were co-cultured, a time course was performed to evaluate T 
cell proliferation rates at day 1, 3 and 5 induced by Memory, Naïve and Transitional B 
cells (Fig25 B). Proliferation started after 3 days of co-culture and by day 5, Memory B 
cells induced the highest CD4+ proliferation rate compared to the other B cell subsets.  
Once it was established that day 5 was the optimal time to measure proliferation, 
a new large-scale experiment was undertaken to measure, in the T-B cell co-cultures, 
cell proliferation, expression of activation markers and cytokine production (Fig25 C). 
This experiment had two new conditions (compared to the time course experiment); 
CD4+ T cells alone to measure the basal proliferation rate, and CD4+ T cells with total B 
cells (33.3%/each subset) to control T cell proliferation in the presence of total B cells. 
Results showed that CD4+ T cells cultured with Memory B cells significantly increased 
proliferation rates compared to CD4+ T cells cultured alone (*p=0.0169), or with 
Transitional B cells (*p=0.0146). However, no difference was observed in the 
proliferation of CD4+ T cells co-cultured with Naïve B cells. Therefore, it can be 




Figure 25: CD4+ T cell proliferation induced by B cell subsets. 
Expression of CD40L was measured in the cell surface of 1.0x106 CD4+ T cells after 0, 12 and 24 hours 
of activation with anti-CD3 (1ug/ml, plate-bound) (A). A time course was performed to measure T cell 
proliferation in co-cultures of 0.5x106 anti-CD3-activated CD4+ T cells with 0.5x106 Memory, Naïve or 
Transitional B cells after 0, 1, 3 and 5 days of co-culture (B). The statistical analysis used was RM-
ANOVA test * p<0.05 with a Tukey’s multiple comparisons test. Percentages of T cell proliferation were 
measured in co-cultures of 1.0x106 anti-CD3-activated CD4+ T cells with or without 0.5x106 B cells, 
Memory, Naïve or Transitional B cells after 5 days of co-culture (C). The statistical analysis used was 
RM-ANOVA test * p<0.05 with a Holm-Sidak’s multiple comparisons test.             
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6.2.2 Transitional B cells did not induce expression of CD25 and CD69 molecules 
on CD4+ T cells compared to Memory B cells after five days of culture 
 Expression of activation molecules CD25 and CD69 were measured by surface 
staining on CD4+ T cells co-cultured with total B cells and B cell subsets, after 5 days of 
culture. These proteins were measured as an indication of T cell activation induced by B 
cell subsets.  
Results showed that CD25 was significantly up-regulated in CD4+ T cells 
cultured with Memory B cells compared to CD4+ T cells cultured alone (*p=0.0260) or 
with Transitional B cells (*p=0.0350) (Fig26 A).  
In terms of CD69, it was found that this marker was also significantly increased 
in CD4+ T cells cultured with Memory B cells compared to CD4+ T cells cultured alone 
(*p=0.0499) or with Transitional B cells (*p=0.0152) (Fig26 B). There was also a 
significant increase of CD69 expression in CD4+ T cells cultured with Memory B cells 
compared to CD4+ T cells cultured with Naïve B cells (*p=0.0192) (Fig26 B).  
Altogether Memory, but not Transitional, B cells were able to induce up-


















Figure 26: Activation molecules in CD4+ T cells co-cultured with B cells. 
CD25 (A) and CD69 (B) expression was measured in 1.0x106 anti-CD3-activated CD4+ T cells, co-
cultured with or without 0.5x106 B cells, Memory, Naïve or Transitional B cells after 5 days using surface 
staining. The statistical analysis used was RM-ANOVA test * p<0.05 with a Holm-Sidak’s multiple 
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6.2.3 Transitional B cells did not induce production of pro-inflammatory cytokines 
by CD4+ T cells compared to Memory B cells after five days of culture 
 Pro-inflammatory cytokine production was measured in activated CD4+ T cells 
co-cultured with or without B cells and B cell subsets after 5 days of culture; IFN-γ and 
TNF-α were measured using intracellular staining and ELISA.  
Similarly to proliferation and expression of activation markers, Memory B cells 
were, once again, the main activating population in terms of cytokine production. A 
higher percentage of CD4+IFN-γ+ T cells was found in co-cultures of T cells with 
Memory B cells, compared to CD4+ T cells alone (*p=0.0122) or with Transitional B 
cells (**p=0.089) (Fig27 A). Results obtained with ELISA revealed that CD4+ T cells 
co-cultured with Memory B cells also induced higher levels of IFN-γ, compared to 
CD4+ T cells cultured alone (**p=0.0069) or with Transitional B cells (*p=0.0183). Co-
cultures of CD4+ T cells with total B cells also exhibited a significant increase in IFN-γ 
production compared to CD4+ T cells cultured alone (**p=0.0078) or with Transitional 
B cells (*p=0.0201) (Fig27 B). This implies that IFN-γ induced by total B cells is 
mainly coming from the activation with the Memory population.  
TNF-α, the second pro-inflammatory cytokine studied, was also measured by 
intracellular staining and ELISA. In the first case, high percentages of CD4+TNF-α+ T 
cells were found in co-cultures with Memory B cells, compared to CD4+ T cells alone 
(*p=0.0282) or with Transitional B cells (*p=0.0282) (Fig27 C). In the second case, 
CD4+ T cell co-cultures with Memory B cells secreted significantly higher levels of 
TNF-α, compared to CD4+ T cells cultured alone (**p=0.0028) or with Transitional B 
cells (*p=0.0144). Co-cultures of T cells with total B cells also significantly increased 
TNF-α production, compared to CD4+ T cells cultured alone (*p=0.0255) (Fig27 D). 
In summary, Memory B cells were the main population that induced pro-
inflammatory cytokine production by CD4+ T cells. Naïve B cells also participated in 
cytokine production, but at a lower scale, and Transitional B cells did not induce pro-






Figure 27: Identification of pro-inflammatory cytokines produced by CD4+ T cells co-cultured with 
B cells. 
Percentage of CD4+IFN-γ+ cells (A) and levels of IFN-γ (B) from co-cultures of 1.0x106 anti-CD3-
activated CD4+ T cells with or without 0.5x106 B cells, Memory, Naïve or Transitional B cells after 5 
days of co-culture. Percentage of CD4+TNF-α+ cells (A) and levels of TNF-α (B) from co-cultures of 
1.0x106 anti-CD3-activated CD4+ T cells with or without 0.5x106 B cells, Memory, Naïve or Transitional 
B cells after 5 days of co-culture. The statistical analysis used was RM-ANOVA test * p<0.05 with a 








6.3 Role of Memory, Naïve and Transitional B cells as CD4+ T cell 
activating cells. 
6.3.1 Memory, Naïve and Transitional B cell viability after five days of co-culture 
with CD4+ T cells 
After finding that Memory B cells induced proliferation, activation and cytokine 
production in low-activated autologous CD4+ T cells, whereas Transitional B cells were 
incapable of inducing any activation, the properties of B cell subsets were studied in 
order to explain the differences observed in the CD4+ T cell activation.  
Cell apoptosis and viability were the first properties measured within the B cells. 
Down-regulation of BAFFr was used to measure apoptosis, and Live/Dead dye was 
used to measure viability as shown previously in Fig4 B and Fig4 A, respectively. Non-
apoptotic cells were measured as CD20+BAFFr+ cells from the live population, after 1, 
3 and 5 days of co-culture by surface staining (Fig28 A). Transitional B cells was the 
first population that experienced apoptosis and cell death, because at day 1, half of the 
cells significantly lost BAFFr expression (****p<0.0001), whereas 75% of Naïve and 
Memory B cells maintained their expression. By the third day of culture, all subsets 
experienced apoptosis and cell death, however, Transitional B cells were the population 
most affected by this (****p<0.0001). Finally, at day 5, Memory (****p<0.0001), 
Naïve (****p<0.0001) and Transitional B cells (****p<0.0001) presented the highest 
levels of cell death and apoptosis; Transitional B cells were more affected, compared to 
Memory (p=0.0164) and Naïve B cells (p=0.0124).  
B cell viability at day five was measured in the large-scale experiment, and 
again, Memory B cells was the population with the highest survival rate, followed by 







Figure 28: Measurement of viability and apoptosis in B cell subsets co-cultured with CD4+ T cells. 
B cell viability and apoptosis were measured in co-cultures of 0.5x106 Memory, Naïve or Transitional B 
cells with 0.5x106 anti-CD3-activated CD4+ T cells at day 0, 1, 3 and 5 of culture; apoptotic live cells 
were identified as CD20+Live/Dead-BAFFr- (A). The statistical analysis used was RM-ANOVA test * 
p<0.05 with a Tukey’s multiple comparisons test. Viability of 0.5x106 B cells, Memory, Naïve and 
Transitional B cells cultured with 0.5x106 anti-CD3-activated CD4+ T cells was measured after 5 days of 
co-culture; live cells were identified as CD20+Live/Dead- (B). The statistical analysis used was RM-
ANOVA test * p<0.05 with a Holm-Sidak’s multiple comparisons test.                
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6.3.2 Memory B cells exhibited higher levels of expression of CD86 and CD25 
compared to Naïve and Transitional B cells, after five days of culture with CD4+ T 
cells 
 CD86 and CD25 up-regulation on B cells induces T cell activation, via CD28 
interaction, and cell survival, respectively. For this reason, expression of CD86 and 
CD25 was measured in B cell subsets after CD40 activation mediated by anti-CD3 
activated CD4+ T cells.  
The same time course used to measure T cell proliferation and CD20 viability 
was used to measure CD86 expression at day 1, 3 and 5 of co-culture (Fig29 A). 
Memory B cells had the highest expression of CD86 at day 1 (*p=0.0160), 3 
(**p=0.0017) and 5 (***p<0.0001) compared to the other subsets, exhibiting the 
highest expression at day 5. Naïve and Transitional B cells did not increase CD86 
expression in this assay.   
Expression of CD86 and CD25 was then measured at day 5 in the previously 
described large-scale experiment, and once again, an increase in CD86 expression was 
found in Memory B cells, compared to Naïve (*p=0.0489) and Transitional B cells 
(*p=0.0198) (Fig29 B). Regarding CD25 expression, as IL-2 was added in cultures, 
high expression of CD25 in all B cell subsets was predicted, however, Memory B cells 
exhibited the highest CD25 expression compared to Naïve (***p=0.0006) and 
Transitional B cell (**p=0.0046) (Fig29 C). 
In conclusion, the differential CD86 expression observed in Memory B cells 
could explain the reason why these cells were inducing more activation on CD4+ T cells. 
Low expression of this activation molecule in Transitional B cells corresponded with 
low T cell activation of these cells.  CD25, on the other hand, could be an indirect signal 
of IL-2 capture, and therefore, an indicator of viability. This could imply that if Memory 
B cells have better survival compared to Naïve and Transitional (demonstrated by CD25 
expression, viability and apoptosis results), they can activate CD4+ T cells during a 
longer period of time before cell death.  
These two main results, in isolation or together, provide an explanation of why 
Memory B cell were the main CD4+ T cell activating cells and Transitional B cells were 




Figure 29: CD86 and CD25 expression in B cell subsets. 
Expression of CD86 was measured in 0.5x106 Memory, Naïve or Transitional B cells co-cultured with 
0.5x106 anti-CD3-activated CD4+ T cells at day 0, 1, 3 and 5 of culture (A). The statistical analysis used 
was RM-ANOVA test * p<0.05 with a Tukey’s multiple comparisons test. Expression of CD86 (B) and 
CD25 (C) was measured in 0.5x106 B cells, Memory, Naïve or Transitional B cells co-cultured with 
1.0x106 anti-CD3-activated CD4+ T cells after 5 days of culture. The statistical analysis used was RM-
ANOVA test * p<0.05 with a Holm-Sidak’s multiple comparisons test.                
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6.3.3 Memory B cells produced higher levels of TNF-α  compared to Naïve and 
Transitional B cells after five days of culture with CD4+ T cells 
Pro-inflammatory cytokine production was measured on B cell subsets to 
understand whether the presence of these cytokines was relevant for CD4+ T cell 
activation. TNF-α and IFN-γ were measured, but only TNF-α was produced by B cells. 
CD20+TNF-α+ cells were measured in B cell subsets after 5 days of culture with 
activated CD4+ T cells, and a significant increase of CD20+TNF-α+ was observed 
mostly within the Memory B cells compared to Naïve B cells (****p<0.0001) and 
Transitional B cells (****p<0.0001) (Fig30). 
In conclusion, Memory B cells were the main CD4+ T cell-activating cells, as 
shown previously, and these cells were the main TNF-α-producing population as well. 
This cytokine is a well-known pro-inflammatory cytokine (Gaur et al. 2003), therefore 
it is possible to believe that this cytokine is actively participating in CD4+ T cell 

























Figure 30: TNF-α  expression in B cell subsets co-culture with CD4+ T cells. 
CD20+TNF-α+ cells were identified in 0.5x106 B cells, Memory, Naïve or Transitional B cells co-cultured 
with 1.0x106 anti-CD3-activated CD4+ T cells after 5 days of culture. The statistical analysis used was 























6.3.4 IL-10 production by B cell subsets and their effect in CD4+ T cell 
proliferation 
IL-10 has been shown to be a relevant anti-inflammatory cytokine in this study, 
since Blair et al. showed that Transitional B cells are capable of regulating Th1 
responses through IL-10 production (Blair et al. 2010). CD40-CD40L interaction 
induced IL-10 production specifically by Transitional B cells, as was shown in Fig11 B 
and C. Because of these two main results, production of IL-10 was studied by B cell 
subsets after CD40 activation using intracellular staining, and then, the role of IL-10 in 
CD4+ T cell proliferation was analysed by using a neutralising IL-10 receptor antibody.  
In the same large-scale experiment performed previously, IL-10 production was 
measured in Memory, Naïve and Transitional B cells after 3 and 5 days of culture with 
anti-CD3 activated CD4+ T cells, using intracellular staining. Examples of CD20+IL-10+ 
B cells non-activated and activated with CD4+ T cells after 3 (Fig31 A) and 5 (Fig31 B) 
days of co-culture are presented in dot plots.  
CD20+IL-10+ Memory, Naïve and Transitional B cells from all the experiments 
performed were plotted at day 3 (Fig31 C) and 5 (Fig31 D) after co-culture with anti-
CD3 (1ug/ml) activated CD4+ T cells. Significant differences between B cell subsets 
were observed at day 3, but not at day 5, and the percentages of CD20+IL-10+ 
Transitional B cells were significantly higher compared to Memory B cells (*p=0.0282). 
Percentages of CD20+IL-10+ Naïve B cells were also significantly higher compared to 
Memory B cells (*p=0.0282), but no difference between Naïve and Transitional were 
observed at day 3. In terms of day 5, no differences were observed between B cell 
subsets, and percentages of all CD20+IL-10+ B cell subsets were lower compared to day 
3. 
Finally, the effect of IL-10 on CD4+ T cell proliferation was studied (Fig31 E). 
In order to evaluate the effect of IL-10 produced by B cell subsets on CD4+ T cell 
proliferation, a neutralising IL-10 receptor antibody was used in the CD4+ T cell-B cell 
co-cultures. Proliferation was measured with a Violet Cell Trace dye in CD4+ T cell, 
and results were presented as peaks of proliferation cycles using histograms. The 
blocking effect of IL-10 moderately increased proliferation in CD4+ T cells cultured 
alone, did not induce any difference in Memory B cells, and induced a higher 
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proliferation in CD4+ T cells cultured with Naïve and Transitional B cells. Although an 
increased proliferation was observed in CD4+ T cells cultured with Naïve and 
Transitional B cells, only CD4+ T cells co-cultured with Transitional B cells reached 
statistical significance (Fig31 F). 
In this last set of experiments, a differential release of IL-10 was observed 
between day 3 and 5 of culture, with IL-10 present at day 3 but absent at day 5.  
Looking at CD4+ T cell proliferation, proliferation between the third and the fifth day of 
culture could be seen, but was very low prior to these days (Fig25 B). Together, these 
two sets of results suggest that IL-10 is participating in the control of the T cell 
proliferation when Naïve and Transitional B cells were co-cultured with T cells.   
Interestingly, increments of T cell proliferation was observed when the IL-10 
neutralising antibody was added into CD4+ T cells cultured without B cells; this may be 
explained because of the effect of regulatory CD4+ T cells present in the CD4+ T 
population. Regulatory T cells secrete IL-10 (Barrat et al. 2002; Taylor et al. 2006), 
therefore if this pathway was blocked in CD4+ T cell cultures, CD4+CD25- T cells 
should proliferate more, as IL-10 cannot be up taken by these cells. In contrast, 
differences were observed when IL-10 was neutralised in co-cultures with Memory B 
cells, although, Memory B cells were the lowest IL-10 producing cells after CD40 
activation.  
Finally, T cell proliferation induced by Naïve and Transitional B cells was 
severely affected by IL-10 blocking. Proliferation was significantly increased in co-
cultures with Transitional B cells, suggesting that IL-10 production by Transitional B 
cells was important in the control of the proliferation. Activation markers and pro-
inflammatory cytokine secretion were also increased in CD4+ T cell – Transitional B 
cells co-cultures when anti-IL-10 receptor antibody was present in culture (data not 
shown). All these data suggest that IL-10, produced by Transitional B cells, is 








Figure 31: IL-10 expression on B cell subsets after 3 and 5 days of co-culture with CD4+ T cells. 
Dot-plots examples of CD20+IL-10+ B cells found co-cultures of 0.5x106 Memory, Naïve or Transitional 
B cells with 1.0x106 anti-CD3-activated CD4+ T cells after 3 (A) and 5 (B) days of culture. CD20+IL-10+ 
cells were identified in 0.5x106 Memory, Naïve or Transitional B cells co-cultured with 1.0x106 anti-
CD3-activated CD4+ T cells after 3 (C) and 5 (D) days of culture. Friedman test with a Dunn’s multiple 
comparisons test was used; * p<0.05 was considered significant. Histograms of T cell proliferation (E) 
and total percentages of T cell proliferation (F) of 1.0x106 anti-CD3-activated CD4+ T cells co-cultured 
with or without 0.5x106 Memory, Naïve or Transitional B cells, and with and without blocking anti-IL-10 
receptor (0.1ng/ml), after 5 days of culture. Two-way RM ANOVA test with a Sidak’s multiple 
comparisons test was used; * p<0.05 was considered significant.               
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6.3.5 Expression of IL-10 receptor on B cell subsets 
 Finally, the expression of IL-10 receptor on B cell subsets was evaluated by 
surface staining in order to identify whether B cells could be consuming IL-10.  
Sorted Memory, Naïve and Transitional B cells were stained with an anti-IL-10 
receptor antibody; examples of the staining are presented in dot-plots of CD20+IL-10-
receptor+ cells from Memory, Naïve and Transitional B cell samples (Fig32 A). Overall, 
the expression of the IL-10 receptor was significantly increased on Transitional B cells 
compared to Naïve B cells before culture (Fig32 B).  
In summary, these results showed an increased expression of the IL-10 receptor 
in the Transitional population, compared to Memory and Naïve B cells. This may 
indicate that IL-10 could be playing an important role in the Transitional B cell function, 
perhaps either as a survival signals, as an activation signal, or as a positive signal for IL-
10 positive feedback. This could also explain the conflicting results obtained when IL-
10 was measured in supernatants, possibly because Transitional B cells were not only 
secreting this cytokine, they were also consuming it. Why Transitional B cells exhibited 
a high expression of the IL-10 receptor, or what is the role of IL-10 in these cells will 


















Figure 32: Expression of IL-10 receptor in B cell subsets. 
Expression of IL-10 receptor was observed in Memory, Naïve and Transitional B cells (A). CD20+IL-10 
receptor+ B cells were measured in 0.5x106 Memory, Naïve and Transitional B cells samples by surface 












The cognate interaction between B and T cells through MHC-class II-TCR is 
crucial for both lymphocytes as it can lead to T and B cell activation, cytokine 
production, proliferation and antibody production (O'Rourke et al. 1997). Another 
interaction between the same two cells has been shown to be important in the immune 
regulation and anti-inflammatory responses in humans; namely CD40/CD40L 
interaction in the absence of BCR-specific recognition. Blair at al. described that CD40-
activated CD19+CD24hiCD38hi B cells were capable of inhibiting the Th1 response, 
in vitro. They demonstrated that this interaction induced a B cell suppressive response 
mediated by IL-10 production and CD80 and CD86 expression (Blair et al. 2010). This 
chapter was designed to evaluate T cell activation induced by CD40 activated B cells in 
vitro, to then apply this principles in the context of transplantation tolerance.   
6.4.2 T cell activation and proliferation  
The CD40-CD40L interaction was studied to evaluate the immune responses 
induced by B cell subsets in CD4+ T cells and the first parameter analysed in this 
chapter was the T cell proliferation. It is well described that CD3 activation induces T 
cell proliferation (Meuer et al. 1984); it is also known that CD28 enhances this 
proliferation when it is activated at the same time as CD3 (Azuma et al. 1992); besides 
proliferation, these two signals can induce CD40L up-regulation, and consequently, B 
cell activation (Srahna et al. 2001). It was found that activation with anti-CD3/CD28 
antibodies or with high concentrations of anti-CD3 antibody, not only induced up-
regulation of CD40L, but also induced high levels of CD4+ T cell activation and 
proliferation. These effects did not seem to be mediated by the B cell subsets. Low 
concentrations of anti-CD3 antibody were then used to determine differences between 
the B cell subsets. These results imply that in the context of transplantation, B cells can 
regulate or mediate T cell activation in a CD40-CD40L specific manner, only when T 
cell activation is low. Then, unactivated T cells do not up-regulate CD40L and therefore, 
do not activate B cell subsets, whilst highly activated T cells do not respond to B cell 
mediation.  
6.4.3 IL-10 production by Transitional B cells  
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Claudia Mauri’s group in 2010 demonstrated for the first time in human cells, 
that only Transitional B cells had the ability to suppress the Th1 response after CD40 
activation via IL-10 production (Blair et al. 2010). Following on from these findings, 
the Th1 response in B-T cell co-cultures was measured in this thesis to evaluate the 
capacity of the B cells to induce T cell activation and cytokine production. These results 
showed that Transitional B cells did not induce activation nor cytokine production, 
whereas Blair et al. showed that Transitional B cells inhibited IFN-γ and TNF-α 
secretion by T cells (Blair et al. 2010). In summary, two different experimental designs 
gave the same message; only Transitional B cells regulate the pro-inflammatory 
response generated by activated T cells.     
Cytokine production was measured in B cells during co-culture with CD4+ T 
cells. Memory B cells were the highest TNF-α-producing cells within total B cells. It 
was shown that TNF-α can induce T cell activation, proliferation and apoptosis (Gaur et 
al. 2003), depending on the surrounding signals, therefore, Memory B cells may be 
inducing T cell activation through TNF-α secretion in this system. On the other hand, 
the anti-inflammatory response was regulated by IL-10, a cytokine that inhibits human 
T cell proliferation and activation (Taga et al. 1992; Sieg et al. 1996; Ebert 2000; 
Lemoine et al. 2011). This cytokine was identified after 72 hours of activation, 
predominantly in the Transitional B cells, secondly in Naïve B cells and poorly in the 
Memory B cell population; interestingly, the signal was completely lost afterwards. 
Because Naïve and Transitional B cells were the main IL-10 producing cells compared 
to Memory B cells, IL-10 was associated with the regulatory control of CD4+ T cell 
activation. Interestingly, IL-10 secretion during the first three days of culture was 
consistent with the low CD4+ T cell proliferation rate observed. After day three, B cells 
stopped the secretion of IL-10 the same time that proliferation started to increase.  
In order to evaluate any effects of B cell-induced IL-10, an anti-IL-10 receptor 
was used in co-cultures to block this signalling pathway in cells that were consuming 
the cytokine. Interestingly, increments in CD4+ T cell proliferation were observed in co-
cultures with Naïve and Transitional B cells when the anti-IL-10 receptor was added. In 
addition, a moderate increment of proliferation was observed in the CD4+ T cells alone, 
after the addition of the anti-IL-10 receptor. As it has been reported that regulatory T 
cells (Barrat et al. 2002; Taylor et al. 2006) and B cells (Bouaziz et al. 2010) regulate 
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proliferation through IL-10 secretion, the increment in the proliferation observed in the 
CD4+ T cell condition must be due of the blocking effect of regulatory T cells, as they 
were not excluded from the system. Proliferation was not affected in co-cultures with 
Memory B cells when anti-IL-10 receptor was added; in fact the variation between 
samples was minimal.  
When the IL-10 pathway was blocked, Transitional and Naïve B cells induced a 
higher T cell proliferation, activation and cytokine production (data not shown) 
compared to Memory B cells, this suggests that IL-10 produced by these two 
populations is able to regulate T cell proliferation in an IL-10-dependent manner. These 
results imply either an immune regulation through a direct mechanism, in which IL-10 
produced by B cells is directly regulating T cell proliferation; or an indirect mechanism 
in which IL-10 produced by B cells is regulating a T cell subset (within total CD4+ T 
cells) that in turn regulates proliferation; or a combination of both mechanisms. Flores-
Borja et al. reported that Transitional B cells convert effector T cells into Tregs partially 
via the release of IL-10 (Flores-Borja et al. 2013). In this chapter IL-10 secretion and 
FoxP3 expression were measured in T cells co-cultured with different B cell subsets but 
no significant differences in the expression of this Treg marker could be found (data not 
shown). However this thesis does not disagree with Flores-Borja’s study since results 
from the CD4+ T cells cultured only with the blocking IL-10 antibody suggest that the 
regulatory properties of a T cell subset within total CD4+ T cells was negatively affected. 
Roncarollo’s group showed that CD49b+LAG-3+ Tr1 cells secrete large amounts of IL-
10 (Gagliani et al. 2013), this population may also be affected by the IL-10 blocking 
antibody and it would be interesting to evaluate the interaction between Transitional B 
cells and these cells.  
In summary the main idea of this chapter was to demonstrate the differences 
between B cell subsets in the induction of T cell proliferation, activation and cytokine 
production. From all the results generated in these co-culture assays, it can be concluded 
that Transitional B cells are not efficient activator cells, as they do not induce T cell 
proliferation, activation, or pro-inflammatory cytokine production. They produced IL-
10 after CD40 activation, mainly at the beginning of the culture, and during this time, 
they controlled T cell proliferation via this cytokine release. On the contrary, Memory B 
cells exhibited better viability, higher CD86 expression, high TNF-α production and 
low IL-10 secretion. Because these cells had all the features required to be a proper T 
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cell activating-cell, it is not surprising that they induced more proliferation, activation 






Kidney transplant recipients that developed spontaneous tolerance exhibited 
maintained percentages and numbers of total B cells and Transitional B cells in 
circulation (Newell et al. 2010; Pallier et al. 2010; Sagoo et al. 2010; Silva et al. 2012). 
B cells have been traditionally linked to antibody production (Hidalgo et al. 2009), and 
hence, a detrimental graft function (Kimball et al. 2011; Loupy et al. 2012; Mohan et al. 
2012; Page et al. 2012). Thus, a protective or regulatory function by B cells has been 
unexpected in transplantation. In order to clarify the role of this population in this 
clinical field, different groups have use Rituximab to reduce acute and/or chronic 
rejection via inhibition of B cell participation in the immune response, however results 
are contradictory (Becker et al. 2004; Faguer et al. 2007; Clatworthy et al. 2009), and 
the role of the B cells in transplantation still remains inconclusive. The existence of 
different B cell subsets inducing or participating in different immune responses may 
explain these conflicting results (Sims et al. 2005; Palanichamy et al. 2009).  
Transitional B cells have been proposed as the main regulatory population 
within human B cells as they are able to regulate the pro-inflammatory Th1 response 
(Blair et al. 2010) and to induce regulatory T cells (Flores-Borja et al. 2013) via IL-10 
production. However, there are several aspects that must be considered when these cells 
are proposed as a regulatory source in transplantation tolerance. Transitional B cells are 
about 5-10% of B cells and 1% of total PBMCs (Bouaziz et al. 2010). They can be 
found mainly in the bone marrow and peripheral blood (Sims et al. 2005), rather than in 
lymphoid organs (Cuss et al. 2006). They are in a transitory state as they do not 
maintain their phenotype over time, and they easily undergo to apoptosis and cell death 
after activation (Sims et al. 2005). How is it then possible that a small and fragile 
population is regulating or modulating tolerance in kidney transplant recipients? Three 
different mechanisms are described in this thesis to try to understand the role of 
Transitional B cells in this particular clinical state.  
This study proposes that Transitional B cells contribute to tolerance in kidney 
transplant recipients by IL-10 production, low levels of BCR activation and absence of 
donor-specific responses. These three mechanisms are not necessarily independent of 
each other, and they depend on the type of activation received by the B cells.  
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In the first mechanism this study proposes that in tolerant recipients, low 
activated T cells in circulation are able to activate Transitional B cells via CD40-CD40L 
interaction in a non-antigen specific manner. As a consequence of this activation, 
Transitional B cells secrete IL-10 that inhibits cell proliferation only in low activated T 
cells. This inhibition possibly reduces the activation of the T cells in tolerant patients; 
therefore T cell activation will be lower in these, compared to patients with low 
numbers of Transitional B cells within the total B cell population.  
In the second mechanism, the signalling pathway triggered after BCR activation 
is decreased specifically in all B cell subsets from tolerant recipients, preventing or 
diminishing B cell activation and Plasma cell differentiation after antigen encounter. 
Also it is known that Memory B cells produce LT and TNF-α after BCR/CD40 
stimulation, whereas Naïve and Transitional B cells secreted mainly IL-10 after CD40 
stimulation alone (Duddy et al. 2004; Duddy et al. 2007). Therefore, if B cells exhibited 
a defect in BCR activation, Memory B cells will not produce LT and TNF-α, and Naïve 
and Transitional B cells will mainly produce IL-10, not only after CD40 activation, but 
also in combination with BCR stimulation.  
In the last mechanism donor-specific responses mediated by the different B cells 
subsets were measured in kidney transplant recipients. Results showed that all B cells 
subsets from tolerant recipients failed to induce a Th1 response. These results could be 
explained because: 1) all B cells from tolerant recipients exhibited a defect in the BCR 
signaling pathway; 2) B cells from tolerant recipients did not recognised and/or 
internalise donor-antigens; 3) B cells from tolerant recipients did not induce any 
response after donor-antigens presentation; 4) T cells from tolerant recipients did not 
respond after donor-antigen presentation, specifically by B cells; and/or 5) differences 
between antigens from tolerant recipients and their respective donors are not sufficient 
(in numbers or antigenicity) to induce a B or T cell response. When the same 
mechanism was studied in chronic rejector, results revealed that only Transitional B 
cells failed to induce a Th1 response compared to Naïve and Memory B cells, 
demonstrating a specific defect by Transitional B cells in donor-specific presentation.  
In conclusion this thesis proposes that these three mechanisms, together or 
independent from each other, are contributing to kidney transplantation tolerance. 
Although the presence of Transitional B cells may be beneficial to regulate donor-
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specific responses and to inhibit T cell activation, other clinical and immunological 








8.1 Characterisation of Transitional B cells in kidney transplant 
patients.  
1. Transitional B cells were maintained in tolerant recipients.  
2. Higher percentages of Transitional B cells were found in peripheral blood rather 
than spleen or lymph nodes. 
3. Transitional B cells exhibited a higher density of CD20, but not CD19, compared to 
other B cell subsets.  
4. B cells from stable and chronic rejector patients exhibited a lower BAFFr expression 
which implies a lower B cell viability compared to tolerant and healthy controls.    
5. CD25 and CD86 were up-regulated in B cells after CD40L activation, but only 
CD25 expression was significantly increased in B cells from tolerant recipients 
compared to chronic rejector. 
6. TLR-9 was up-regulated in B cells after CpG activation in all patient groups except 
chronic rejector. 
7. CpG induced IL-10 production mainly by Memory B cells, while CD40L induced 
IL-10 mainly by Transitional B cells.  
8. B cells from tolerant recipients produced higher levels of IL-10 compared to B cells 
from chronic rejector after CD40L activation. This difference was due to different 
percentages of Transitional B cells between these two groups.   
9. B cells from tolerant recipients produced higher levels of IL-10 compared to B cells 
from chronic rejector after CpG activation. Despite that, non-B cells from chronic 
rejector also produced IL-10 as evidenced in ELISA results. 
10. Patients who lost tolerance exhibited a decrease in the percentages of Transitional B 
cells, despite total B cells remained unchanged. B cells from these patients did not 






8.2 Donor-specific responses in kidney transplant patients. 
1. B cell activation via the BCR was lower in B cells from tolerant recipients, 
compared to B cells from healthy controls. This suggests that B cells from tolerant 
recipients showed an anergic or non-responsive state.  
2. BCR activation was higher in Memory B cells compared to Transitional B cells 
from healthy controls. This pattern was not observed in kidney transplant recipients, 
except chronic rejector.  
3. Donor-specific proteins were predominantly recognised by B cells from chronic 
rejector. After antigen processing and presentation, B cells from tolerant recipients 
failed to induce a Th1 response. On the other hand, almost all B cell subsets from 
stable and chronic rejector patients induced IFN-γ production by CD4+ T cells. Only 
Transitional B cells from chronic rejector failed to induce a Th1 response. In terms 
of IL-10 effects, no participation of this cytokine was observed in donor-antigen 
responses in tolerant recipients. 
4. HLA specificities were equally distributed in DSAs from kidney transplant 
recipients. Chronic rejector was the group with the most positive patients for DSAs, 
suggesting a direct relationship between DSA and rejection, but because three 
tolerant recipients also presented DSAs, the presence of these antibodies in serum 




8.3 B cell subsets and CD4+ T cell interaction. 
1. Transitional B cells did not induce CD4+ T cell proliferation, activation and pro-
inflammatory cytokine production compared to Memory B cells. 
2. Transitional B cells exhibited the lowest viability rates, compared to Naïve and 
Memory B cells.   
3. Memory B cells expressed high levels of CD86, CD25 and TNF-α after CD4+ T cell 
activation, compared to Transitional B cells.   
4. IL-10 was secreted by all B cell subsets, but mostly by Transitional B cells, after 3 
days of CD4+ T cell activation; the secretion of this cytokine was lost at day 5. IL-
10 was controlling proliferation in T cells co-cultured with Naïve and Transitional B 
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Genes differentially expressed in kidney transplant patients and 
healthy controls. 
A genetic B cell signature associated to renal transplant tolerance was found in 
humans in three independent cohorts (Brouard et al. 2007; Newell et al. 2010; Pallier et 
al. 2010; Sagoo et al. 2010). These studies identified several transcriptional biomarkers 
in peripheral blood related to B cells; MS4A1, the CD20-encoding gene, CD79B, a 
member of the B cell co-receptor, FCRL1 and FCRL 2, two Fc receptor-like proteins 
and genes related with the immunoglobulin conformation as IGKV4-1, IGLL1, and 
IGKV1D-13. The genetic B cell signature found in all these studies revealed at the same 
time, an augmented number of B cells in tolerant recipient compared to stables and 
chronic rejector; these suggest that presence of genes related to B cells, may be a 
potential biomarker of transplantation tolerance.  
In this thesis, B cell genes were evaluated in isolated B cells, to identify any 
relevant gene that could help to understand the mechanism or the relationship between 
B cells and transplantation tolerance. The results from the microarray used in this study 
presented some technical problems due to the low number of B cells in some patients, 
but they were solved with the pre-amplification of critical samples. Five patient samples 
per groups were included from tolerant, chronic rejector, healthy controls and stable 
patients. Results did not reveal any significant p value due to a low number of samples, 
but an interesting tendency was observed in some relevant B genes (Fig33). Thus this 
section has been added as an appendix.  
CD20-encoding gene, exhibited a higher expression in tolerant patients 
compared to stable, and even more compared to chronic rejector; this finding was 
interesting as Transitional B cells were shown to express high levels of this protein in 
chapter 4 (Fig7 A), therefore the gene expression in periphery was consistent with 
protein levels in the cell surface.  
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CD19, CD79A, CD79B, FCRL1, FCRL2 and CD27 shared a similar pattern than 
CD20, in which chronic rejector always exhibited the lowest expression of these genes 
compared to other groups.  
CD38 and CD24 genes were increased in tolerant B cell samples; this result can 
be explained by the fact that tolerant patient exhibited a higher percentage of 
CD24hiCD38hi Transitional B cells (Fig3 D).  
Interestingly, CD86 and ERK, two genes related with post-activation signals, 
were decreased in both tolerant and chronic rejector. These results were consistent with 
ERK-p experiments from the second chapter, in which B cells from tolerant patients 
failed to phosphorylate ERK after BCR activation. They were also consistent with 
CD86 expression, as no differences in neither non-activated nor activated samples 
between patients groups were observed in the first chapter. CD40 did not exhibit any 
difference in both, gene or protein expression. No clear difference were observed 
regarding TLR-9 expression (cells were not CpG-activated). Finally, BLK and BLNK 
exhibited the same pattern than phenotypic markers. 
In summary, gene expression from isolated B cells was consistent with protein 
expression found in different kidney transplant recipients. Unfortunately, because of the 
low number of patients per group, no statistical significance was found in the 












Figure 33: B cell-related genes expressed in healthy controls and kidney transplant patients. 
Box-plots of MS4A1, CD19, CD79A, CD79B, FCRL1, FCRL2, CD38, CD24, CD27, CD86, CD40, ERK, 
TLR5, TLR9, BLK and BLNK expression in isolated B cells from healthy control (HC), tolerant, stable and 





CD20, CD79b, FcRL1 and FcRL2 are the proteins encoded by the genes MS4A1, 
CD79B, FCRL1 and FCRL2, respectively. These genes were associated to kidney 
transplantation tolerance (Brouard et al. 2007; Newell et al. 2010; Sagoo et al. 2010). 
CD20 was the first differentiation marker identified in human B cells, and 
MS4A1 is the name of the gene that encodes this protein. This was the fifth gene 
differentially high expressed in tolerant patients from the IOT study (Sagoo et al. 2010), 
was also identified in the ITN study (Newell et al. 2010) and Brouard’s study (Brouard 
et al. 2007). Moreover, only the CD20 transcript from urine sediments was significantly 
higher in tolerant patients compared to patients with stable function or healthy controls 
(Newell et al. 2010). CD20 was also differentially expressed between B cell subsets, in 
which Transitional B cells expressed higher levels of CD20 compared to Naïve and 
Memory B cells (Cuss et al. 2006). Because CD20 was highly expressed in tolerant 
recipients, and especially in Transitional B cells, a potential role as a biomarker can be 
attributed to this protein.  
The functional role of the CD20 is not well defined in the literature; therefore, it 
is difficult to establish a mechanistic relation between CD20 and tolerance. The only 
evidence obtained from a reported case of a patient that naturally did not express CD20 
on B cells, demonstrated that this protein was important in the generation of T cell–
independent (TI) antibody responses (Kuijpers et al. 2010); however, no participation 
was observed in B cell proliferation or activation. But because biomarkers are not 
necessary required to have a specific function, CD20 can still be considered to detect 
tolerance. This marker could be a direct indication of an increased number of B cells in 
the patient, but this seems unlikely as CD19 gene was much lower in the significance 
scale in the IOT microarray (Sagoo et al. 2010).  
A new microarray was performed in our group of kidney transplant patient, this 
time isolated B cells were used, instead of whole blood used in previous reports. The 
idea was to identify any specific role of B cell-related genes in tolerance or rejection. 
Here, MS4A1 and CD19 gene expression was fairly similar in all patient groups. 
Healthy controls, stable and tolerant recipients exhibited a similar expression of CD19, 
but only healthy controls and tolerant recipient exhibited a similar MS4A1 expression, 
251	  
	  
while in stable it remained low and even closer to chronic rejector that exhibited the 
lowest expression in both genes. 
CD79 is the signalling component of the BCR and its signal is triggered after the 
BCR cross-linking. This interaction can induce apoptosis or, in the presence of a rescue 
signals from T cells, can drive cell activation and division (Niiro et al. 2002). CD79B 
was the first, and CD79A was the eighteenth gene differentially expressed in tolerant 
patients in the IOT study (Sagoo et al. 2010). CD79B expression was measured by flow 
cytometry but no differences were found between patient groups (data not shown). 
Regarding the microarray, CD79A and CD79B exhibited the same expression in all 
groups, except chronic rejector; again they exhibited the lowest expression in both 
genes. 
FcRL1 and FcRL2 are transmembrane glycoproteins from a large family of Fc 
receptor-like (FCRL) molecules. Although they share a common ancestor with the 
classical Ig-binding Fc receptors (FCR), these proteins do not bind Igs, therefore cannot 
be considered Fc receptors (Davis 2007). FCRL1–5 are all expressed in B cells; 
however, the distribution of these proteins is variable depending on the subpopulation 
(Davis 2007). FcRL1 ligation enhances BCR-induced Ca2+ mobilization and cell 
proliferation, suggesting a potential role as an activating protein of the B cell co-
receptor (Leu et al. 2005). FcRL1 and FcRL2 were two proteins encoded by genes 
differentially expressed in tolerant recipients found in the IOT study and in the INT 
study (Newell et al. 2010). Both proteins are highly expressed on B cells, and their 
transcription is predominantly high in B cells from the follicular mantle zone, mainly 
Naïve  B cells (Davis 2007). Preliminary results from the microarray shown the 
presence of FcRL1 on B cells, but not on CD14+ cells (data not shown), corresponding 
with published data that reported that FcRL1 was found on all of circulating B cells, but 
not on T cells, NKs, monocyte/macrophages, granulocytes, and platelets (Leu et al. 
2005). Despite the fact that literature had only reported FcRL2 on CD20+ B cells, and 
mainly in human CD27+ Memory B cells (Davis 2007), FcRL2 protein expression was 
found in this study in both populations, CD20+ and CD14+ cells (data not shown). 
Whereas FCRL1, as CD19, CD79A and CD79B, exhibited a high expression in all 
group samples except in chronic rejector, FCRL2, as CD20, exhibited a lower 
expression in stable patient, and even lower in chronic rejector compared to healthy 
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controls and tolerant recipients. Despite all this data, the relation between both proteins 
and tolerance is still unknown. 
CD27, CD24 and CD38 are B cell membrane proteins and their differential 
expression allowed identifying Memory, Naïve and Transitional by surface staining. 
Chronic rejector samples had reduced expression in CD27, but no difference was 
observed between healthy controls, stable and tolerant patients. CD24 and CD38 were at 
the limit of detection, therefore the differences in their expression cannot be discussed.  
Although CD86 and CD40 encode activation proteins, only basal levels can be 
evaluated in these results. I cannot discuss their role as activation markers because cells 
were not activated at the moment of sample preparation. CD86 exhibited a high 
expression in Healthy Controls and Stable patients while Tolerant patients exhibited a 
median expression. Chronic Rejector exhibited the lowest CD86 expression. CD40 gene 
expression, as well as CD40 protein expression, did not exhibit any difference between 
patient groups. Contrary to these results, Pallier et al. found that tolerant patients high 
express CD86 and CD40 at basal levels (Pallier et al. 2010).     
TLR5 and TLR9 are Toll like receptors-encoding genes. Even though is difficult 
to evaluate differences in TLRs expression in non-activated cells, TLR5 was an 
important gene to evaluate because was found down-regulated in Tolerant patients from 
the IOT study (Sagoo et al. 2010). Low expression of TLR5 in chronic rejector was 
detected, while TLR9 expression did not manifest any difference between the other 
patient groups. 
Regarding proteins-encoding genes from the BCR pathway signalling, BLNK 
and BTK exhibited the same pattern than phenotypic proteins-encoding genes in which 
genes were highly express in all patient groups except chronic rejector. ERK exhibited a 
high expression in healthy controls, a median expression in stable patients and a poor 
expression in tolerant and chronic rejector. This is an interesting result because agrees 
with data from the flow panel, and together with CD86 expression, both suggest that B 
cells from tolerant patients present a poor activation pattern at basal levels.   
